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ABSTRACT 
 
 
Porcine circovirus type 2 (PCV2) is a small, non-enveloped, circular, single stranded DNA 
virus of economic importance in the swine industry worldwide. The focus of this dissertation 
was to investigate different aspects of horizontal transmission including the use of serology 
to accurately detect infection, the infectivity and amount of PCV2 present in various 
secretions and excretions following experimental or natural PCV2 infection, the use of 
disinfectants in the prevention of PCV2 transmission on livestock trailers, the potential for 
spread of infectious PCV2 in spray-dried plasma, and evaluation of disinfection protocol of a 
swine facility following a natural PCV2 outbreak. Results of the first study indicated that 
evaluated ELISAs had area under the receiver operating curve values greater than 0.94, 
detected both anti-PCV2a and -2b antibodies with no differentiation, and did cross react with 
anti-PCV1 antibodies in infected animals. The second study determined that PCV2 exposure 
(natural or experimental) results in a chronic infection and PCV2 is shed in similar amounts 
by nasal, oral and fecal routes. In addition, PCV2 DNA present in excretions, secretions or 
on mechanical vectors is infectious to naïve pigs and therefore important for PCV2 
transmission. The third study determined that although PCV2 DNA was detected on trailer 
surfaces by PCR following three different disinfection protocols, PCV2 was not transmitted 
to naïve animals exposed to the contaminated trailers. The fourth study provided direct 
evidence that an experimental spray-drying process was not effective in inactivating PCV2 
and it is therefore possible that spray-dried porcine plasma from pigs could represent a 
biosecurity risk for the industry. The final study showed that the combination of a multistep 
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disinfection protocol with an improved, strict biosecurity plan can result in establishment of a 
PCV2 naïve herd and this status can be maintained for up to 10 months (300 days).    
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CHAPTER 1: General Introduction 
 
DISSERTATION ORGANIZATION 
This dissertation is prepared in an alternate manuscript format. The dissertation is 
composed of eight chapters and includes a general introduction, a literature review, five 
separate scientific manuscripts, and a general conclusion. References cited in the general 
introduction and the general conclusion chapters are listed at the end of the dissertation. The 
Ph.D. candidate, Abby Rae Patterson is the primary author of the manuscripts and is the 
principal investigator for the experimental work described.  The included co-author’s on each 
paper provided input in the study design, facilitated animal work, or provided critical review 
of the manuscript prior to submission. 
The first chapter of this work includes a general introduction to porcine circovirus 
type 2 (PCV2) followed by a section entitled “Statement of the Problem” which briefly 
summarizes the objectives and reasons for performing each study. The second chapter is a 
manuscript which provides a review of previously published literature on the epidemiology 
and horizontal transmission of PCV2 and has been submitted to Animal Health and Research 
Reviews. The third chapter is a manuscript which describes the diagnostic accuracy of three 
commonly used ELISAs for PCV2 and the ability of specific assays to differentiate between 
anti–PCV2a, anti–PCV2b, and anti–PCV1 antibodies. This manuscript was published in the 
Journal of Veterinary Diagnostic Investigation. The fourth chapter is a manuscript which 
describes the amount and infectivity of PCV2 shed in nasal, oral and fecal secretions 
following natural or experimental PCV2 infection. The manuscript has been submitted to 
Veterinary Microbiology. The fifth chapter is a manuscript which describes the ability of 
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PCV2 to withstand disinfection and be horizontally transmitted to naïve animals placed on 
livestock transportation trailers. The manuscript has been submitted to the Journal of Swine 
Health and Production. The sixth chapter is a manuscript which describes whether 
experimentally generated spray-dried plasma derived from a pig suffering from clinical 
porcine circovirus associated disease (PCVAD) was infectious in a swine bioassay using 
PCV2 naïve animals. This manuscript has been submitted to the Journal of Animal Science. 
The seventh chapter is a manuscript which documents a natural outbreak of PCV2 in a naïve 
population including a description of the procedures used to disinfect the premise and an 
attempt to derive PCV2 negative animals for use as replacement stock in the facility. This 
manuscript has been submitted to Journal of Swine Health and Production. The last chapter 
provides general conclusions.  
 
INTRODUCTION 
 
Porcine circovirus type 2 (PCV2) is a small, non-enveloped, circular, single-stranded 
DNA virus that was associated with pigs exhibiting multisystemic wasting disease in the late 
1990’s (Ellis et al., 1998). Since the initial description, PCV2-associated disease (PCVAD) 
has been reported in most pig producing countries worldwide and the virus is now considered 
ubiquitous (Ramamoorthy and Meng, 2009). PCVAD is now manifested in a variety of ways 
including multisystemic disease with wasting, reproductive failure, enteritis, respiratory 
disease, porcine dermatitis and nephropathy syndrome or a combination of these (Opriessnig 
et al., 2007). In cases of PCVAD, a morbidity rate of 4-30% with a mortality rate of 70-80% 
in affected animals has been reported (Segalés et al., 2005a). Commercial PCV2 vaccines are 
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now available and have generally been very effective in reducing morbidity and mortality in 
the field (Desrosiers et al., 2009) and under experimental conditions (Fenaux et al., 2004). To 
date, the question of how a highly prevalent virus such as porcine circovirus was and 
continues to cause epidemics of disease in populations of swine worldwide remains 
unanswered. The role of multiple co-infections, immune stimulation, immune suppression, 
management practices and many other factors in the development of clinical disease have 
been previously investigated (Gillespie et al., 2009; Madec et al., 2008; Opriessnig et al., 
2007; Ramamoorthy and Meng, 2009). However, very little information exists on the role of 
horizontal transmission in the spread of PCV2 between pigs, farms, and countries. 
 
STATEMENT OF THE PROBLEM 
 
In order to accurately assess horizontal transmission of any pathogen, an assay with 
high diagnostic specificity and sensitivity is essential to detect when and if the pathogen is 
circulating in a herd. One useful, common and cost-effective method is to conduct a cross-
sectional serological survey to determine the prevalence and levels of antibodies to the 
pathogen over time using one or more serological tests.
 
 For PCV2, most currently available 
ELISA tests use the open-reading frame (ORF) 2 region as an antigen since it is specific and 
immunogenic for PCV2 (Truong et al., 2001). Although most assays are based on PCV2 
ORF2, the methods of antigen production can differ among assays (Blanchard et al., 2003; 
Liu et al., 2004; Walker et al., 2000; Wu et al., 2008). In addition, differences in the length of 
the PCV2 capsid protein used in the assay, antibody specificity, selection of cut-off value, or 
variability between technicians also increases variability between assays and between 
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diagnostic laboratories performing the same assay. While reports indicate that ELISAs based 
on the ORF2 region of PCV2 are useful, a direct comparison of the diagnostic accuracy of 
currently available ELISAs has not yet been performed to the authors’ knowledge. To 
address the gaps in knowledge on current PCV2 ELISAs, the following objectives were 
defined in Chapter 3: (1) to determine the diagnostic accuracy of 3 commonly used ELISAs, 
(2) to determine whether each assay can detect and/or differentiate between anti-PCV2a and 
anti-PCV2b antibodies, and (3) to determine whether PCV2–based ELISAs cross-react with 
anti–PCV1 antibodies.  
Effective transmission depends on a number of factors falling under three main 
categories, characteristics of the host, characteristics of the pathogens and effective contact 
(Thrusfield, 2005). Specifically, the host must be susceptible; the pathogen must be virulent, 
infective and stable in the environment; and the interaction between the pathogen and host 
must be favorable for infection (correct infectious dose, adequate contact time, etc.) 
(Thrusfield, 2005). Previous studies which investigated both natural and experimental 
infection have reported detection of PCV2 DNA in various secretions and excretions 
including nasal and oral secretions and urine and feces (Bolin et al., 2001; Caprioli et al., 
2006; Carasova et al., 2007; Grau-Roma et al., 2009; Segalés et al., 2005b; Shibata et al., 
2003). However, the infectivity of the PCV2 in these samples has not been evaluated. The 
majority of work to date on transmission of PCV2 has focused on co-mingling of PCV2-
infected and naïve animals and the infectivity of PCV2 in various secretions has not been 
assessed (Albina et al., 2001; Andraud et al., 2008; Bolin et al., 2001). In addition, the 
infection dynamics in naturally PCV2 infected segregated weaned PCV2 pigs or naïve pigs 
experimentally infected with PCV2 under controlled conditions has not been reported. 
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Therefore, the objectives of Chapter 4 were to determine the amount of PCV2 shed in nasal 
and oral  secretions and feces following natural (Trial 1) or experimental (Trial 2) PCV2 
infection and to demonstrate the infectivity of the PCV2 DNA detected in excretions, 
secretions or on the surface of a mechanical vector (needle) (Trial 3). 
Knowledge of the modes of transmission of PCV2 is vital in understanding the 
ecology, epidemiology and control of PCVAD. While both vertical (Madson et al., 2009) and 
horizontal (Andraud et al., 2008) transmission by direct contact have been documented for 
PCV2, the focus of this thesis was on horizontal transmission by indirect contact. In general, 
horizontal transmission can occur by one of two routes. The first being direct contact with an 
infected host or the infected hosts secretions and the second, through indirect contact of a 
virus with a living vector, contaminated inanimate object or aerosol droplets (Thrusfield, 
2005). As previous work has focused on direct contact (Dupont et al., 2009), Chapters 5 and 
6 were focused on indirect transmission of PCV2. Key to both chapters is the hardiness of 
PCV2. Based on previous in vitro assays, PCV2 is quite stable following exposure to a wide 
range of temperatures (O'Dea et al., 2008) (Welch et al., 2006) and various pH conditions 
(Kim et al., 2009).  
In Chapter 5, the ability of PCV2 to withstand disinfection and be horizontally 
transmitted to naïve animals placed on livestock transportation trailers was evaluated. 
Previous work suggests that under in vitro conditions, mean PCV2 titers were reduced but 
not consistently eliminated following exposure to various disinfectants (Kim et al., 2009; 
Royer et al., 2001). While the above information exists on the effectiveness of disinfectants 
under in vitro conditions, no information is available on the effectiveness of disinfectants 
under field conditions. A number of factors that need to be considered under field conditions 
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that cannot be accurately recreated under in vitro conditions include the following: property 
of the surface that will be cleaned, water quality, and the presence of organic material 
contamination (Amass, 2004). Therefore, the hypothesis underlying the work performed in 
Chapter 5 was that the efficacy of various disinfectants against PCV2 is lower than described 
for in vitro work such that transmission of PCV2 through contaminated fomites is possible. 
To test this hypothesis, the specific objective of the study described in Chapter 5 was to 
evaluate the ability of four disinfection protocols with known in vitro effectiveness against 
PCV2 to prevent transmission of PCV2 under simulated field conditions. 
Continuing in the theme of investigation of horizontal transmission of PCV2, another 
indirect method, spread of PCV2 in a contaminated feed product, was the focus of Chapter 6. 
The value of incorporating spray-dried plasma (SDP) protein into the diet of weanling pigs to 
improve feed intake and growth performance, especially following disease challenge has 
been well documented (Coffey and Crowell, 2001; Torrallardona, 2010).  However, bacteria 
(DeRouchey et al., 2004), antibodies (Borg et al., 2002) and even PCV2 DNA (Pujols et al., 
2008) can be detected in the spray-dried products. In the only study which has evaluated 
commercial SDP in regards to transmission of PCV2, PCV2 present in SDP was not found to 
be infectious. Specifically, commercially manufactured SDP protein containing 2.47 × 10
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PCV2 genomic copies per ml fed to weaning pigs, which had maternally-derived PCV2 
antibodies, did not result in seroconversion or viremia during the 45 day observation period 
(Pujols et al., 2008). As the animals used in the study were not serologically naïve to PCV2 
and maternal antibodies can limit viremia and seroconversion in a titer dependent manner 
(McKeown et al., 2005), the hypothesis underlying Chapter 6 was that in immunologically 
PCV2-naïve animals, if infectious PCV2 is present in SDP this would be evidenced by 
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seroconversion and viremia. The specific objective of the study was to determine whether an 
experimentally generated SDP derived from a pig experimentally-infected with PCV2b was 
infectious in a swine bioassay using PCV2 naïve animals.   
While animal work was ongoing for the data presented in the previous chapters, the 
swine herd supplying PCV2 negative animals for these studies underwent a natural PCV2 
outbreak. As this is a fairly rare event due to high seroprevalence of PCV2 in multiplication 
herds worldwide, the situation presented a unique opportunity to implement knowledge 
gained in the previous studies on horizontal transmission on a large scale basis. The specific 
objectives of Chapter 7 were; therefore, to document a natural outbreak of PCV2 in a naïve 
population, to describe the procedure used to disinfect the premise, and to document the 
attempt to derive PCV2 negative animals for use as replacement stock in the facility. 
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CHAPTER 2.  Literature review:  Epidemiology and horizontal transmission of porcine 
circovirus type 2 (PCV2) 
 
A paper submitted to Animal Health and Research Reviews 
 
Abby Patterson, Tanja Opriessnig
 
 
 
ABSTRACT 
Porcine circovirus type 2 (PCV2) is a small, non-enveloped, circular, single stranded DNA 
virus of economic importance in the swine industry worldwide. Based on the sequence 
analyses of PCV2 strains, isolates can be divided into five subtypes (PCV2a-e). It is well 
documented that PCV2 is a ubiquitous virus based on serological and viremia data from 
countries worldwide. In addition, PCV2 DNA was discovered in archived samples prior to 
the documented onset of clinical disease. Recently a worldwide shift in PCV2 subtype from 
PCV2a to PCV2b has occurred. However, limited data exists on the horizontal transmission 
of PCV2. Previous studies have documented that transmission of PCV2 occurs by direct or 
nose-to-nose contact with infected animals and limited evidence to date also suggests that 
transmission through indirect contact is possible.  
The objective of this review was to summarize data on the epidemiology and horizontal 
transmission of PCV2.   
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INTRODUCTION 
Porcine circovirus (PCV), a small, non-enveloped, circular, single stranded DNA virus, was 
first discovered as a picornavirus-like contaminate of PK-15 cells in 1974 (Tischer et al., 
1974). Although further studies on the virus indicated that it was non-pathogenic (Tischer et 
al., 1986), the discovery of the virus later designated PCV type 1 (PCV1) initiated worldwide 
investigations into the prevalence of the PCV in the swine population and led to the eventual 
discovery of PCV type 2 (PCV2).  PCV2 is shares between 68-76% nucleotide sequence 
identity with PCV1 (Hamel et al., 1998; Morozov et al., 1998).  Unlike PCV1, PCV2 was 
initially associated with clinical disease in the 1990’s (Allan et al., 1998; Harding et al., 
1998) and today is of economic importance in the swine industry worldwide.  Based on the 
sequence analyses of PCV2 isolates, they can be divided into five subtypes (PCV2a-e). 
PCV2a and PCV2b have been documented worldwide (Segalés et al., 2008), PCV2c has 
been documented in archived samples from Denmark (Dupont et al., 2008), and PCV2d and 
PCV2e have only been identified in China to date (Wang et al., 2009).   
 
Clinical signs of PCV2 infection manifest in a variety of ways including multisystemic 
disease with wasting, reproductive failure, enteritis, respiratory disease, porcine dermatitis 
and nephropathy syndrome (PDNS) or a combination of these (Opriessnig et al., 2007) 
summarized as porcine circovirus associated disease (PCVAD). In cases of PCVAD, a 
morbidity rate of 4-30% with a mortality rate of 70-80% in affected animals has been 
reported (Segalés et al., 2005a). It is clear is that PCV2 is ubiquitous and was present many 
years prior to the onset of clinical PCVAD. To date, the question of how a highly prevalent 
virus such as PCV2 was able to cause epidemics of disease in populations of swine 
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worldwide remains unanswered. The presence of PCV2 prior to recognition of clinical 
PCVAD outbreaks in multiple countries indicates that the presence of co-factors contribute to 
the onset of clinical disease manifestation. Multiple factors including co-infections, immune 
stimulation, immune suppression, management practices and many others have recently been 
reviewed (Gillespie et al., 2009; Madec et al., 2008; Opriessnig et al., 2007; Ramamoorthy 
and Meng, 2009). To the author’s knowledge, an in depth review of the epidemiology and 
horizontal transmission of PCV2 has not been conducted to date. 
 
EPIDEMIOLOGY 
PCV2 is prevalent world-wide 
Following the initial detection of PCV in 1974 (Tischer et al., 1974), the seroprevalence of 
this virus was determined in Germany (Tischer et al., 1986), Canada (Dulac and Afshar, 
1989), England (Edwards and Sands, 1994) and in the United States (Hines and Lukert, 
1995).  Because these studies were published in the early 1990’s, the exact PCV type 
represented in the reports is unknown.  Specifically, persistently infected porcine kidney cells 
(PK-15) were used for the immunofluorescent assay (IFA) making the differentiation of 
PCV1 and PCV2 difficult. Based on these initial studies it was determined that PCV was 
widespread in swine populations in the investigated countries (Table 1). By the late 1990’s 
however, diagnostic tests which differentiated non-pathogenic PCV1 from pathogenic PCV2 
became available allowing further characterization of PCV isolates.  PCV2 has since been 
identified in countries worldwide (Table 2).   
 
PCV2 is identified in archived tissue samples prior to onset of clinical disease 
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Retrospective studies have indicated that PCV2 had been present years prior to the onset of 
clinical cases of PCVAD (Fig. 1). However, based on the limited sequencing information 
from these studies, little to no changes were detected in the viral genome between isolates 
recovered prior to and following clinical outbreaks of PCVAD (Grierson et al., 2004; 
Jacobsen et al., 2009). Interestingly, there has been a shift in the predominant PCV2 subtype 
to PCV2b which may have contributed to the increased severity and frequency of PCVAD.   
 
A global shift in the predominant PCV2 subtype 
Several studies have evaluated the temporal differences in identification of PCV2a and 
PCV2b and concluded that a global shift in the predominant subtype has occurred. In a study 
published in 2007, 218 PCV2 genome sequences were analyzed and the authors’ concluded 
that a major shift from PCV2a to PCV2b occurred on a global scale in or prior to 2003 
(Dupont et al., 2008). Interestingly, based on the analysis in the study which included 
sequences from 1997 to 2006, the shift in subtypes did not affect Korea, Japan or Australia 
(Dupont et al., 2008). Since that time, PCV2b has been demonstrated as the predominant 
subtype in Korea based on analysis of isolates from 2005-2007 (Kim et al., 2009b) and in 
Japan where both PCV2a and PCV2b were detected in isolates collected between 2006 and 
2007 (Takahagi et al., 2008). Additionally in a study by Olvera et al., 148 PCV2 isolates 
were analyzed.  Of these, 63.5% (94/148) were PCV2b sequences of which 92.5% (87/94) 
were published after 2003.  Numerically fewer (62.2%; 33/53PCV2a sequences were 
published after 2003 (Olvera et al., 2007).  However, the authors’ cautioned that the time of 
sequence publication in relationship to when the virus was first detected can be variable 
12 
 
(Olvera et al., 2007). In the following section, summaries of selected reports which document 
the predominance of the PCV2b subtype are provided for each continent.    
 
Asia 
In China, 49 isolates from various geographic regions were sequenced (Wang et al., 2009). 
Results revealed that only PCV2a isolates were recovered in 2001 (n=3). In isolates 
recovered between 2002 and 2006 (n=34), a mixture of PCV2a, PCV2b, PCV2d and PCV2e 
was detected with the majority of samples (n=18) clustering with PCV2b. Of the isolates 
recovered in 2007 and 2008 (n=12), all clustered with PCV2b (Wang et al., 2009).  
Similarly, in a 2010 publication evaluating a total of 136 isolates from Eastern China 
collected between 2001 and 2009, 127 of the isolates clustered with PCV2b (Li et al., 2010), 
while only nine clustered with PCV2a.  Of these nine, eight were collected between 2001 and 
2004.  The remaining 48 isolates collected during this period were identified as PCV2b (Li et 
al., 2010).   
 
In Korea, PCV2 isolates detected by PCR in tissue samples collected from PCVAD affected 
herds (n=29) and non-PCVAD affected herds (n=9) in 2007 were sequenced and categorized 
as PCV2a and PCV2b. All of the 29 sequences from PCVAD affected herds and four of the 
sequences from non-PCVAD affected herds clustered into the PCV2b group (Chae and Choi, 
2009). Similarly, in a study by An et al. (2007) 36 Korean PCV2 sequences from pigs with 
PDNS or PCVAD collected from 1999 to 2006 were compared to other PCV2 sequences 
available in GenBank. The phylogenetic analysis indicated that PCV2b was detected in 
66.7% (24/36) of the samples. Although the specific year when these 24 isolates were 
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collected is not provided, the authors’ suggest that more severe PCVAD cases in Korea in 
2004 were related to the increased incidence of PCV2b (An et al., 2007).   
 
In Japan, 150 serum samples were collected from 2- to 4-month old pigs on 10 farms (15 
samples/farm). PCV2 DNA positive samples were analyzed by restriction fragment length 
polymorphism (RFLP) analysis. In two farms, RFLP type 311 (which corresponds to PCV2a) 
was identified in 2006. Six months later in the two farms, RFLP type 111 (which corresponds 
to PCV2b) was indentified indicating a shift in the PCV2 subtype over a short temporal span 
(Takahagi et al., 2008).   
 
Europe 
In Ireland, PCV2a was recovered from five of six farms classified as PCVAD-affected based 
on samples collected from 1997 to 2003 (Allan et al., 2007). However, PCV2b was isolated 
from the remaining farm which had increased mortality (peak mortality of 35%) in 
comparison to the other five farms. In all samples after 2003 from both PCVAD-affected and 
non-PCVAD-affected farms, only PCV2b was isolated (Allan et al., 2007). As severe 
PCVAD outbreaks occurred between 2003 and 2006 in Ireland, this is suggestive of a 
temporal link between the identification of PCV2b and severe outbreaks (Allan et al., 2007).  
 
In Brittany, de Boisséson et al. (2004) sequenced and compared isolates from PCVAD 
(n=25) and non-PCVAD (n=31) affected farms collected from 2000 to 2002. Results 
indicated that two main clusters were present with the majority of the PCV2 sequences 
clustering into the PCV2b group (de Boisséson et al., 2004).  While the author’s concluded 
14 
 
that a new subtype of PCV2 was not responsible for the increased outbreaks of PCVAD in 
Brittany as PCV2b was detected in both PCVAD and non-PCVAD affected herds (de 
Boisséson et al., 2004), this is consistent with PCV2b being the predominant strain during 
this time.   
 
In Denmark, Dupont et al. sequenced and compared a total of 45 isolates from PCVAD 
affected and non-PCVAD affected herds collected between 2003 and 2004. Similar to the 
study by de Boisséson et al., a distinctive clustering of isolates by disease status was not 
noted; however, all isolates clustered within the PCV2b group (Dupont et al., 2008).  
 
North America 
In North America, the shift to increased prevalence of PCV2b was documented by several 
recent studies. The first identified the presence of PCV2b in Canada in samples from 13 
PCVAD cases collected in 2005 in the province of Quebec (Gagnon et al.,2007). Further 
investigation of 83 sequences collected from both PCVAD affected and non-PCVAD 
affected animals from four provinces in Canada between 2005 and 2006 revealed that 79.5% 
(66/83) of sequences clustered with PCV2b (Gagnon et al.,2007).  In a separate study, 121 
cases from animals with and without clinical signs of PCVAD submitted to the Institut 
National de Santé Animale between October 2006 and January 2007 were analyzed by a 
PCV2a/PCV2b differential PCR (Gagnon et al., 2008). Of the 121 cases, PCV2b was 
detected in 92.6% (112/121), PCV2a in 4.1% (5/121) and both subtypes were detected in 
3.3% (4/121) of cases (Gagnon et al., 2008).  Another publication identified 12 PCV2b 
isolates in four finishing facilities in Kansas experiencing severe PCVAD (Horlen et al., 
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2007).  PCV2b was also identified in tissue homogenates from pigs manifesting severe 
PCVAD in Kansas, North Carolina and Iowa in 2005 (Cheung et al., 2007).  Previous to 
these reports, PCV2a had been the only strain detected in North America (Fenaux et al., 
2000; Larochelle et al., 2002; Olvera et al., 2007).  However, these reports included sequence 
information from limited numbers of North American isolates. 
 
Oceania 
The paucity of sequencing information available on Australian and New Zealand isolates 
limits drawing conclusions on whether a shift in predominant subtype occurred in this region 
or what the predominant subtype currently is.  To the author’s knowledge, there are only two 
studies evaluating isolates from this region.  In the first, Muhling et al. evaluated seven 
PCV2 isolates collected between 1999 and 2002.  Six of the isolates clustered with previous 
isolates from Japan and Canada and had an overall 94-99% nucleotide identity with previous 
reported strains from other countries (Muhling et al., 2006). Specific designations of the 
isolates into PCV2a and PCV2b were not made. The second study evaluating isolates from 
New Zealand found that isolates from the 2006 PCVAD outbreak share 94-100% nucleotide 
identity with other reported PCV2 isolates (Neumann et al., 2007).  
 
South America 
In tissues from pigs with respiratory signs collected between 2000 and 2004, eight PCV2 
sequences were identified (Castro et al., 2008). In a later study by Chiarelli-Neto et al. 
(2009) 11 Brazilian isolates from PCVAD-affected animals collected in 2005 were 
sequenced.  The majority of Brazilian isolates clustered with the PCV2b group and the 
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author’s concluded that Brazilian strains emerged from a common ancestor identical or 
descendent from strains which were common in Europe and Asia (Chiarelli-Neto et al., 
2009). While this provides information that PCV2b is currently likely the predominant 
subtype, it does not determine when or if a shift occurred.  The information for other South 
American countries is limited (Cano et al., 2005). 
 
While broad and firm conclusions from the above referenced studies cannot be made because 
of the low numbers of isolates evaluated (especially those collected prior to 2005), the 
available data suggests that PCV2b subtypes currently predominate.  Additional sequences, 
especially from isolates collected prior to 2005, are necessary to determine a more precise 
estimate of the time when the shift in subtypes occurred. Interestingly, while the studies in 
which both PCVAD-affected and non-affected animals were evaluated support an increased 
identification of PCV2b, they do not necessarily support the association of clinical disease 
with PCV2b as this subtype was found in both clinically affected and non-affected animals.   
 
HORIZONTAL TRANSMISSION 
Effective transmission depends on a number of factors falling under three main categories, 
(1) characteristics of the host, (2) characteristics of the pathogens and (3) the type of 
exposure (Thrusfield, 2005). Specifically, the host must be susceptible; the pathogen must be 
virulent, infective and stable in the environment; and the interaction between the pathogen 
and host must be favorable for infection (correct infectious dose, adequate contact time, etc.) 
(Thrusfield, 2005). In general, horizontal transmission can occur by one of two routes, direct 
contact with an infected host or the infected host’s secretions or through indirect contact of a 
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virus with a living vector, contaminated inanimate object or aerosol droplets (Thrusfield, 
2005). The following focuses on routes of PCV2 shedding, environmental stability, and 
evaluation of the transmission of PCV2 through direct and indirect contact.   
 
PCV2 is shed in large quantities through multiple routes 
Following experimental infection of naïve animals with PCV2, PCV2 DNA has been 
detected in multiple sample types. Caprioli et al. (2006) oronasally inoculated 4 week old 
colostrum-deprived (CD) specific pathogen free (SPF) pigs with a PCV2 isolate recovered 
from a clinically affected Canadian pig.  Blood, fecal swabs and tonsillar swabs were 
collected at 1, 3, 6, 9, 12, 15, and 21 days post inoculation (dpi). Results indicated that 10/12 
and 11/12 pigs had PCV2 DNA-positive tonsillar and fecal swabs, respectively, at 1 dpi. 
Interestingly, at dpi 6, only 1/12 and 0/12 animals were PCV2 DNA positive on tonsillar and 
fecal swabs, respectively. However, by the last day of the trial (dpi 21), 11/12 and 11/11 
animals were PCV2-positive by tonsillar and fecal swabs, respectively. Additionally, PCV2 
DNA was not detected in serum, plasma or whole blood until 9 dpi. Based on these findings, 
the authors’ concluded that PCR had detected inoculum in the nasal and fecal swabs prior to 
dpi 6. In a separate study, Bolin et al. (2001), intranasally and subcutaneously inoculated 
mixed breed, cesarean-derived, colostrum-deprived (CDCD) pigs at 20 or 25 days of age 
with a PCV2 isolate obtained from a clinically affected Canadian pig to determine tissue 
distribution of PCV2 DNA and duration of viral persistence (Bolin et al., 2001). Virus was 
recovered by isolation from nasal, rectal or tonsil swabs between 12 and 19 dpi (Bolin et al., 
2001). Analysis of shedding in CDCD pigs was also evaluated by Shibata et al. in 2003. In 
this study, pigs were intranasally inoculated with PCV2 at 2 weeks of age and oropharyngeal 
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and nasal swabs and feces were collected among other samples at the time of necropsy 
(necropsy occurred on dpi 7, 14, 21, 35, 49, or 70). Results indicated early and consistent 
shedding in the majority of animals for an extended period of time.  All oropharyngeal and 
nasal swabs and fecal samples contained PCV2 DNA on dpi 1 (excluding 1 nasal swab).  
Between dpi 1 and dpi 70 all fecal samples were PCV2 PCR positive and 83 out of 86 nasal 
and oropharyngeal swabs were PCV2 DNA positive (Shibata et al., 2003). In a similar study 
in which CDCD pig were inoculated with PCV2, PCV2 DNA was detected in nasal and 
rectal swabs in a high percentage of sampled animals (67-100% excluding one nasal 
sampling at dpi 35 in which only 1 of 3 animals had detectable PCV2 DNA) between 7 and 
49 dpi  (Harms et al., 2001). Several other studies detected PCV2 DNA or viable virus (by 
virus isolation) from nasal swabs, feces, ocular swabs or a combination of these samples at 
various time points in low numbers of animals following experimental infection (Krakowka 
et al., 2000; Magar et al., 2000a; Resendes et al., 2002).   
 
Limited data on the amount of PCV2 in nasal fluid and saliva following experimental 
infection is available. Chung et al. (2005) intranasally challenged 14 cross-bred commercial 
pigs which were serologically naïve to porcine reproductive and respiratory syndrome virus 
(PRRSV) and PCV2 at 10 weeks of age with a tissue homogenate containing PRRSV and 
PCV2 (n=12) or animals were left as negative controls (n=2). As part of the study, six of the 
animals challenged with PCV2 and PRRSV were injected intramuscularly with inactivated 
Salmonella choleraesuis and complete Freund’s adjuvant prior to infection. In 
experimentally infected pigs PCV2 concentrations at 14 dpi were similar to those found in 
naturally infected animals. Samples were collected from nine dyspneic pigs naturally infected 
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with PRRSV and PCV2 (based on PCR detection in serum) and nasal fluid and saliva of 
these pigs contained between 3.7± 0.2 to 4.4±0.2 log10 PCV2 genomic copies/ml (Chung et 
al., 2005).   
 
While the above studies included relatively low numbers of pigs with varying immune status 
(CDCD, CD or commercial SPF pigs) and pigs were inoculated with different PCV2 isolates, 
PCV2 DNA was consistently detected in the secretions and excretions evaluated.  In 
addition, PCV2 DNA was detected early in the infection process (dpi 1) and generally 
persisted in a high number of the animals through the end of the evaluation period indicating 
persistent infection.  To the author’s knowledge, there is only one study to date investigating 
the actual amount of PCV2 DNA in various secretions following experimental infection 
(Chung et al., 2005) and more work in this area is needed to determine whether shedding 
occurs equally by various routes.  
 
Additional studies have described PCV2 shedding following natural infection of pigs and 
PCV2 was detected and quantified in multiple sample types.  The PCV2 shedding patterns in 
three naturally PCV2 infected farms was investigated between 1999 and 2000 (Shibata et al., 
2003). Nasal swabs and fecal samples were collected from 313 pigs in five different age 
groups. Results suggested that infection occurred post-weaning as an increased frequency of 
PCV2 detection occurred in both sample types after the nursery phase (n=64), peaked in 3-4 
month old animals (n=81) and declined in the sampled population of adult animals (n=47). 
Overall, PCV2 was detected in 20.4% (64/313) of fecal samples and 19.2% (60/313) of nasal 
samples (Shibata et al., 2003). In 2009, a longitudinal case-control study of two PCVAD 
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farms located in Spain and Denmark was designed to describe the dynamics of a natural 
PCV2 infection (Grau-Roma et al., 2009). In contrast to the previously described cross-
sectional study, this study provided data on a specific cohort of animals over time. Serum, 
nasal swabs and fecal swabs were collected from selected animals at four time points from 1 
to 9 (Denmark) or 11 (Spain) weeks of age and at the time of necropsy (between 9 to 21 
weeks of age). Of the 108 Spanish animals evaluated, 78 animals were defined as “case” and 
30 as “controls” based on clinical evaluation. A similar clinical evaluation resulted in 91 case 
and 27 control animals from farms in Denmark. On Spanish farms, PCV2 was detected by 
PCR sporadically in all samples between week 1 (first sampling point) and week 11. At the 
time of necropsy, PCV2 was detected in 87.0% of nasal and 50.5% of fecal swabs. A 
significantly higher percentage of positive pigs were detected in animals classified as “case” 
animals. The amount of PCV2 DNA in nasal and fecal samples ranged from approximately 
4-6 log10 genomic copies PCV2 per swab throughout the study period with significantly 
higher amounts detected in “case” animals. In Danish farms at one week of age, 69.3% of 
nasal swabs and 22.8% of rectal swabs were PCV2 DNA positive. By the time of necropsy, 
the percentage of PCV2 positive PCR samples had risen to 100% in nasal samples and to 
98.5% of rectal swabs.  Throughout the study period, the amount of PCV2 DNA ranged from 
approximately 4 to 8 log10 genomic copies PCV2 per swab in fecal samples and 4 to 10 log10 
genomic copies PCV2 per swab in nasal samples.  By the time of necropsy, “case” animals 
had significantly larger amounts of virus in both nasal and fecal swabs in comparison to 
healthy controls (Grau-Roma et al., 2009).  Quantitative data on the amount of PCV2 DNA 
in various samples collected from 146 pigs submitted to the Pathological Diagnostic Service 
at the Veterinary School of Barcelona between 2000 and 2001 was reported in 2005 (Segalés 
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et al., 2005b).  Serum samples (n=57), nasal swabs (n=99), tonsillar swabs (n=108), 
tracheobronchial swabs (n=72), urinary swabs (n=91) and fecal swabs (n=42) were collected 
and were tested quantitatively for the presence of PCV2 DNA.  The results were divided into 
three categories: PCVAD affected pigs, PCV2 subclinically infected pigs and non-PCVAD 
pigs, based on presence of histopathological lesions and amount of PCV2 antigen detected by 
in-situ-hybridization and into two categories based on age (≥1.5 or less than 1.5 months of 
age). PCV2 was found in 100% of all swabs and serum samples from animals classified as 
PCVAD affected pigs with significantly more PCV2 DNA present in comparison to PCV2 
subclinically infected pigs and non-PCVAD pigs.  Additionally, significantly more PCV2 
DNA was present in older animals (≥1.5 months of age) except for tonsillar swabs.  
Quantitative results for PCVAD pigs ranged from approximately 5 to 8 log10 PCV2 genomic 
copies/ng for all sample types with the highest PCV2 load detected in trachea-bronchial 
swabs followed by serum, tonsillar, nasal, fecal and urinary swabs.  In all sample types, the 
amount of PCV2 was higher in PCVAD affected pigs compared to non-PCVAD pigs.  The 
authors’ concluded based on these results that the more severe the PCV2 lesions, the more 
PCV2 is present within serum and various swabs (Segalés et al., 2005b).   
 
While larger numbers of animals were used in studies evaluating naturally PCV2 infected 
pigs, the impact of management, co-infections and other co-factors in PCV2 shedding are 
difficult to evaluate.  However, the above studies suggest that PCV2 is present in high 
quantities in nasal and fecal samples for extended periods of time following natural PCV2 
infection of a population.  In addition, there is evidence that increased shedding is present in 
animals with clinical signs associated with PCV2 in comparison to healthy controls (Grau-
22 
 
Roma et al., 2009). Similar to the limited data available on the amount of PCV2 present in 
secretions from experimentally infected animals, few studies have evaluated this aspect 
following natural infections.   
 
In summary, the above information suggests that PCV2 DNA can be detected in fecal, nasal, 
oral, and tonsillar swabs as well as in urine and feces from both naturally and experimentally 
infected pigs. In addition, PCV2 DNA can be detected early in the infectious process and 
persists for extended periods of time.  However, in the majority of the studies, the infectivity 
of the PCV2 DNA was not investigated. 
 
PCV2 is stable in the environment and resistant to disinfectants 
Relatively few studies have evaluated the stability of PCV2; however, available results 
indicate that the virus is very resistant under high temperatures and a wide range of pH 
conditions.  In a study by Welch et al. (2006), PCV2 virus stock was subjected to one of two 
treatments. The first treatment was pasteurization at 60°C for 0, 2, 5, 10 and 24 hrs and the 
second treatment was dry heat treatment on freeze-dried virus (selected vials were partially 
rehydrated) at 80°C for 8, 24, 48 or 72 hrs. Following application of the treatments, an 
infectivity reduction factor was calculated. For pasteurization, a 1.33 log reduction 
(corresponding to 5% of the starting material) was calculated at 24 hrs. Following dry-heat 
treatment, a 0.75 log reduction (corresponding to 18% of the starting material) was calculated 
at 72 hrs. Due to the lack of efficacy of temperatures utilized, additional temperatures were 
evaluated. Results indicated pasteurization at a temperature of 65°C, 70°C and 75°C for 30 
min lead to a 0.25, 1.59 and 1.92 log reduction, respectively. Interestingly, only a 1 log 
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reduction in infectivity was calculated following dry-heat treatment at 120°C for 30 min 
(Welch et al., 2006). Resistance of PCV2 to heat was also shown in a study by O’Dea et al. 
in which PCV2 virus stock in cell culture media was incubated in a water bath at 
temperatures of 56, 65, 70, 75, 80, and 85°C (O'Dea et al., 2008). The presence of PCV2 
antigen following treatments was determined by immunohistochemistry (IHC) and the 
presence of replicating PCV2 was determined by RT-PCR for replicative intermediates. 
Results indicated that PCV2 antigen was detected at temperatures up to 70°C and PCV2 
RNA was detected up to 75°C but not at 80°C. The author’s suggested that PCV2 was more 
labile when heated in liquid culture then when freeze-dried explaining the differences noted 
between this study and previous work by Welch et al (O'Dea et al., 2008; Welch et al., 
2006). In 2009, the in vitro stability of PCV2 was again investigated by incubating PCV2 at 
various temperatures and ranges of pH. Results confirmed extreme environmental resistance 
as evidenced by an unchanged virus titer following incubation at 56°C for one hour, a 
reduction from 10
5.5
 to 10
2.5
 50% tissue culture infective dose (TCID50) per ml following 
incubation at 70°C for one hour, and a reduction from 10
5.5
 to 10
2.7
 TCID50 per ml following 
incubation at a pH of 2 for 30 minutes (Kim et al., 2009a).   
 
In addition to showing environmental stability, PCV2 has been shown to withstand several 
types of disinfectants.  In a study by Kim et al., various disinfectants were evaluated for 
efficacy against PCV2 in an in vitro model. Specifically, incubation of a potassium 
peroxomonosulphate, a sodium hypochlorite product, or 3% sodium hydroxide with 1 × 10
4.5 
to 1 × 10
5.5 
TCID50/ml for 10 min resulted in complete reduction of PCV2 (Kim et al., 
2009a).  When the incubation time was increased to 30 min with a quaternary ammonium 
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compound or 12 hrs with a quaternary ammonium/gludaraldehyde compound there was also 
a complete reduction of PCV2 infectivity (Kim et al., 2009a). When PCV2 was incubated 
with 0.05 or 0.1% formalin, PCV2 was detected; however, a specific mean TCID50/ml was 
not provided (Kim et al., 2009a). In an earlier study, an in vitro suspension assay was 
performed to determine the virucidal efficacy of nine disinfectants against a French PCV2 
isolate (Martin et al., 2008). Equal volumes of double strength disinfectant were mixed with 
PCV2 virus stock for 30 min at 20°C. Results indicated a reduction of the mean PCV2 titer 
of greater than 1.61 log10 at the authorized concentration for the two disinfectants which 
contained potassium monopersulfacte as the active ingredient and the oxidizing agent with a 
combination of peracetic acid and hydrogen peroxide as active ingredients. Products 
containing a combination of aldehydes and quaternary ammonium active ingredients resulted 
in a reduction greater than 1.74 log10 of the PCV2 titer.  Products containing iodine and 
phenolic compounds as active ingredients did not reduce the infectivity titer of PCV2. While 
results indicate several of the products evaluated reduced the infectivity titer of PCV2, none 
of the products resulted in a 3 log10 TCID50/ml reduction in infectivity titer (French 
regulation for determination of virucidal efficacy) due to the low initial titer of the PCV2 
used in the suspension (Martin et al., 2008). In a similar study by Royer et al. (2001), PCV2 
virus stock was incubated at room temperature for 10 min with the recommended dilution of 
various disinfections, passed through a detoxification column and assessed for infectivity by 
cell culture. Results indicated several disinfects significantly reduce the mean infectivity tiers 
of PCV2 following exposure including two phenol products (30.6-40.3% mean reduction 
titer), two quaternary ammonium compounds (34.7-50.0%), two oxidizing agents (45.8-
73.6%) and an alkali agent (61.1%). However, products containing alcohol, iodine, 
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formaldehyde and chlorhexidine compounds did not result in a significant reduction in mean 
infectivity titer. While several products were efficacious, none of the products completely 
eliminated infectious PCV2 under optimal, laboratory conditions (i.e. no organic material 
present, optimal contact time, optimal physical surface) (Royer et al., 2001).  
 
Taken together, these studies provide evidence that reduction of PCV2 titers under in vitro 
conditions is most likely to occur when an oxidizing, halogen, or sodium hydroxide 
containing product is used while products containing iodine, alcohol, phenol or formaldehyde 
are likely to be less effective.  Complete inactivation of PCV2 under in vitro conditions is 
difficult (only accomplished in 1 of 3 studies) and results are difficult to interpret as neither a 
cytotoxicity control nor a virus control (virus plus media alone) were used in the study.  
Lastly, all published work with disinfectants has been done under in vitro conditions and it is 
unknown if these results would be repeatable under in vivo conditions.   
 
Documentation of horizontal transmission of PCV2 by direct contact with infected 
animals 
The majority of evidence to date on the transmission of PCV2 by direct or nose-to-nose 
contact comes from investigations where comingling of infected pigs with naïve animals was 
done following experimental infection. Bolin et al. comingled mixed-breed, CDCD pigs 
which were intranasally and subcutaneously inoculated at 20 or 25 days of age with a 
Canadian PCV2 isolate with naïve contact pigs. Contact pigs were comingled at 42 dpi and 
all three contact pigs seroconverted within 3 weeks of contact exposure (Bolin et al., 2001). 
In a similar study, six 10-13 week old pigs from a PCVAD affected conventional farm were 
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comingled with 10 week old specific pathogen free pigs (Albina et al., 2001).  Following co-
mingling, 5 of 5 contact pigs developed clinical signs including pyrexia and diarrhea. 
Additionally, separate groups of 5-9 week old SPF or conventional pigs were inoculated with 
a tissue homogenate derived from pigs showing clinical signs of PCVAD. PCV2-naïve 
contact animals were comingled with these animals immediately following experimental 
inoculation. Ninety percent of contact animals (10 of 11 pigs) developed pyrexia and growth 
retardation. These clinical signs were also seen in 82% (45/55) of the inoculated animals.  
Severe wasting was noted in 7.2% (4/45) of the inoculated animals and was not noted in 
contact animals. The onset of disease in contact animals was approximately 16 days 
following the onset of clinical disease in inoculated animals (Albina et al., 2001).   
 
While the above studies documented that naïve animals can be infected with PCV2 following 
exposure to infected animals, low numbers of animals were used and information on specific 
transmission parameters including latency, basic transmission rate and mean disease 
generation time were not determined.  The incubation period was found to be approximately 
16 days in one study (Albina et al., 2001); however, the information was based on only four 
animals.   
 
Several aspects of transmission have been evaluated by Andraud et al. (2009) using a time-
dependent transmission model.  Using experimentally infected pigs comingled with naïve 
contact pigs in six successive transmission trials, the latency period for PCV2 was estimated 
to be 8 days, the basic reproduction ratio was estimated to be 5.9 and the mean disease 
generation time was estimated to be 18.4 days. Interestingly, in the study, the transmission 
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rate decreased between 15 and 55 dpi even though pigs remained viremic with viral loads 
between 10
3
-10
6
 genomic copies/ml. This suggested a correlation between the presence of 
neutralizing antibodies and decreased transmission secondary to reduced viremia. 
Alternatively, the infectious period did not correspond to the period of viremia (Andraud et 
al., 2009). In a second study by the same research group, further modeling was done to 
determine specific transmission parameters including the basic reproduction ratio (Ro), 
within pen transmission rate (βwithin) and the transmission rate between pens (βbetween) by 
comingling experimentally infected and naïve animals (Andraud et al., 2008). A maximum 
likelihood model including a constant six day latent period (based on previous in vitro 
infectivity titer data) and an assumption of the duration of infection were used. Under the 
assumption that pigs were “recovered” following seroconversion and decreased PCV2-
viremia, the within pen R0 was 8.9 (5.1-15.4) and βwithin was 0.28 (0.18-0.42). Using the same 
assumptions, the R0 between-pen was 1.2 (0.5-2.9) and the βbetween was 0.04 (0.02-0.08). In 
the between pens or indirect contact group, the first viremic contact pig was detected at 17 
days post comingling; by the first necropsy date (35 days), 16/16 pigs were viremic. In this 
group, seroconversion was first noted at 35 days; 3/16 pigs had seroconverted at the time of 
either the first or second necropsy (35 and 42 days, respectively). In the within pen or direct 
contact group, viremia was first detected at 21 days and all 16/16 pigs were viremic by 35 
days post exposure.  In this group, seroconversion was first detected at 35 days and 7/16 pigs 
were positive at either the first or second necropsy date.  These results suggest that 
movement of PCV2 between pens is expected to be low, and hence the risk of movement of 
PCV2 between farms without direct contact to PCV2 infected pigs or fomites is low. 
Combined with information on age susceptibility to PCV2, the authors’ suggested that 
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segregation of pigs from different sources until the risk of PCV2 infection decreases [more 
than 7 weeks; (Rose et al., 2009)] would likely result in decreased incidence of clinical 
disease associated with PCV2 (Andraud et al., 2008).   
 
While these studies provide the only available information on transmission parameters for 
PCV2, they are based on low numbers of animals using a single replicate.  For example the 
information for the direct contact group is based on a single replicate of four experimentally 
infected PCV2 animals which were comingled with four PCV2 naïve animals for a two day 
contact period.  Assumptions in the model included homogenous infectious potential of 
experimentally infected animals and random mixing of the experimentally infected pigs and 
naïve contact animals.  These assumptions may or may not be valid under field conditions.  
In addition, as noted by the authors, these results were generated from subclinically infected 
animals whereas results may differ in animals experiencing systemic clinical manifestations 
of PCVAD (Andraud et al., 2009). 
 
In addition to providing evidence that PCV2 can be transmitted from pig to pig, the ability of 
PCVAD to be “spread” between groups of pigs has been evaluated. One such investigation 
comingled 108, 6-11 week old pigs from four herds defined as PCVAD-affected with 216, 4-
5 week old pigs from two non-affected herds for 46-48 days. Pigs were divided into four 
compartments to evaluate direct contact, nose-to-nose contact between pens and no contact 
(separation by an aisle). In each compartment there were two pens containing comingled pigs 
from PCVAD-affected and non-affected herds (direct contact), one pen of non-affected pigs 
with nose-to-nose contact to the comingled pigs, one pen of pigs from PCVAD-affected pigs 
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in nose-to-nose contact with comingled pigs and one pen of non-affected animals with no 
contact (Dupont et al., 2009). Compartments had concrete floors with straw bedding and 
partitions between pens allowed nose-to-nose contact and movement of feces between pens 
(Kristensen et al., 2009).  Disinfection was done with formaldehyde prior to initiation of the 
study with 2 week downtime without pigs (Kristensen et al., 2009).  PCVAD was diagnosed 
by histopathology and immunofluorescence in 44 of the 324 pigs included in the study. Of 
the 44 PCVAD animals, 30 pigs were from PCVAD-affected herds and 14 were from non-
affected herds. Transmission was confirmed by comparing PCV2 sequence data within 
individual animals (prior to the trial and following exposure) and among all animals. 
Sequencing results indicated that of the 14 animals from non-affected herds, eight were 
infected through direct contact, four from nose-to-nose contact, and two were infected 
without direct contact to infected animals. On-site control animals (housed in a separate 
compartment did not develop clinical disease; however, PCV2 genomic copies per ml serum 
increased from 10
4
 to 10
9
 during the study in two animals indicating exposure by an indirect 
means (Dupont et al., 2009). During the study, personnel changed gloves, clothes and boots 
between pens (Kristensen et al., 2009).  Based on this work, the transmission of PCV2 with 
the subsequent development of clinical PCVAD can occur following comingling or nose-to-
nose contact of animals from PCVAD-affected and non-PCVAD affected farms.   
 
Overall, information on horizontal transmission of PCV2 comes from studies in which 
PCV2-naïve animals are exposed to experimentally or naturally PCV2-infected animals for a 
minimal contact period.  Although in the majority of studies small numbers of animals were 
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used, it is clear that PCV2 can be transmitted to naïve animals by direct or close contact.  
However, more information is necessary to determine basic transmission parameters.    
 
Limited, inconclusive information is present on indirect transmission of PCV2 by the 
oral route, aerosol route and contact with other species 
Transmission of PCV2 by the oral route 
Published information to date suggests that PCV2 may be infectious via the oral route as 
PCV2-naïve animals became infected following oral consumption of uncooked meat from an 
experimentally infected pig (Opriessnig et al., 2009b).  In this study, skeletal muscle, bone 
marrow and lymphoid tissues collected from experimentally PCV2-inoculated pigs 
transmitted PCV2 by the oral route to naïve animals evidenced by seroconversion and 
viremia.  Tissues were collected from animals at the time of peak infection and fed raw to 
naïve animals for three consecutive days. PCV2 genomic copies in the inoculum were 10
7.8
 
and 10
5.8
 in lymphoid tissues and bone marrow, respectively.   Interestingly, skeletal muscle, 
which is not a commonly demonstrated source of PCV2, contained 10
4.0 
PCV2 genomic 
copies/ml and was able to transmit PCV2 by the oral route to naïve animals. It was not 
determined whether the low levels of PCV2 were due to residual blood within the muscle or 
the presence of the virus within endothelial cells.  Additionally, it was noted in the study that 
seroconversion (both anti-IgM and anti-IgG responses) was delayed in pigs inoculated with 
skeletal muscle and bone marrow suggesting that a lower infectious dose may result in 
delayed infection (Opriessnig et al., 2009b).  Based on this study, it is known that PCV2 can 
be transmitted through oral consumption of uncooked meat; however, delayed 
seroconversion suggests that this route is not as efficient as direct contact with infected 
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animals.  In addition, the significance of this route of infection in animals with passive or 
active immunity to PCV2 remains unknown.   
 
Limited work has been done on indirect transmission of PCV2 through contaminated feed 
additives.  In a study by Fenaux et al. (2004), a porcine-derived commercial pepsin product 
was found to contain PCV2 DNA (Fenaux et al., 2004).  However, both in vitro analysis and 
a bioassay indicated the PCV2 detected by PCR was non-infectious.  The bioassay portion of 
the study included 16, 5 week old SPF pigs of which six were intranasally and 
intramuscularly inoculated with the reconstituted commercial pepsin product.  Evaluation of 
animals for clinical signs, seroconversion and viremia was done for 42 dpi.  (Fenaux et al., 
2004).   
 
In another study, oral transmission of PCV2 via spray-dried plasma was evaluated.  
Numerous studies have documented the value of incorporating spray-dried plasma protein 
into the diet of weanling pigs to improve feed intake and growth performance, especially 
following disease challenge (Coffey and Crowell, 2001; Torrallardona, 2010). However, due 
to the inherent stability of PCV2, withstanding the spray-drying process is possible. To date, 
one study has evaluated the presence of PCV2 in spray-dried plasma.  In this study, pigs with 
low levels of maternal PCV2 antibody were fed a diet containing 8% of a commercial spray-
dried plasma product which contained 2.47 × 10
5
 PCV2 DNA copies/ml for 45 days (Pujols 
et al., 2008). Results of weekly PCV2 PCR and ELISA analysis on serum samples indicated 
neither treated nor control pigs became viremic or seroconverted to PCV2 during the trial 
period.  Based on the results, the authors suggested that spray-dried plasma containing PCV2 
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DNA fed to pigs with low levels of maternal antibodies represents a low risk of infection 
(Pujols et al., 2008).  However, it is unknown whether the animals were susceptible to 
infection as a PCV2 challenge control was not included in the study.  Previously, in animals 
with high levels of passively-acquired antibodies, PCV2 viremia and seroconversion were 
decreased following experimental challenge with PCV2; however, low levels of passively 
acquired antibody titers were not found to be generally protective (McKeown et al., 2005). 
As anti-PCV2 antibodies can mask or delay infection, PCV2 seroconversion, viremia or both 
may have been detected if the study by Pujols et al. (2008) had been carried out for a longer 
period. Because commercial products are known to contain PCV2 DNA, the use of spray-
dried plasma on farms does represent a potential risk for PCV2 infection but the risk is likely 
low in comparison to direct exposure to infected animals or their secretions.   
 
PCV2 transmission via the aerosol route 
PCV2 transmission via airborne spread has been evaluated; however, to date there is a lack of 
conclusive evidence that this route results in PCV2 transmission to naïve animals.  In a study 
by Hermann et al. (2008), four 63-day old pigs were inoculated with PCV2 at a dose of 1 × 
10
4.8
 TCID50/ml.  Following infection, oral and nasal swabs, air samples from the pigs, and 
samples of ambient room air were collected at various intervals for 28 dpi and tested by PCR.  
Air samples from pigs were collected for 5 min using an impinger and a surgical mask which 
covered the snout of the pig.  PCV2 DNA was not detected in nasal swabs until 14 dpi and 
only in 3 of 20 samples taken.  PCV2 DNA was also not detected from either the aerosol 
samples taken of the room or directly from the pig.  The limit of detection for PCV2 using 
the impinger detection system is unknown; however, 1 × 10
1.1 
TCID50 and 1 × 10
1.4 
TCID50 
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of PRRSV and swine influenza virus were previously detected in a 5 min sampling period 
(Hermann et al., 2008).  No studies have been conducted at the time of this publication which 
evaluate the spread of PCV2 by aerosol contaminates under field conditions.  However, 
PCV2 DNA has been detected in air samples obtained from swine facilities.  Specifically, in 
a study by Verreault et al., (2009) air samples from 23 commercial swine buildings including 
multiple finisher facilities, one nursery, and one farrowing building were taken.  Each farm 
was sampled either two or three times, the air samples were evaluated by quantitative real-
time PCV2 PCR, and correlated to total dust and bacterial concentrations.  While airborne 
concentrations of PCV2 ranged from 2 × 10
3
 to 10
7
 genomes per m
3
 of air, only 40.5% of the 
virus concentration was explained by the variation in dust concentration and no correlation 
was found between PCV2 concentrations and airborne bacterial concentrations (Verreault et 
al., 2009).  Additionally, no correlation was found between PCV2 concentration and factors 
including relative humidity, temperature, CO2 concentration, or animal density, which were 
evaluated by questionnaire or monitoring devices in the buildings.  Interestingly, on three 
sampling occasions, PCV2 was not detected from the farrowing site indicating the presence 
of less than 1,389 to 2,778 PCV2 genomic copies per m
3
 of air (the limit of detection for the 
sampling apparatus) (Verreault et al.,2009). Because only one farrowing site was sampled 
and individual animals were not tested for the presence of virus or antibodies, it is unclear 
whether passive immune protection of piglets resulted in reduced shedding or if this 
concentration of airborne PCV2 on this site was within a normal farm-to-farm variation. 
Results of this study indicate that PCV2 DNA can be detected in high concentrations in air 
samples from commercial swine buildings. However, it is unknown whether the high 
concentrations of airborne PCV2 DNA were correlated to PCV2 prevalence in the herds.  
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Additionally, health factors including PCV2 vaccination and the presence of concurrent 
disease challenges were not analyzed in the study (Verreault et al., 2009).  To the author’s 
knowledge only two studies are available on the topic of aerosol transmission of PCV2 and 
as only 1/2 studies evaluated PCV2 infection of animals in conjunction with air samples, 
much more information is needed before it can be determined whether aerosol transmission 
is a significant risk factor in horizontal transmission of PCV2. 
 
Potential for transmission of PCV2 through contact of pigs with non-porcine species 
Previous studies have shown that PCV2 can replicate in mice (Cságola et al., 2008; Kiupel et 
al., 2001; Opriessnig et al., 2009a) and can be transmitted between mice (Cságola et al., 
2008) indicating a potential role for mice in the transmission of PCV2. Clinical signs were 
not observed in mice and microscopic lesions in PCV2-experimentally infected mice were 
minimal and not similar to those in PCVAD-affected pigs (Kiupel et al., 2005; Opriessnig et 
al., 2009a). In a recent study by Lőrincz et al. (2010), PCV2 DNA was detected in tissues 
from 13/20 (65%) of dead mice and 5/21 (23.8%) of dead rats collected from two PCV2-
infected swine farms while PCV2 DNA was not detected in tissues from 25 rodents (yellow-
necked mice, house mice, common voles) collected in areas not directly connected to PCV2-
infected farms (Lőrincz et al., 2010).  Limitations of this short communication included a 
lack of information on the source of control rodents and determining the basis of PCV2-
infection status of the herd on detection of PCV2 DNA in 8 or 10 sampled porcine tissues 
without correlation to data on mortality or clinical PCVAD cases. However, based on the 
limited information available, indirect transmission of PCV2 secondary to contact with 
PCV2-infected rodent species is a potential risk factor.  Increased information on the 
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presence of PCV2-infected rodents in association with the PCVAD status of multiple herds is 
necessary to determine the magnitude of the risk of transmission by this route.     
 
Experimental infection of PCV2 isolates derived from pigs exhibiting PCVAD in cattle (Ellis 
et al., 2001), sheep (Allan et al., 2000) and rabbits (Quintana et al., 2002) have been 
unsuccessful as evidenced by the lack of clinical disease, microscopic lesions, PCV2 viremia 
and seroconversion following infection. Based on the apparent failure of these species to 
replicate PCV2, evidence to date suggests that it is unlikely that these species pose a risk for 
transmission of PCV2 to swine.  To date no information exists to the author’s knowledge on 
experimental infection of avian species with PCV2. However, due to lack of detection of 
PCV2 in species other than swine (Segalés et al., 2005a) and the host specificity of 
circoviruses within avian species (Todd, 2004), transmission by this route seems unlikely.   
 
To date, there is no serological evidence of PCV2 infection in human, avian, bovine, ovine, 
caprine, and equine species (Table 3). This data supports the hypothesis that transmission of 
PCV2 to swine from other species is unlikely.  However, PCV2 has been detected by PCR 
from bovine respiratory and abortion cases (Nayar et al., 1999) and from cases of 
hemorrhagic diathesis syndrome (Kappe et al., 2010) (Table 3) indicating there remains some 
risk of cross-species infection. Serological evidence of PCV1 is inconclusive as two studies 
did not find antibodies against PCV1 in human, bovine, ovine, caprine, murine, avian, and 
lagomorphs species (Allan et al., 1994; Tischer et al., 1982) while one study reported 
evidence of exposure to PCV1 in humans, murine and bovine species (Tischer et al., 1995) 
(Table 3). 
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In summary, limited information is present on the transmission of PCV2 through indirect 
routes including the oral and aerosol routes and little (bovine, ovine, lagomorphs, murine 
species) or no work (avian) has been done to date to directly evaluate transmission of PCV2 
between porcine and other species. Of the available information, only the murine species 
seems to support PCV2 replication making this species a potential for horizontal transmission 
of PCV2.   
 
SUMMARY 
It is well documented that PCV2 is a ubiquitous virus based on serological and viremia data 
from countries worldwide.  In addition, PCV2 DNA has been discovered in archived samples 
prior to the first reports of clinical disease and a shift in PCV2 subtype has occurred 
worldwide.  Following both natural and experimental infection of naïve animals with PCV2, 
PCV2 DNA has been detected in multiple sample types; however, limited information on the 
amount of PCV2 present is available and it is unknown whether the detected PCV2 DNA is 
infectious.  Relatively few studies have evaluated the stability of PCV2 in the environment; 
however, the results indicate that the virus is very resistant to high temperatures and a wide 
range of pH.  In addition, disinfectants have been shown to have variable efficacy against 
PCV2.   Previous studies have documented that transmission of PCV2 occurs by direct or 
nose-to-nose contact with infected animals and limited evidence to date also suggests that 
transmission through indirect contact is possible.  
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Table 1.  Initial seroprevalence of porcine circovirus (PCV) prior to differentiation of PCV1 and PCV2 
between 1986-1995. 
Country Sample
# 
Pig type Location Farm# Percentage Assay Year Reference 
Germany  269 Slaughter 
animals 
Northern 
Germany 
NA
a
 84% IFA
b
 
 
1986 
 
Tischer et 
al. 
6 Wild boars Berlin NA 62% 
6 Breeding 
animals 
Berlin 1 83% 
Canada 
 
18 Conventional NP
c
 1 55% IFA 
 
1989 
 
Dulac and 
Afshar 
120 Cull sows NP NA 26% 
27 SPF research 
herd 
NP 1 0% 
England 87 Porcine 
serum 
submitted to 
a diagnostic 
laboratory 
NP 44 86% IPMA
d
 1994 Edwards 
and Sands 
USA 328 Conventional Georgia 11 51% IFA 
 
1995 Hines and 
Lukert 40 Conventional North 
Carolina 
1 60% 
20 Conventional Iowa 1 55% 
a
NA, not applicable 
b
IFA, immunofluorescent assay 
c
NP, not provided Timeline of first identification of PCV2 in conventional pigs in various countries as part of retrospective 
analyses by immunoperoxidase monolayer assay (IPMA), immunofluorescent assay (IFA), immunohistochemistry (IHC), 
polymerase chain reaction (PCR) or in-situ hybridization (ISH). 
 
d
IPMA, immunoperoxidase monolayer assay 
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Table 2.  Porcine circovirus type 2 (PCV2) detection separated by countries/continents 
by serological, molecular or antigen-based assays  
Continent Country Reference 
Asia China Wen et al., 2005  
 Indonesia Manokaran et al., 2008  
 Japan Onuki et al., 1999  
 Korea Choi et al., 2000  
 Philippines Maldonado et al., 2004  
 Taiwan Chang et al., 2002  
 Thailand Tantilertcharoen et al., 1999  
Europe Austria Schmoll et al., 2002  
 Belgium Labarque et al., 2000  
 Bulgaria Motovski et al. ,2004  
 Croatia Jemeršić et al., 2004  
 Czech Republic Celera et al., 2002  
 Denmark Allan et al., 1999  
 France LeCann et al., 1997  
 Germany Hinrichs et al., 1999  
 Greece Kyriakis et al., 2001  
 Hungary Kiss et al., 2000  
 Ireland Spillane et al., 1998; Kennedy et al., 1998  
 Netherlands Wellenberg et al., 2000  
 Poland Podgorska et al., 2009  
 Romania Cadar et al., 2006  
 Scotland Thomson et al., 2000  
 Slovakia Pistl et al., 2009  
 Spain Segalés et al., 1997  
 Sweden Wattrang et al., 2002  
 Switzerland Borel et al., 2001  
 United Kingdom Done et al., 2001  
North America Canada Harding et al., 1998  
 Costa Rica Liu et al., 2002  
 Cuba Peréz et al., 2009  
 Mexico Trujano et al., 2001  
 United States Daft et al., 1996  
Oceania Australia Muhling et al., 2006  
 New Zealand Kok-Mun et al., 2003  
South America Brazil Castro et al., 2003  
 Venezuela Cano et al., 2005  
 Argentina Machuca et al., 2000; Sarradell et al., 2002  
   
   
 
  
 
Table 3:  Prevalence of porcine circovirus (PCV) in species other than porcine. 
Reference 
PCV 
type 
Testing 
method
a
 
Sample information Sample type Species tested 
No. samples 
positive/Total no. 
samples tested 
Tischer et al., 
1982 
PCV1 Not provided Specific information on sample 
source not provided 
Serum Bovine, murine, 
human, lagomorph 
0/not provided 
Allan et al., 
1994 
PCV1 IFA Specific information on sample 
source not provided 
Serum Ovine  0/200 
Bovine  0/350 
Avian (Turkey, 
duck and chicken) 
0/600 
Human  0/200 
Murine  0/50 
Lagomorph  0/60 
Caprine  0/150 
Tischer et al., 
1995 
PCV1 IFA Healthy persons, blood donors and 
hospitalized patients 
Serum Human  189/1149 
Three strains of mice Serum Murine  37/120 
Slaughter house serum from 3 
different groups of animals 
Serum Bovine 35/90 
Nayar et al., 
1999 
PCV2 PCR Bovine respiratory disease case 
submissions 
Lung Bovine  6/100 
Bovine abortion case submissions Fetal 
lung/thymus 
Bovine  4/30 
Allan et al., 
2000 
PCV2 IFA 40 herds Serum Bovine 0/185 
10 farms (cattle had contact with 
swine) 
Serum Bovine 0/120 
14 flocks  Serum Ovine 0/120 
 Healthy humans Serum Human 0/120 
       
  
5
8
 
  
a
Testing methods:  IFA = immunofluorescent assay, PCR = polymerase chain reaction, cELISA = competitive enzyme linked 
immunosorbent assay, ISH = in-situ hybridization, IPMA = immunoperoxidase monolayer assay, IHC = immunohistochemistry
Table 3:  (Continued) 
Reference 
PCV 
type 
Testing 
method
a
 
Sample information Sample type Species tested 
No. samples 
positive/Total no. 
samples tested 
Ellis et al., 2000 PCV2 
and 
PCV1 
cELISA and 
Whole-cell 
ELISA 
High-risk population of swine 
veterinarians (n=56) and healthy 
blood donors (n=33) 
Serum Human 0/89 
Ellis et al., 2001 PCV2 cELISA 
IPMA 
cELISA 
Beef and dairy case submissions 
from 42 farms or feedlots 
Serum Bovine 0/100 
Case submissions from 
multiparous dairy cows from 53 
farms 
Colostrum Bovine 0/100 
Case submissions  Serum Equine  0/100 
Rodríguez-
Arrioja  et al., 
2003a 
PCV2 ISH  Case submissions  Lymphoid 
tissue and/or 
lung 
Bovine 0/26 
Ovine 0/24 
Caprine 0/8 
Equine 0/7 
Canine 0/21 
Lagomorph 0/15 
Rodent (Guinea 
pigs) 
0/3 
Avian 0/20 
IPMA Case submissions Serum Bovine 0/20 
Caprine 0/20 
Equine 0/21 
Canine 0/13 
Feline 0/15 
Rodent (mice) 0/73 
Kappe et al., 
2010 
PCV2 PCR Case submissions of fatal 
hemorrhagic diathesis syndrome 
(HDS)  
Tissue Bovine 5/25 
Non-HDS cases submissions  Bovine 1/8 
IHC HDS cases submissions Tissue Bovine  1/8 5
9
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Fig. 1. Timeline of first identification of PCV2 in conventional pigs in various countries as 
part of retrospective analyses by immunoperoxidase monolayer assay (IPMA), 
immunofluorescent assay (IFA), immunohistochemistry (IHC), polymerase chain reaction 
(PCR) or in-situ hybridization (ISH). 
 
 
  
Northern Germany:  PCV2 DNA 
detected by ISH and PCR from pig 
tissues (Jacobsen et al., 2009) 
1962 
Brazil:  PCV2 DNA 
and antigen detected by 
PCR and IHC in 
formalin-fixed, paraffin-
embedded tissues from 
pigs (Ciacci-Zanella et 
al., 2006) 
Japan:  PCV2 DNA 
detected by PCR on 
formalin-fixed, paraffin-
embedded lymph nodes 
(Hasegawa et al., 2001) 
1988 
Canada:  PCV2 
detected by IFA on 
serum samples collected 
from slaughterhouse 
sows (Magar et al., 
2000b) 
Spain: PCV2 DNA 
detected by ISH in 
archived formalin-fixed, 
paraffin-embedded 
tissues (Rodríguez-
Arrioja et al., 2003b) 
1985 
Mexico: PCV2 detected by IPMA 
from serum samples (Ramírez-
Mendoza et al., 2009) 
Northern Ireland: PCV2 detected by 
competitive ELISA on serum samples 
collected from commercial herds 
(Walker et al., 2000) 
1973 
Belgium:   PCV2 detected by IMPA in 
serum collected from sows in slaughter 
houses (Sanchez et al., 2001) 
1969
  
United Kingdom:  
PCV2 DNA detected 
by PCR from DNA 
extracted from archived 
paraffin wax-embedded 
tissue blocks (Grierson 
et al., 2004) 
 
1970
 
197 
Switzerland: PCV2 antigen detected 
by IHC on paraffin-embedded 
lymphoid tissues from pigs (Staebler 
et al., 2005) 
 
1986 
Thailand: PCV2 DNA detected by 
PCR in paraffin-embedded tissues 
(Kiatipattanasakul-Banlunara et al., 
2002) 
1993 
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CHAPTER  3.  Comparison of three enzyme-linked immunosorbent assays to detect 
porcine circovirus-2 (PCV-2)-specific antibodies after vaccination or inoculation of pigs 
with distinct PCV-1 or PCV-2 isolates 
 
A paper published in the Journal of Veterinary Diagnostic Investigation 
 
Abby R. Patterson, John Johnson, Sheela Ramamoorthy, Xiang-Jin Meng, Patrick G. Halbur, 
Tanja Opriessnig 
 
ABSTRACT 
 
Porcine circovirus type 2 (PCV2) serology is frequently used to determine PCV2 
status and optimal timing of PCV2 vaccination in the field. The objectives of the current 
study were to determine the diagnostic accuracy of 3 currently available commercial anti-
immunoglobulin G (IgG)–PCV2 enzyme-linked immunosorbent assays (ELISAs) and to 
compare the ability of the 3 assays to detect and differentiate between anti–PCV2a and anti–
PCV2b antibodies as well as anti–PCV2 and anti–PCV1 antibodies.  Fifty-five, 3-week-old, 
conventional pigs were randomly allocated to 7 groups: 1) negative controls (n = 7); 2) 
PCV2a (n = 8; inoculated with PCV2 ISU-40895); 3) PCV2b (n = 8; inoculated with PCV2 
NC-16845); 4) PCV1 (n = 8); 5) vaccine A (n = 8; Ingelvac
®
 CircoFLEX
™
); 6) vaccine B (n 
= 8; Circumvent
®
 PCV2); and 7) vaccine C (n = 8; Suvaxyn
®
 PCV2 One Dose). Blood 
samples were collected weekly, and all sera were tested by 3 different anti–PCV2–IgG 
ELISAs. The results indicated that all ELISAs had area under the receiver operating curve 
values greater than 0.94, detected both anti–PCV2a and -2b antibodies with no 
differentiation, and did not detect anti–PCV1 antibodies in infected animals. One of the 
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ELISAs was able to distinguish pigs vaccinated with vaccine B from pigs inoculated with 
either PCV2a or PCV2b.  
 
Key words: Antibodies; enzyme-linked immunosorbent assay; Porcine circovirus 
type 2; serology; vaccination. 
 
INTRODUCTION 
 
Porcine circovirus (PCV; family Circoviridae; genus Circovirus) was first identified 
as a contaminant of the permanent porcine kidney cell line PK-15 in 1974.
26
 The virus is 
nonenveloped and comprised of a single-stranded, circular DNA genome. Two major types 
of PCV have been identified, PCV type 1 (PCV1) and type 2 (PCV2).
19
 PCV1 has been 
shown to be nonpathogenic in pigs under experimental conditions.
1,27
 In contrast, infection 
with PCV2 has been associated with respiratory disease, enteritis, reproductive failure, 
porcine dermatitis and nephropathy syndrome (PDNS), and systemic infections, which are 
known as porcine circovirus associated disease or PCVAD.
22
 While the pathogenesis of 
PCVAD remains unclear, it can result in high levels of PCV2 viremia in 5–30% of a swine 
population. In affected animals, mortality can reach 70–80%.22  
Based on sequence analyses of PCV2, type 2 can be further divided into 2 main 
phylogenetic clusters, PCV2a and PCV2b.
5
 The PCV2 genome is comprised of 2 known 
open reading frames (ORFs) that code for functional proteins. The ORF1 gene encodes for a 
replication-associated protein (Rep), which is essential for virus replication.
4
 The ORF2 gene 
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encodes for the capsid protein, which has been shown to be immunogenic 
20,21
 and which has 
a greater nucleotide variation than ORF1.
15
  
Several commercial PCV2 vaccines became available in North America in 2006. As 
of January 2008, 3 products are fully licensed and available in the United States for use in 
healthy pigs. Two of the vaccines contain the PCV2 capsid protein expressed in a 
baculovirus (BA) system as an antigen
6,8
 The third vaccine is comprised of an inactivated 
PCV1–2 chimera virus.7 Other notable differences between the 3 vaccines include the dose 
and timing of administration: 2-ml versus 1-ml injections, and one time administration versus 
booster vaccination.
22
 
The release of PCV2 vaccines provides an impetus for assessing the PCV2 status of 
herds in order to determine the best time for vaccination. One method of assessing when and 
if PCV2 is circulating in a herd is to conduct a cross-sectional serological survey to 
determine the prevalence and levels of anti–PCV2 antibodies over time using one or more of 
the serological tests for PCV2 including various ELISAs.
3,16,20,25,29,30
 Most ELISA tests use 
the ORF2 region as antigen since it is specific and immunogenic for PCV2.
28
 Although most 
assays are based on PCV2 ORF2, the methods of antigen production differ among assays. 
Specifically, antigen has been produced by expression of the capsid protein in a BA vector 
system,
3,16,20
 in live virus preparations in PK-15 cells,
29
 or through expression in Escherichia 
coli.
25,30
 While reports indicate that ELISAs based on the ORF2 region of PCV2 are useful, a 
direct comparison of the diagnostic accuracy of currently available ELISAs has not yet been 
performed to the authors’ knowledge. Additionally, reports on the ability of the assays to 
detect and differentiate between anti–PCV2a, anti–PCV2b, or vaccine-induced antibodies are 
lacking. 
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To address the gaps in knowledge on current PCV2 ELISAs, the current study had the 
following objectives: (1) to determine the diagnostic accuracy of 3 commonly used ELISAs, 
(2) to determine whether each assay can detect and/or differentiate between anti–PCV2a and 
anti–PCV2b antibodies, and (3) to determine whether PCV2–based ELISAs can detect anti–
PCV1 antibodies.  
 
 
MATERIALS AND METHODS 
 
Animals and housing 
Animals were purchased from a PCV2–negative herd, weaned at 2 weeks of age, and 
transported to the Livestock Infectious Disease Isolation Facility at Iowa State University 
(Ames, IA). On the day of delivery, the pigs were randomly assigned to 1 of 7 rooms, each 
containing a 1.2 × 2.4 m raised wire deck pen equipped with 1 nipple drinker and 1 self-
feeder.  
Experimental design 
Three-week-old, conventional pigs were randomly allocated to 7 groups and 
inoculated with either PCV1, PCV2a, or PCV2b, vaccinated with commercially available 
PCV2 vaccines, or left as negative controls as follows: 1) negative controls (n = 7); 2) 
PCV2a (n = 8); 3) PCV2b (n = 8); 4) PCV1 (n = 8); 5) vaccine A (n = 8); 6) vaccine B (n = 
8); and 7) vaccine C (n = 8). Upon arrival, pigs were bled and serum was tested by 
quantitative real-time PCV2 polymerase chain reaction (PCR)
23
 to detect PCV2 DNA and by 
a PCV2 fluorescent antibody test (FAT)
 24
 to detect anti-PCV2 antibody. The experimental 
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inoculations and vaccinations were performed on trial day 0 at which time the pigs were 3 
weeks of age. All pigs were bled at weekly intervals until trial day 49. All serum samples 
were tested by 3 different ELISAs, and results were compared. The experimental protocol 
was approved by the Iowa State University Institutional Animal Care and Use Committee. 
Inoculation 
On trial day 0, pigs in the PCV2a, PCV2b, and PCV1 groups were inoculated with 2 
ml intramuscularly (IM) and 3 ml intranasally of 10
4.5
 50% tissue culture infective dose 
(TCID50)/ml of the appropriate virus inoculum. Animals were inoculated with the following 
vaccines: PCV2a group (ISU-40895; GenBank accession number AF264042); PCV2b group 
(NC-16845; GenBank accession number EU340258); and PCV1 group (well-characterized 
PCV1 clone).
7
 To confirm that the pigs in the PCV1 group were infected with PCV1, serum 
samples were analyzed by PCR for PCV1 DNA.
13
 To confirm that PCV2–inoculated pigs 
were infected, serum samples from all pigs were tested by PCR for PCV2 DNA.
23
 
Additionally, a PCR product recovered on trial day 49 from a PCV2a– and a PCV2b–
inoculated pig was sequenced and compared to the respective inoculum. 
Vaccination 
Pigs in vaccine groups A, B, and C were each vaccinated with the respective vaccines 
according to the recommendations of the manufacturers. Briefly, animals in the vaccine A 
group (Ingelvac® CircoFLEX™,a) received a 1-ml IM injection on trial day 0. Pigs in the 
vaccine B group (Circumvent® PCV
b
) received a 2-ml IM injection on day 0 and a second 2-
ml IM injection on day 14. Pigs in the vaccine C group (Suvaxyn® PCV2 One Dose
c
) 
received a 2-ml IM injection on trial day 0. 
Serology 
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All serum samples collected from the pigs over time were tested by a previously 
described indirect PCV2 FAT
24
 and each of the following 3 ELISAs: 
ELISA 1. This in-house, modified, indirect PCV2 ELISA was performed as 
previously described.
20
 For this assay, alternating rows on the ELISA plate were coated with 
an ORF2 antigen (expressed in a BA expression vector) or a BA antigen (BA expression 
vector without the PCV2a ORF2 insert). The PCV2 isolate used for antigen production, ISU-
31 (GenBank accession number AJ223185) had 99% similarity to the PCV2a isolate used for 
inoculation. The following modifications were made to the previously described protocol: 
following incubation, the plates were washed 5 times with 0.1 M of phosphate buffered 
saline (PBS
d
; pH 7.2) and 0.1% Tween 20
e
 using a microplate washer. For visualization of 
results, 100 µl of 3,3’,5,5’-tetramethylbenzidinef was added to the wells. Following a 15-min 
incubation at 25°C, the reaction was stopped by adding 50 µl of 1 M H2SO4. Results were 
reported as sample-to-positive (S/P) ratios. All samples were run in duplicate. 
Initially, a corrected optical density (OD) value was calculated for the 2 replicates of 
each sample and the positive control: [(ORF2 OD + ORF2 OD)/2] – [(BA OD + BA OD)/2], 
where ORF2 is ORF2 antigen, and OD is optical density value at 450 nm. To generate the 
S/P ratio, the sample-corrected OD was divided by the positive control–corrected OD20; S/P 
ratios <0.2 were considered negative, and S/P ratios ≥0.2 were considered positive. The 
previously determined diagnostic sensitivity and specificity of this method using a 0.2 cut-off 
were 79.9% and 99.6%, respectively.
20
 
ELISA 2. This commercially available competitive ELISA (Serelisa® PCV2 Ab 
Mono Blocking
g) was preformed according to manufacturer’s recommendations. The plates 
provided by the manufacturer were coated with purified PCV2 antigen. Results were reported 
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as an OD ratio of the sample OD value to the negative control OD value. A plate-specific 
cut-off was used such that samples with OD ratios ≤0.15 were considered positive, samples 
with an OD ratio of 0.15–0.20 were considered suspect, and samples with an OD ratio ≥0.20 
were considered negative as recommended by the manufacturer. 
ELISA 3. This commercially available capture PCV2 ELISA (Ingezim Circovirus 
IgG
h
)
 was also preformed according to manufacturer’s recommendations. The plates 
provided in the assay came coated with monoclonal antibodies specific for swine IgG. The 
antigen provided in the assay was a recombinant PCV2b protein produced through 
expression in a BA vector (Jacques Delbecque, personal communication, 3/5/08). Results 
were reported as an OD ratio of the sample OD value to the positive-control OD value. The 
plate-specific cut-off was based on the OD 450 nm value of the positive control × 0.3 as 
recommended by the manufacturer. 
Statistics 
Diagnostic accuracy of each assay was evaluated using receiver operating 
characteristic (ROC) analysis. This method results in area under the ROC curve (AUC) 
values ranging from 0.5 to 1, where 0.5 indicates the test is not discriminating between 
positive and negative animals and 1 indicates perfect discrimination.
31
 Area under the ROC 
values were compared pairwise between tests using a previously described method.
11
 All 
ROC calculations were preformed on continuous data with infection status as the indicator of 
true infection status using MedCalc.
i
 Summary statistics were calculated for all groups to 
assess the overall quality of the data including normality. Continuous data was analyzed 
using multivariate analysis of variance (MANOVA). If a significant (P < 0.05) change over 
time was noted for the outcome variable, a nonparametric Kruskal-Wallis 1-way analysis of 
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variance (ANOVA) was performed at each time point. If this nonparametric ANOVA test 
was significant (P < 0.05), then pairwise Wilcoxon tests were used to assess differences 
between groups. Statistical analysis was performed using JMP software.
j
 
 
RESULTS 
Diagnostic accuracy of assays 
All assays had AUC values greater than or equal to 0.94 for all trial days using ROC 
generated optimal cut-offs; no statistical differences were noted among the assays (Table 1). 
When data was dichotomized using the manufacturer’s recommended cut-off values (suspect 
samples were considered negative), the sensitivity of all 3 assays was substantially reduced at 
trial day 14 (Table 2). In contrast, the specificity of ELISAs 2 and 3 was improved.  When 
the manufacturer’s recommended cut-off was utilized at trial day 49, the sensitivity of 
ELISAs 2 and 3 was substantially reduced (Table 2).  The number of pigs classified as 
positive or negative based on a sample-to-positive ratios of 0.2 (ELISA 1) or the 
manufacturer’s recommendations (ELISA 2 and 3) by the 3 ELISAs at trial days 14 and 49 is 
presented in Table 3. 
Detection of PCV2a and PCV2b  
Infection status for PCV2a and PCV2b groups was confirmed by PCR and sequence 
analysis (Opriessnig T, Ramamoorthy S, Madson DM, et al.: 2007, Experimental comparison 
of the virulence of PCV2a and PCV2b isolates in a conventional pig model.  Proc Conf Res 
Workers Anim Dis 88:145). To assess whether PCV2a could be differentiated from PCV2b 
on any of the 3 ELISAs, the following null hypothesis was tested: there is no difference 
between PCV2a and PCV2b ELISA S/P or OD values on ELISAs 1, 2, or 3. Statistical 
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analysis using a Wilks’ lambda multivariate test indicated a significant (P < 0.0001) 
difference over time between control, PCV2a and PCV2b groups. A nonparametric ANOVA 
at each time point revealed a significant difference between negative controls, PCV2a and 
PCV2b groups (P < 0.05) for all tests. Further analysis using pairwise Wilcoxon tests 
indicated that no significant differences were noted between PCV2a and PCV2b groups on 
any of the assays (Fig. 1).  
Detection of PCV1 
 Serum samples from pigs in the PCV1 group were positive for PCV1 DNA by PCR 
starting on trial day 7 (data not shown). No positive reactions were detected in serum samples 
from PCV1–inoculated animals on any of the 3 ELISAs at any time during the trial (data not 
shown).  
Detection of antibodies in vaccinated animals 
Mean and standard error S/P and OD ratios for each group are provided in Figure 2. 
Results from ELISA 1 indicated that animals in the vaccine A group had significantly lower 
mean S/P ratios in comparison to PCV2a– and PCV2b–inoculated animals from trial days 
14– 49 (P < 0.0005 for all days; Fig. 2a). Animals in the vaccine B group also had 
significantly lower mean S/P ratios from trial days 28–49 (P < 0.03 for all days) in 
comparison to PCV2–inoculated animals. In contrast, animals in the vaccine C group had a 
significantly (P = 0.01) higher mean S/P ratio at trial day 28 in comparison to PCV2–
inoculated animals (Fig. 2a). In contrast to ELISA 1, no significant difference was noted 
between animals in either the vaccine A or B group and the PCV2–inoculated animals based 
on ELISA 2 (P > 0.05 for all days; Fig. 2b). Animals in the vaccine C group had a 
significantly lower (more positive) OD ratio than that in challenged animals at trial day 28 
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and 35 (P < 0.008 for both days; Fig. 2b). Results from ELISA 3 were similar to ELISA 1 
(Fig. 2c); animals in the vaccine A group had significantly lower mean OD ratios in 
comparison to PCV2–inoculated animals at trial days 14–49 (P < 0.0006 for all days). 
Following comparative analysis of the S/P values of vaccinated and PCV2–inoculated 
animals on ELISA 1, an S/P ratio decrease in the vaccine B group from trial days 21–28 was 
noted. Further analysis at trial day 21 revealed that in comparison to PCV2a– and PCV2b–
inoculated pigs, the OD values of the wells containing BA antigen were significantly higher 
(P = 0.0006) in the vaccine B group. This significant increase in OD values of the BA wells 
for the vaccine B group was apparent through the end of the trial (P < 0.0001 for trial days 
28–49). The effect of an increase in OD values in the BA wells on the S/P ratio is illustrated 
graphically in Figure 3. Optical density values of the BA wells for all groups except the 
vaccine B group were indistinguishable from background levels (data not shown). A similar 
increase in OD values of the BA wells was not noted on any trial days in the vaccine A or C 
group or with ELISA 2 and 3. 
 
DISCUSSION 
 
Receiver operating characteristic analysis has become an increasingly valuable tool 
for comparison of diagnostic tests.
9,32
 Unlike the kappa statistic, ROC analysis determines the 
sensitivity and specificity of the test based on classification of true status (infected vs. 
negative controls in the current study) at multiple cut-offs by utilizing the complete set of 
continuous data.
9
 Interestingly, when the 3 ELISAs were compared by ROC analysis, AUC 
values were very high (>0.9). This indicated that all tests were able to distinguish between 
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negative and positive animals using ROC analysis generated optimal cut-offs (cut-offs that 
provide the highest sensitivity and specificity) based on continuous data from the experiment. 
In contrast, when the manufacturer’s cut-off values were used, sensitivity was substantially 
reduced. While the current study was limited by a small sample size, ROC analysis data 
suggests that altering the cut-off value will increase the sensitivity of ELISAs 2 and 3. 
Further studies with larger sample sizes are necessary to determine an appropriate cut-off. 
The manufacturers’ sensitivity and specificity for ELISAs 2 and 3 at the recommended cut-
offs were not indicated on the package insert and could not be compared to the results in the 
present study. 
As the majority of herds worldwide are seropositive for PCV2, ELISAs are most 
commonly used in cross-sectional analyses to target optimal timing of vaccination. Recent 
trends indicate an increased incidence of detection of PCV2b isolates and the association of 
these strains with high mortality in herds with increased incidence of severe mortality in 
swine populations.
5,12
 This has stimulated interest in the use of serological tests to monitor 
PCV2b. As such, there is a need to know whether commonly used ELISAs are detecting both 
anti–PCV2a and anti–PCV2b antibodies. Results of the current study indicate that all 3 
ELISAs can detect both antibodies but cannot differentiate between anti–PCV2a and anti–
PCV2b antibodies. This was independent of the origin of the coating antigen used since at 
least one assay used PCV2a (ELISA 1) and one assay used PCV2b (ELISA 3) for antigen 
production. 
Nucleotide sequence homology between PCV1 and PCV2 ranges from 69% to 
79.5%.
10,18,19
 A previous report indicated that there was no serological cross-reactivity 
between the ORF2 region of PCV2 and PCV1,
17
 or between PCV1 and PCV2 polyclonal 
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antisera and monoclonal antibodies using an indirect FAT.
2
 Conversely, ORF1 regions of 
PCV2 do exhibit serological cross-reactivity with PCV1.
17
 Results of the current study 
confirm previous reports and indicate that PCV1–inoculated animals were not detected with 
any of the ELISAs evaluated. Although the PCV1–inoculated animals were found to be 
PCV1–positive by PCR, an anti–PCV1 ELISA assay was not available to confirm the 
presence of anti–PCV1 antibodies in these animals. 
Following the introduction of vaccines into the U.S. market in 2006, the prevalence of 
seropositive animals has grown steadily. Therefore, an assay able to differentiate vaccinated 
and naturally infected animals would provide a useful tool for veterinary practitioners in 
situations where they are assessing vaccination protocol compliance issues. Although 
distinguishing vaccinated animals on the basis of either an S/P or OD ratio would not be 
possible based on the results of the current study, using the OD value of the BA well on 
ELISA 1 may provide a means of differentiation for vaccine B. In contrast to the other 2 
ELISAs, ELISA 1 utilizes BA derived from a baculovirus expression vector that does not 
contain the PCV2 ORF2 insert to control for nonspecific background binding.
20
 Serum 
samples from both vaccine A and B group pigs were expected to have increased OD values 
for the BA wells as both products utilize the baculovirus expression vector for antigen 
production. Interesting, only the serum samples from the vaccine B group showed a 
significant increase in OD value in the BA well. As the increase in OD value of the BA well 
occurred following the administration of the second dose of vaccine B, it can be speculated 
that 2 doses of vaccine A may lead to the same response as seen with vaccine B. 
Alternatively, differences in vaccine preparation or type of adjuvant between the 2 products 
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may account for the lack of cross-reactivity in BA well OD values of animals in the vaccine 
A group. 
While providing a means of differentiating vaccinated and naturally infected animals, 
significant increases in OD values alone should be interpreted carefully as results could be 
confounded by vaccination with other products in which the baculovirus vector is utilized, 
serum factors other than antibodies against BA, or other unknown nonspecific reactions.  
These nonspecific reactions could falsely elevate the OD value. As an S/P ratio is not 
generated when looking at the individual OD value from the BA well, no control for this is in 
place with the current assay.  
The lack of increase of the S/P ratio in ELISA 1 for vaccine B group cannot be 
interpreted as a lack of seroconversion because a high OD value for the BA could be 
lowering the S/P ratio. Therefore, the OD value for the BA well should be observed in 
addition to the S/P ratio or one of the other 2 assays should be utilized to assess 
seroconversion with this product. Reasons for the decreased average OD on ELISA 3 for the 
vaccine A group may include vaccine preparation, type of adjuvant, or dose of 
administration. It should be noted that while antibody levels following vaccination were 
determined in the current study, there was no challenge of animals. Therefore, the ability of 
vaccination to protect against disease was not evaluated in this trial.  
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Table 1. Area under the receiver operating curve (AUC) values (±standard error) for each of 
the 3 enzyme-linked immunosorbent assays (ELISAs) on different trial days.* 
Assay 
Trial day 
14 21 28 35 42 49 
ELISA 1 0.94±0.03
 
0.99±0.01 1.00±0.00 1.00±0.00 1.00±0.00 1.00±0.00 
ELISA 2 0.97±0.03 1.00±0.00 1.00±0.00 1.00±0.00 1.00±0.00 1.00±0.00 
ELISA 3 0.96±0.03 0.99±0.01 1.00±0.00 1.00±0.00 1.00±0.00 1.00±0.00 
IFA 0.98±0.02 1.00±0.00 0.96±0.02 1.00±0.00 1.00±0.00 0.99±0.01 
* Receiver operating characteristic analysis was preformed by denoting Porcine circovirus 2 
subtype a (PCV2a), PCV2b, vaccine A, vaccine B, and vaccine C pigs as “true positive” (n = 
40) and negative controls and PCV1 as “true negative” animals (n = 15). AUC values range 
from 0.5 to 1, where 1 indicates the diagnostic test would perfectly discriminate between 
PCV2–positive and –negative pigs when using a given sample, and 0.5 indicates there is no 
discrimination between groups. 
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Table 2. Comparison of sensitivity and specificity of each of the 3 enzyme-linked 
immunosorbent assays (ELISAs) at trial days 14 and 49 using various cut-offs for data 
dichotomization. 
Assay 
Trial day 14 Trial day 49 
Cut-off 
Sensitivity 
(%) 
Specificity 
(%) Cut-off 
Sensitivity 
(%) 
Specificity 
(%) 
ELISA 1 0.03* 87.5 100 0.34 100 100 
0.20† 45 100 0.20 100 100 
ELISA 2 0.52* 97.5 93.3 0.25 100 100 
0.15‡ 22.5 100 0.15 57.5 100 
ELISA 3 0.10* 85 93.3 0.15 100 100 
0.45§ 30 100 0.45 75 100 
* Cut-off determined by receiver operating characteristic (ROC) analysis. 
† Cut-off determined from previous in-house data on test performance. 
‡ Cut-off determined by generating an optical density (OD) ratio by dividing the average 
sample OD value by the average OD value of the negative control well; an OD ratio ≤0.15 
was considered positive as recommended by the manufacturer.  
§ Average plate cut-off. Individual plate cut-offs were determined by multiplying the average 
OD value of the positive control well by 0.3 as recommended by the manufacturer. 
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Table 3. Number of pigs classified as positive (+) or negative (–) by the 3 enzyme-linked 
immunosorbent assays (ELISAs) and a PCV2 fluorescent antibody test (FAT) at trial days 14 
and 49.* 
 
 
* For ELISA 1, data was dichotomized such that sample-to-positive ratios ≥0.2 were 
considered positive. For ELISAs 2 and 3, data was dichotomized as recommended by 
manufacturer. Suspects were considered to be negative. For the FAT, data was dichotomized 
such that titers ≥ 1:20 were considered positive.  
Assay 
Trial day 14 Trial day 49 
ELISA 2 FAT  ELISA 3 ELISA 2 FAT  ELISA 3 
(+) (–) (+) (–) (+) (–) (+) (–) (+) (–) (+) (–) 
ELISA 1             
(+) 2 9 11 0 8 3 23 17 40 0 34 6 
(–) 7 37 22 22 4 40 0 15 0 15 0 15 
ELISA 3             
(+) 3 6 13 20 - - 22 12 34 6 - - 
(–) 9 37 0 22 - - 1 20 0 15 - - 
FAT             
(+) 8 25 - - - - 23 17 - - - - 
(–) 1 21 - - - - 0 15 - - - - 
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Figure 1. Mean sample-to-positive (S/P) ratio and standard error for enzyme-linked 
immunosorbent assay (ELISA) 1 (a), and mean optical density (OD) ratio and standard error 
for ELISA 2 (b) and ELISA 3 (c). Controls (n = 7; negative controls), Porcine circovirus 
type 2 subtype a (PCV2a; n = 8; inoculated with PCV2 ISU 40895), and PCV2b (n = 8; 
inoculated with PCV2 NC 16845). 
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Figure 2. Mean sample-to-positive (S/P) ratio for enzyme-linked immunosorbent assay 
(ELISA) 1 (a), and mean optical density (OD) ratio and standard error for ELISA 2 (b) and 
ELISA 3 (c). Negative controls (n = 7), Porcine circovirus type 2  (PCV2; n = 16; combined 
PCV2a and PCV2b groups), vaccine A (n = 8), vaccine B (n = 8), and vaccine C (n = 8). 
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Figure 3. Mean and standard error sample to positive (S/P) ratio and average optical density 
for the baculovirus (BA) antigen and open reading frame 2 (ORF2) wells on enzyme-linked 
immunosorbent assay (ELISA) 1. All values are for animals in the vaccine B (n = 8) group.  
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CHAPTER 4.   Shedding and infection dynamics of porcine circovirus type 2 (PCV2) in 
pigs naturally or experimentally infected 
 
A paper submitted to Veterinary Microbiology  
 
A.R. Patterson, N.M. Juhan, D.M. Madson, X.J. Meng, P.G. Halbur and T. Opriessnig 
 
ABSTRACT 
The objective of this study was to determine the amount and infectivity of porcine 
circovirus type 2 (PCV2) shed in nasal, oral and fecal secretions following natural or 
experimental infection.  Fecal, oral and nasal swabs and serum were collected at regular 
intervals until 209 days post-farrowing (DPF) from four PCV2-naturally infected pigs (Trial 
1) or until 69 days post-inoculation (DPI) from five PCV2-experimentally inoculated pigs 
(Trial 2). To assess the infectivity of the PCV2 present in excretions, secretions, and on a 
hypodermic needle, 28 PCV2-naïve pigs were inoculated with various samples obtained from 
Trial 2 pigs (Trial 3).  In Trial 1 and 2, PCV2 DNA was detected in all sample types. There 
were no differences in the onset of virus shedding (Trial 2) or in the amount of PCV2 DNA 
present in different sample types over time (Trial 1or Trial 2). PCV2 DNA was detectable in 
sera and secretions in pigs at 209 DPF (Trial 1) and at 69 DPI (Trial 2). Intraperitoneal 
inoculation with contaminated fecal, nasal and oral samples; intranasal inoculation of nasal 
secretions; and feces fed to naïve animals resulted in viremia and seroconversion (Trial 3). 
Viremia and microscopic lesions were noted in one animal injected using a contaminated 
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needle (Trial 3). Natural or experimental PCV2 exposure results in a long term infection. 
PCV2 is shed in similar amounts by nasal, oral and fecal routes. The detected PCV2 DNA in 
Trial 2 was infectious to naïve pigs and therefore multiple routes are likely important in 
PCV2 transmission. 
 
Key words: Epidemiology, infectivity, Porcine circovirus type 2, PCV2, shedding, 
transmission  
 
INTRODUCTION 
Porcine circovirus type 2 (PCV2) is a small, non-enveloped, single-stranded DNA 
virus
 which emerged in the 1990’s as an economically important swine pathogen (Harding et 
al., 1998). While the majority of the swine population worldwide is seropositive for PCV2, 
severe clinical disease manifest as respiratory, reproductive, enteric or systemic disease 
occurs only in 5 to 30% of infected populations (Opriessnig et al., 2007). Based on the 
sequence analyses of PCV2 strains, isolates can be divided into five genotypes (PCV2a-e). 
PCV2a and PCV2b have been documented worldwide (Segalés et al., 2008), PCV2c has been 
documented only in archived samples from Denmark (Dupont et al., 2008), and PCV2d and 
PCV2e have only been identified in China to date (Wang et al., 2009). 
Molecular diagnostic tools have been used to better understand PCV2 transmission by 
detecting and quantifying PCV2 DNA in various excretions and tissues (Segalés et al., 
2005b) from naturally infected pigs with various clinical presentations. The length of PCV2 
viremia and onset of seroconversion in naturally-infected populations has also been 
investigated from 6 through 25 weeks of age (Carasova et al., 2007) and the authors found 
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that anti-PCV2 IgM appeared first at 8 weeks of age followed by anti-PCV2 IgG which 
appeared at 10 weeks of age. PCV2 viral load also peaked at 10 weeks of age but PCV2 
viremia was present until termination of the study (Carasova et al., 2007).  A longitudinal 
case-control study beginning at 1 week of age and extending through 8-21 weeks of age was 
conducted on farms naturally-affected by porcine circovirus associated disease (PCVAD) in 
Denmark and Spain (Grau-Roma et al., 2009) and the authors found  an increasing PCV2 
load parallel to waning of passively-acquired antibody levels. The highest PCV2 loads 
correlated with clinical signs of disease and clinically-affected pigs had a higher PCV2 
prevalence and higher PCV2 loads compared to unaffected pigs. Moreover, the amount of 
PCV2 DNA present in sera correlated well with the amount present in nasal and fecal swabs 
in these pigs (Grau-Roma et al., 2009). However, results from these observational studies of 
naturally-infected pigs may be influenced by pathogen and environmental co-factors that are 
known to increase the duration and level of PCV2 replication (Dorr et al., 2007).  
Detection of PCV2 DNA in various samples following experimental PCV2-infection 
has been reported (Bolin et al., 2001; Caprioli et al., 2006; Krakowka et al., 2000; Shibata et 
al., 2003); however,  little is known about the amount of PCV2 DNA shed within secretions 
or whether the PCV2 DNA detected by PCR remains infectious. In one study, 5-week-old 
colostrum-deprived (CD) pigs were oronasally inoculated with PCV2 and PCV2 DNA was 
detected in fecal and tonsillar swabs from 1 to 21 days post-inoculation; however, PCV2 
DNA was not detected in serum, plasma or whole blood until 9 DPI (Caprioli et al., 2006). 
Similarly, PCV2 DNA was detected in oropharyngeal and nasal swabs, feces and sera in CD 
pigs intranasally-inoculated with PCV2 from 1 to 70 DPI (Shibata et al., 2003). In another 
study, in order to determine tissue distribution of PCV2 DNA and duration of viral 
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persistence, cesarean-derived, colostrum-deprived (CDCD) pigs were intranasally and 
subcutaneously inoculated with PCV2. PCV2 DNA was detected by PCR from all tissues 
examined including brain, lymphoid tissue, bone marrow, kidney, ileum, liver, heart, lung, 
spleen, thymus, tonsil and pancreas on 20 and 28 DPI (Bolin et al., 2001). The length of 
PCV2 persistence in different organs varied; however, at 125 DPI, virus was only detected in 
spleen and distal ileum (Bolin et al., 2001).  
With numerous routes of virus shedding and persistence of virus in multiple tissues, 
both direct contact with infected animals and indirect contact through exposure to secretions 
or contaminated fomites are likely routes of PCV2 transmission. Naïve contact pigs exposed 
to experimentally-infected pigs at 42 DPI seroconverted 21 days post-exposure indicating 
that the experimentally-infected pigs remained infectious until at least 42 DPI (Bolin et al., 
2001). Similarly, PCV2-naïve contact animals were comingled with 5-to-9 week old SPF or 
conventional pigs immediately following experimental PCV2 inoculation and 90% of the 
contact animals (10 of 11 pigs) developed clinical PCVAD (Albina et al., 2001). When 
experimentally-PCV2-infected pigs were co-mingled with naïve contact pigs (within pen) or 
placed in a separate pen in the same room (between-pen), transmission (as evidenced by 
viremia and seroconversion) occurred most efficiently when naïve animals were mixed with 
infected pigs between 11 and 18 days post-infection.  Comingling at 25, 32 and 39 days post 
infection resulted in fewer primary infections indicating decreased transmission (Andraud et 
al., 2008).  
To our knowledge, a detailed investigation of the infection dynamics in segregated 
early weaned, PCV2-positive or naïve pigs experimentally-infected with PCV2 without 
coinfection with porcine reproductive and respiratory virus (PRRSV), swine influenza virus 
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(SIV) or parvovirus (PPV) has not been reported to date. The objectives of this study were to 
determine and compare the amount of PCV2 shedding in nasal, oral and fecal secretions 
following natural (Trial 1) or experimental (Trial 2) PCV2 infection and to determine the 
infectivity of the PCV2 DNA detected in excretions, secretions or on the surface of a 
mechanical vector (needle) (Trial 3). 
 
MATERIALS AND METHODS 
2.1 Experimental Design  
The experimental protocol for all studies was approved by the Iowa State University 
Institutional Animal Care and Use Committee (study #10-07-6441-S). The experimental 
design is summarized in Table 1. The pigs used for experimental inoculation were purchased 
from different herds routinely tested for major swine pathogens and known to be free of 
PRRSV, SIV and PPV. The pigs were weaned at three weeks of age and transported to a 
BSL-2 animal holding facility at Iowa State University. All pigs were housed in separate 
rooms by trial and groups, respectively, with a solid concrete floor, a separate ventilation 
system, and one nipple drinker. The pigs were fed with a balanced, pelleted, complete feed 
ration free of animal proteins and antibiotics (Nature’s Made, Heartland Coop) once a day. 
All samples collected during the experiments were tested for the presence of PCV2 DNA and 
anti-PCV2-antibodies. At the termination of each trial, the animals were humanely 
euthanized. 
2.1.1. Trial 1 (Naturally PCV2-infected pigs) 
At arrival in the research facility, the pigs for Trial 1 (n=4) were PCV2 positive as 
evidenced by the presence of PCV2 DNA and anti-PCV2-antibodies in serum at 13 DPF. The 
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pigs originated from 4 litters. The litters were selected based on high amounts of PCV2 DNA 
in serum at 13 DPF. The dams of these pigs were also PCV2 positive (DNA and antibodies; 
data not shown); horizontal transmission cannot be confirmed or ruled out as the piglets were 
not tested immediately after birth. Sequence analysis of the open-reading frame 2 (ORF2) 
indicated that the 4 pigs were infected with PCV2b. All 4 pigs were housed in one common 
room. Nasal swabs, oral swabs, fecal swabs, serum and fecal samples were collected weekly 
for Trial 1 until termination at 209 DPF. 
2.1.2. Trial 2 (Experimentally PCV2-infected pigs)  
The pigs for Trial 2 (n=5) originated from 3 litters which were all PCV2-naïve at the 
time of PCV2 inoculation since PCV2 DNA and anti-PCV2-antibodies were not detected in 
these pigs. All 5 pigs were housed in one common room. Nasal swabs, oral swabs, fecal 
swabs, serum and fecal samples were collected daily for the first two weeks and weekly 
thereafter. In addition, all pigs were injected with sterile saline intramuscularly at each 
sample collection time and the needle was subsequently flushed in the remaining sterile 
saline which was stored for analysis. Termination of Trial 2 was at 69 DPI. 
2.1.3. Trial 3 (Bioassay) 
The pigs for Trial 3 (n=28) originated from 6 litters and were PCV2-naïve (negative 
for PCV2 DNA and anti-PCV2-antibodies) at arrival. Serum samples were collected once a 
week. The pigs were randomly divided into 8 groups and rooms: Negative controls (n=3), 
Oral-IP [pooled oral samples via intraperitoneal (IP) administration; n=3], Fecal-IP (pooled 
fecal samples IP; n=3), Nasal-IP (pooled nasal samples IP; n=3), Oral-Oral (pooled oral 
samples via oral gavage; n=3), Fecal-Oral (pooled fecal samples via feed; n=4), Nasal-Nasal 
(pooled nasal samples IN; n=4), and Needle-IM (the same needle was used to inject an 
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experimentally-infected pig followed by injection of the naïve pigs; n=3). To avoid cross-
contamination, four separate teams were responsible for inoculation and sampling procedures 
at each time point. Each team was responsible for two rooms and a change of clothes, masks, 
gloves, boots and a shower were required between rooms. Termination of Trial 3 was at 42 
DPI. 
 
2.2. Inoculation 
2.2.1 Trial 2 (Experimentally PCV2-infected pigs) 
At 21 days of age, each Trial 2 pig was inoculated with 5 ml of 10
4.0
 50% tissue 
culture infectious dose (TCID50) per ml of a PCV2b isolate NC-16845 (Genbank 
#EU340258) produced from an infectious DNA clone as previously described (Fenaux et al., 
2002). Three ml of inoculum was injected into the nares, and 2 ml was injected 
intramuscularly.   
2.2.2. Trial 3 (Bioassay)  
2.2.2.1. Inocula preparation 
All samples used for inoculation (oral and nasal swabs, feces, needles) were obtained 
from Trial 2 pigs (experimentally PCV2-infected pigs) collected at 21 DPI.  
For oral or nasal inocula, oral or nasal suspensions used for IP and IN injection 
(Oral-IP, Oral-Oral, Nasal-IP, and Nasal-Nasal groups) were prepared by vortexing the oral 
or nasal swabs for 15 sec, removing the swab and filtering the remaining solution first with a 
0.45 µm and then with a 0.2 µm syringe filter (Fisher Scientific Inc., Pittsburgh, 
Pennsylvania, USA). The log10 PCV2 genomic copies/ml in the inoculum was 7.4 for the 
Oral-IP and Oral-Oral groups, and 8.3 for the Nasal-IP and Nasal-Nasal groups.  
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For fecal inocula, pooled fecal material was used. For intraperitoneal injection 
(Fecal-IP group), a fecal suspension was prepared by mixing 2 g of feces with 12 ml of 
sterile saline solution. The mixture was vortexed for 2 min, centrifuged at 3,000 x g for 10 
min at 10°C, and the supernatant was filtered by using 0.45 and 0.2 µm syringe filters (Fisher 
Scientific Inc.). For oral inoculation (Fecal-Oral group), 17.5 g pooled fecal material/pig was 
mixed with the normal feed ration of each pig. The log10 PCV2 genomic copies/ml was 8.3 
for the Fecal-IP and Fecal-Oral groups.  
For the needle preparation, an 18 GA 1.5 inch needle was used to inject 1 ml sterile 
saline into the muscle 5 cm distal to the base of the ear of a PCV2 viremic Trial 2 pig at 21 
DPI. After usage, the needle was subsequently flushed three times in a sterile glass vial 
equipped with a plungeable rubber top containing 4 ml of sterile saline solution, aseptically 
removed from the syringe, placed into a sterile whirl pack bag, and transferred to a “clean” 
investigator and immediately used. PCV2 DNA was not detected in the sterile saline solution 
used to flush the needle.   
 2.2.2.2. Inoculation procedures 
Inoculation was done at 42 days of age for all pigs in trial 3.  
For intranasal inoculation, this was performed by using a 3 ml syringe to defuse 0.5 
ml inoculum into each nostril for a total of 1 ml per pig.  
For intraperitoneal inoculation, inoculation was performed by disinfecting the 
abdominal epithelium adjacent to the umbilical remnant with alcohol swabs (General 
Medical Corporation, Richmond, Virginia, USA) inserting a butterfly catheter (Jorgensen 
Laboratories, Inc., Loveland, Colorado, USA) into the peritoneal cavity, injecting 0.6 ml of 
the inoculum, and finally injecting 3 ml of sterile saline into the catheter.  
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For oral gavage, the inoculation procedure was performed by placing an 18 French 
red rubber catheter (Covidien, Mansfield, Massachusetts, USA) connected to a 12 ml syringe 
into the esophagus. For each pig, 2 ml of inoculum was placed into the syringe and flushed 
with 10 ml of water.  
For oral inoculation via feeding, fecal material from Trial 2 pigs was mixed in with 
the normal feed ration, to ensure consumption of the material, the pigs were fed half of the 
normal amount of the ration the day prior to inoculation, the mixture was placed in separate 
areas of the pen for each pig, and the feeding was monitored by an observer. 
For needle inoculation, the clean investigator affixed the needle to a new, sterile 
syringe, drew up 1 ml of sterile saline, which was then injected into the naïve animal in the 
muscle distal to the base of the ear.  
 
2.3. Sample collection  
One (Trial 1) or two (Trial 2) oral and nasal swabs were taken per animal using 
polyester swabs (Fisher Scientific Inc). Swabs were stored in 5 ml plastic tubes (Fisher 
Scientific Inc.) containing 1 ml of sterile saline solution (Fisher Scientific Inc.). Blood was 
collected in 8.5 ml serum separator tubes (Fisher Scientific Inc.), centrifuged at 2000 x g for 
10 min at 4°C and serum was stored at -80°C until use. One fecal swab was taken per animal 
and stored in 5 ml plastic tubes containing 1 ml of sterile saline solution. In addition, in Trial 
2 feces were collected from each animal and stored in individual 50 ml plastic centrifuge 
tubes (Fisher Scientific Inc.). At every sampling point, each pig was injected with 1 ml sterile 
saline solution to mimic vaccination procedure. The needle used to inject the pig was 
subsequently flushed three times in the vial containing 4 ml of sterile saline solution. Vials 
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containing the saline, feces, nasal secretions and oral secretions were stored at -80°C until 
testing.  
 
2.4. Diagnostic testing 
2.4.1. Detection of anti-PCV2-IgG antibodies 
Serum samples were tested by an ORF2-based PCV2 IgG ELISA as previously 
described and were considered positive if the calculated sample-to-positive (S/P) ratio was 
0.2 or greater (Nawagitgul et al., 2002).  
2.4.2. PCV2 DNA detection and quantification 
DNA-extraction was performed using the QIAamp® DNA Mini Kit (Qiagen, 
Valencia, California, USA). DNA-extracts were used for quantification of the PCV2 genomic 
DNA copy numbers by a real-time PCR as previously described using ORF1-based primers 
(Opriessnig et al., 2003). The PCR reaction consisted of 25 µl PCR mixtures that
 
contained 
12.5 µl of commercially available master mix
 
(TaqMan Universal PCR Master Mix, Applied 
Biosystems Inc., Foster City, California, USA), 2.5
 
µl DNA extract, 1 µl forward and reverse
 
primers, 7.5 µl water, and 0.5 µl detection probe with concentrations of 10 µM. On each 
plate, five progressive 1:10 dilutions of a known
 
copy number of PCV2 genomic DNA 
excised from a purified PCV2
 
DNA clone was included to generate a standard curve. Each 
plate
 
was run in the sequence detection system (7500 Sequence
 
Detection System; Applied 
Biosystems Inc.) under the following conditions: 2 min at 50°C, 10 min
 
at 95°C, followed by 
40 cycles of 15 sec at 95°C and 1 min
 
at 60°C.
 
Samples which did not generate a signal 
following 40 cycles were considered negative.  
2.4.3. PCV2 sequencing 
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A nested PCR was used to amplify the entire ORF2 gene of PCV2 for sequencing as 
previously described (Opriessnig et al., 2006b). The PCR products were purified using the 
QIAquick PCR purification kit (Qiagen) per manufacturer’s instructions and sequenced at the 
Iowa State University DNA Sequencing facility. Sequences were analyzed with Sequence 
Scanner 1.0 (Applied Biosystems Inc.). Sequences were aligned using MegAlign (Lasergene 
DNAStar version 4.0.43, DNASTAR, Inc., Madison, Wisconsin, USA). PCV2 sequences 
were retrieved from the nucleotide sequence database of the National Center for 
Biotechnology Information (NCBI) to determine whether the viral sequences clustered with 
PCV2a or PCV2b. The ORF2 genes of the available sequences from GenBank database were 
aligned with three sequences obtained from the current study using the ClustalW method.   
2.4.4. PCV2 Immunohistochemistry (IHC)  
IHC detection of PCV2-specific antigen was performed on selected formalin-fixed 
and paraffin-embedded sections of lymph nodes (superficial inguinal, mediastinal, 
tracheobronchial, and mesenteric), tonsil, spleen, Peyer’s patches, and thymus using a rabbit 
polyclonal antiserum (Sorden et al., 1999). PCV2-antigen scoring was done by a pathologist 
blinded to treatment groups. Scores ranged from 0 (no signal) to 3 (more than 50% of the 
lymphoid follicles contain cells with PCV2-antigen staining) (Opriessnig et al., 2004a).   
2.4.5. Assays to exclude the presence of other potential swine pathogens in the samples 
Serum samples collected at initiation and again at termination of Trials 1 (n=4), 2 
(n=5)  and 3 (n=8, one pig in each group) experiments were tested for the presence of 
specific antibodies to PRRSV with a commercial PRRSV ELISA (HerdChek® PRRS 2XR 
Antibody ELISA; IDEXX Laboratories, Inc. Westbrook, MA, USA), for the presence of 
PPV-specific antibodies by a hemagglutination inhibition (HI) assay (Mengeling et al., 
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1988), and for the presence of SIV antibodies by an in house nucleoprotein NS1 ELISA 
(Opriessnig et al., 2010). Real-time PCRs for swine transmissible gastroenteritis virus 
(TGEV), PRRSV, Mycoplasma hyopneumoniae and SIV were performed according to the 
standard operating procedures of the Iowa State University Veterinary Diagnostic 
Laboratory. IHC staining for rotavirus antigen and Lawsonia intracellularis antigen was also 
performed according to the standard operating procedures of the Iowa State University 
Veterinary Diagnostic laboratory.   
 
2.5. Necropsy 
Animals were humanely euthanized with an overdose of pentobarbital (Vortech 
Pharmaceuticals, Dearborne, Michigan, USA) and necropsied on 209 DPF for Trial 1, 69 
DPI for Trial 2, and 42 DPI for Trial 3. Macroscopic lung lesions, scored from 0 to 100% of 
the lung affected, and the size of lymph nodes, scored from 0 (normal) to 3 (enlarged four 
times the normal size), were estimated in a blinded fashion as described previously 
(Opriessnig et al., 2006a). Sections of lymph nodes (superficial inguinal, mediastinal, 
tracheobronchial, mesenteric), lung, tonsil, thymus, ileum, kidney, colon, spleen, and liver 
were collected at necropsy and fixed in 10% neutral-buffered formalin and routinely 
processed for histological examination. 
 
2.6. Histopathology  
Microscopic lesions were evaluated by a pathologist (TO) blinded to treatment 
groups. Lung sections were scored for the presence and severity of interstitial pneumonia 
ranging from 0 (normal) to 4 (severe interstitial pneumonia) as described previously (Halbur 
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et al., 1995). Sections of heart, liver, kidney, ileum, and colon were evaluated for the 
presence of lymphohistiocytic inflammation, and scored from 0 (none) to 3 (severe). 
Lymphoid tissues including lymph nodes, tonsil, and spleen were evaluated for the presence 
of lymphoid depletion ranging from 0 (normal) to 3 (severe) and for histiocytic inflammation 
and replacement of follicles ranging from 0 (normal) to 3 (severe) (Opriessnig et al., 2004a). 
An overall microscopic lymphoid lesion score which accounts for lymphoid depletion, 
histiocytic inflammation, and PCV2-antigen present in lymphoid tissues was calculated for 
each pig as previously described (Opriessnig et al., 2004a) and the scores ranged from 0 
(normal) to 9 (severe).   
 
2.7. Statistics 
The pig was considered the experimental unit for all analyses. Serological and 
viremia data were analyzed using a repeated measures analysis of variance (ANOVA) to test 
the null hypothesis that there was no effect of time on differences between samples (James 
and McCulloch, 1990). For the model, the sample type (fecal swab, oral swab, nasal swab, 
serum) was the fixed, independent variable and the continuous data (log10 PCV2 genomic 
copies/ml or log10 ELISA S/P ratios) were dependent variables. If a significant effect 
(P<0.05) was noted in the repeated measures ANOVA, a one-way ANOVA was performed at 
each DPF or DPI using the described model to assess significant differences between 
samples. For Trial 3 pigs, the time to seroconversion and viremia was calculated. These 
dependent variables were then used in a one-way ANOVA with the group as the independent 
variable. An effect was considered significant if P < 0.05. Statistical analysis was performed 
using JMP® (SAS Institute, Inc., Cary, North Carolina, USA).  
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RESULTS 
 
3.1. Trial 1 (Naturally PCV2-infected pigs) 
3.1.1. Clinical disease 
A dry cough was noted in pig 1A on 121 DPF. Pig 1C developed bilateral rear leg 
ataxia on 146 DPF; however, the animal’s temperature was within normal limits (39.2°C) 
and the joints appeared normal. As pig 1C continued to have non-responsive bilateral rear-leg 
ataxia, pig 1C and pig 1D were moved to a separate room by 148 DPF to allow for better 
access to water and feed. After no response to treatment, pig 1C was humanely euthanized on 
170 DPF. On 181 DPF, pig 1A developed slightly raised, red, multifocal-to-coalescing 
lesions on the ventral thorax, perineum and inner legs (rear and front) which resolved by the 
time of necropsy on 209 DPF.    
3.1.2. Anti-PCV2-IgG antibodies 
All four pigs were seropositive for IgG anti-PCV2 antibodies at 13 DPF (first 
sampling point) and remained seropositive throughout the study until 209 DPF without any 
significant decline (Fig. 1). In addition, all pigs were free of SIV-, PPV-, and PRRSV-
specific antibodies at initiation and termination of the study. 
3.1.3. PCV2 DNA quantification 
All four pigs were PCV2 viremic at 13 DPF (first sampling point) and three animals 
were still viremic at 209 DPF. Interestingly, PCV2 DNA was consistently detected in serum 
samples until 126 DPF after which time PCV2 DNA was detected intermittently (Table 2). 
The detection of PCV2 DNA in fecal, nasal and oral swabs mirrored the PCV2 DNA 
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detection in the serum samples (Table 2). Mean group log10 PCV2 DNA genomic copies/ml 
for each sample type (fecal swab, nasal swab, oral swab and serum) are presented in Fig. 1. 
From 28 through 84 DPF, higher amounts of PCV2 DNA were detected in fecal and oral 
samples compared to that in nasal and serum samples, and the difference was significant 
(P<0.05) on 35, 49, 63, and 84 DPF.    
3.1.4. Macropscopic lesions 
Pig 1C had swollen rear hock filled with purulent material. Other gross lesions were 
not noted.  
3.1.5. Microscopic lesions and PCV2 antigen detection by IHC 
Microscopic lesions characteristic of PCVAD (lymphoid depletion and histiocytic 
replacement) were not present in pigs 1A, 1B, 1C or 1D. Low amounts of PCV2 antigen 
(positive staining detected in less than 10% of follicles) was detected by IHC in the tonsil and 
lymph node of two (1C and 1D) of the animals. 
 
3.2. Trial 2 (Experimental PCV2-infection) 
3.2.1. Clinical disease  
Pig 2D developed dyspnea and diarrhea and had to be euthanized by 35 DPI. No 
clinical signs were noted in other animals. 
3.2.2 Anti-PCV2-IgG antibodies 
No anti-PCV2-IgG antibodies were detected in any of the animals prior to 
experimental inoculation (Fig. 2). Anti-PCV2-IgG antibodies were first detected in one 
animal at 11 DPI, one animal at 16 DPI, two animals at 19 DPI, and the remaining animals at 
21 DPI. Anti-PCV2-IgG S/P ratios continued to increase in the majority of animals 
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throughout the experiment (Fig. 2). Pig 2D which was euthanized on 35 DPI due to advanced 
clinical disease did not seroconvert to PCV2.  
3.2.3. PCV2 DNA quantification 
PCV2 DNA was not detectable in any pre-inoculation samples from any of the groups 
or in sera from negative control animals throughout the experiment. Mean group log10 PCV2 
DNA genomic copies/ml for the different sample types (feces, nasal swab, oral swab and 
serum) are presented in Fig. 2. All pigs became viremic by 1 DPI. All pigs showed a 
moderate decrease in the amount of PCV2 DNA detected from 2 to 4 DPI before resuming an 
increasing trend. Viremia peaked between 14 and 19 DPI with the exception of pig 2C which 
peaked at 42 DPI. The amount of PCV2 DNA present in fecal, nasal and oral swabs mirrored 
the amount detected in the sera. PCV2 DNA was detected in oral swabs, nasal swabs, fecal 
swabs and sera of the majority of the Trial 2 animals from 1 DPI until 7 DPI (Table 3). From 
8 DPI until the termination of the study at 69 DPI, PCV2 DNA was detected in oral swabs, 
nasal swabs, fecal swabs and in sera from all animals. Peak virus shedding in oral, nasal and 
fecal samples appeared between 16 and 19 DPI. There were no significant differences in 
mean log10 PCV2 genomic copies/ml among the sample types (fecal, nasal, oral, or serum) at 
16 or 19 DPI. However, by 69 DPI, a significantly (P=0.04) higher amount of PCV2 DNA 
was detected in nasal swabs in comparison to fecal swabs and sera. PCV2 DNA was not 
detected in any of the saline samples used to flush the needles after IM injection. 
3.2.4. No evidence of infection by other pathogens 
Pig 2D (severe respiratory disease and diarrhea) was negative for the presence of 
TGEV antigen, rotavirus antigen or Lawsonia intracellularis antigen by IHC stains.  The 
presence of PRRSV RNA, Mycoplasma hyopneumoniae DNA and SIV RNA was ruled out 
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by real-time PCR assays.  Routine bacterial culture was negative. All pigs were free of SIV-, 
PPV-, and PRRSV-specific antibodies at initiation and termination of the study. 
3.2.5. Microscopic lesions and PCV2 antigen detection by IHC 
Microscopic lesions in pig 2D characterized by moderate, lymphoplasmacytic 
interstitial pneumonia with mild, histiocytic peribronchiolar and perivascular aggregates and 
type 2 pneumocyte hypertrophy and hyperplasia; mild, multifocal, suppurative alveolitis; 
severe lymphoid depletion and marked histiocytic replacement in germinal centers of 
multiple lymph nodes; severe, segmental, suppurative and histiocytic enterocolitis with 
numerous multinucleated giant cells; and moderate, multifocal, lymphoplasmacytic 
interstitial nephritis. Abundant amounts of PCV2 antigen were present within the cytoplasm 
of mononuclear cells in bronchiolar-associated lymphoid tissues, germinal centers and 
periarteriolar lymphoid sheaths of lymph nodes, and in the lamina propria and submucosa of 
the small intestine consistent with PCVAD.  
Low amounts of PCV2 antigen were detected in the lymph node of one of the 
remaining four pigs (2B) at 69 DPI. In the same animal, moderate lymphoplasmacytic 
interstitial nephritis and mild, lymphoplasmacytic myocarditis was present. Mild 
lymphoplasmacytic interstitial nephritis was noted in one other animal. 
 
3.3. Trial 3 (Bioassay) 
3.3.1. Clinical disease  
One animal in the Oral-Oral group was found dead at 8 DPI and had gross and 
microscopic lesions consistent with Mulberry Heart Disease (nutritional myocardiopathy).  
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No treatments or changes in diet were initiated for the remainder of the group.  No other 
clinical disease was noted in the remaining animals. 
3.3.2. Anti-PCV2-IgG antibodies 
Anti-PCV2-IgG antibodies were not detected in any of the animals prior to 
experimental inoculation. The numbers of anti-PCV2 IgG positive animals in each of the 
experimental groups at each DPI and the mean time to seroconversion are presented in Table 
4. There were no significant differences in mean time to seroconversion among groups. 
Seroconversion was noted in all three of the groups inoculated intraperitoneally, and in the 
groups orally inoculated with feces and nasal secretions. However, seroconversion was not 
detected in the group inoculated by oral gavage with oral secretions or in the group 
intramuscularly injected with contaminated needles. All pigs were free of SIV-, PPV-, and 
PRRSV-specific antibodies at termination of the study.  
3.3.3. PCV2 DNA quantification 
PCV2 DNA was detected in at least one animal from the Fecal-IP, Nasal-IP, Oral-IP, 
Nasal-Nasal, Fecal-Oral and Needle-IM groups (Table 5). Group mean log10 PCV2 genomic 
copies/ml ± SE at 42 DPI and time to viremia (days ± SE) are shown in Table 5. No 
significant differences among groups were noted in time to viremia; however, there was a 
trend toward a shorter time to viremia in groups inoculated intraperitoneally. 
3.3.4. PCV2 Sequencing and sequence analysis  
The ORF2 gene of PCV2 recovered from one selected viremic pig in each group was 
sequenced and showed to have identical or near identical sequences (99-100% identity) when 
compared to that of the original inoculum.  
3.3.5. Microscopic lesions and PCV2 antigen detection by IHC 
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Mean group overall microscopic lymphoid lesion scores and the number of IHC 
positive animals are present in Table 6. Microscopic lesions characteristic for PCV2 
(lymphoid depletion and histiocytic replacement) were detected in lymphoid tissues from all 
groups except the negative control animals and the Oral-Oral group. There were no 
significant differences in overall microscopic lymphoid lesion score between groups. 
However, the most severe lesions were present in the Nasal-IP and Oral-IP groups and these 
groups also had the highest numbers of PCV2 IHC positive animals. Interestingly, animals in 
the Fecal-Oral group had a numerical trend toward more severe lesions and a higher number 
of PCV2 IHC positive animals compared to the animals in the Fecal-IP group. 
3.3.6. No evidence of infection by other pathogens 
Selected pigs in each group were free of SIV-, PPV-, and PRRSV-specific antibodies 
at initiation and termination of the study. 
 
DISCUSSION 
It is well documented that PCV2 infection is widespread in swine herds (Segalés et 
al., 2005a). The main objective of this study was to further investigate the shedding and 
infection dynamics of PCV2 in naturally and experimentally infected pigs to increase 
knowledge on which are the most important routes for horizontal transmission. PCV2 DNA 
was detected in oral, nasal and fecal swabs and in sera in naturally infected Trial 1 animals 
from 28 DPF (first sampling date in the research facility) up to 209 DPF (last sampling date) 
and in experimentally infected Trial 2 pigs from 1 DPI until 69 DPI (last sampling date). To 
our knowledge, 181 days (209 DPF minus 28 DPF) represents the longest documented period 
of PCV2 viremia under controlled conditions. Of studies which examined naturally-PCV2-
104 
 
 
infected populations, PCV2 DNA was detected using PCR in animals at 25 weeks of age 
(Carasova et al., 2007), at 156 days of age (time of slaughter) (McIntosh et al., 2006), and in 
25-50% of sampled 21-25 week old animals (Sibila et al., 2004). In experimental studies 
where the period of viremia is known, the longest documented period of PCV2 viremia by 
PCR is 140 DPI (study termination) (Opriessnig et al., 2010). In addition, successful isolation 
of PCV2 from spleen and distal ileum has been reported from pigs at 125 days post-infection 
(Bolin et al., 2001).   
In Trial 1, peak PCV2 viremia (mean±SE of 5.32 ± 0.41 log10 genomic PCV2 copies 
per ml) and peak PCV2 shedding in oral, nasal, and fecal samples were observed at the 
beginning of the study (DPF 28) with a slow but gradual decline in the amount of PCV2 
DNA in the different sample types analyzed thereafter. In contrast, peak PCV2 viremia was 
detected in Trial 2 pigs at 14 DPI with a mean±SE of 6.17±0.47 log10 genomic PCV2 copies 
per ml. Time of peak shedding in Trial 2 is similar to previous reports in which the highest 
number of PCR-positive animals was detected 14 to 21 DPI (Opriessnig et al., 2010). PCV2 
peak shedding in oral, nasal and fecal samples in Trial 2 appeared between 16 and 19 DPI. 
During subsequent time points, the amounts of virus remained fairly stable in both trials with 
a downward trend in the remaining Trial 2 pen mates after removal of the PCVAD-affected 
pig (Pig 2D) at 35 DPI. This provides evidence to support the practice of removing or 
segregating sick animals from pen mates to reduce the viral load in the remaining animals in 
the same pen. Decreased viral load in the environment has been associated with decreased 
incidence of PCVAD (Larochelle et al., 2003).  
Intermittent shedding was observed in both naturally-infected pigs (Trial 1) and pigs 
experimentally infected with PCV2 (Trial 2). In Trial 1 pigs, PCV2 DNA was consistently 
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shed in all sample types from 28 DPF until 97 DPF and was then there intermittently 
detected. Intermittent shedding was between 1 and 7 DPI and consistent thereafter for Trial 2 
pigs. These discrepant results are likely due to the differences in exposure (experimental 
versus natural; vertical versus horizontal) and duration of testing. Experimental infection 
should result in a consistent time, route, and dosage of exposure. Assuming infected animals 
become resistant to future infections, the population would return to a negative status within 
a certain period of time due to lack of a susceptible population, and thus PCR detection 
would become sporadic as observed in Trial 1 starting on 97 DPF. In Trial 2, the duration of 
sampling was likely too short to see such an effect. In a similar study where experimentally 
infected animals were monitored until 140 DPI, PCV2 DNA was intermittently detected from 
56 DPI to 130 DPI (Opriessnig et al., 2010). Early intermittent shedding of experimentally 
infected animals has also been documented. Following initial detection of PCV2 DNA at 1 
DPI in experimentally infected pigs, the amount of PCV2 DNA decreased between 2 and 8 
DPI before resuming an increasing trend at 9 DPI (Caprioli et al., 2006). In this study, 
samples were collected following oronasal inoculation of CD pigs and PCV2 DNA was 
detected in tonsillar and fecal swabs but not in sera which was attributed to the detection of 
PCV2 inoculum rather than true virus shedding (Caprioli et al., 2006). In contrast, pigs in 
Trial 2 were viremic at 1 DPI indicating that the DNA detected may be consistent with 
viremia. In Trial 1, animals with high concentrations of PCV2 DNA at 13 DPF were selected, 
indicating that PCV2 infection occurred prior to transfer of the animals to the research 
facility and therefore the expected early intermittent shedding pattern was not observed.  
In the naturally infected Trial 1 pigs, clinical disease consistent with PCVAD was not 
observed in any of the animals. This is in contrast to Trial 2, where experimental inoculation 
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of PCV2 naïve pigs with PCV2 resulted in clinical signs consistent with PCVAD in 20% 
(1/5) of the animals. The reasons for this are unclear; however, passively-derived or active 
antibodies may have provided protection from clinical disease as previously reported (Allan 
et al., 2002). Alternatively, the initial infection dose may have been lower in the natural 
outbreak. Also, systemic infections occur in approximately 5 to 30% of infected populations 
(Opriessnig et al., 2007) and the differences between Trial 1 and trial 2 may be due to sample 
size. In addition, experimental reproduction of PCVAD is difficult and based on a meta-
analysis of experimental studies, it is most successful when young (less than 3 weeks of age) 
CD pigs are infected with high doses of PCV2b and co-infected with a secondary pathogen 
(Tomas et al., 2008).   
In Trial 2, seroconversion occurred between 11 and 21 DPI, and anti-PCV2 IgG 
antibodies remained elevated throughout the study. This is in agreement with several 
previous studies in which conventional SPF pigs were infected with PCV2 (Opriessnig et al., 
2010; Segalés et al., 2005a). However, in Trial 1, the antibody response was unusual in that 
no decay of maternal antibodies was evident. Previous studies have shown that dam and 
piglet antibody titers are correlated, that pigs with lower S/P ratios have a higher and earlier 
likelihood of disease development, and that maternal antibodies decay between 4 to 12 weeks 
of age in PCV2 negative pigs (positive for anti-PCV2 IgG but negative for PCV2 DNA) 
(Opriessnig et al., 2004b) (Allan et al., 2002). However, the dynamics of the antibody 
response in PCV2-positive pigs (positive for both anti-PCV2 IgG and PCV2 DNA), as was 
the case for Trial 2 pigs, are largely unknown. Due to the consistent elevated levels of 
antibodies seen in the animals in Trial 1, there was likely a mixture of passively-acquired and 
active antibodies present in the piglets in addition to viable PCV2.  
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To our knowledge, the infectivity of PCV2 shedding in nasal secretions, fecal 
excretions and oral fluids or present on mechanical vectors such as needles has not been 
examined previously. Naïve Trial 3 animals were inoculated either by pooled nasal, oral, or 
fecal samples collected from experimentally infected Trial 2 pigs around the time of peak 
PCV2 shedding. Intraperitoneal inoculation with contaminated fecal, nasal and oral 
excretions resulted in PCV2 viremia and seroconversion in naïve pigs. Nasal secretions 
inoculated directly into the nares and fecal material fed to naïve animals were also infectious 
resulting in seroconversion of all four animals by 35 DPI. Feces fed to naïve animals resulted 
in transmission to two of four animals by 42 DPI. Additionally, viremia and microscopic 
lesions were noted in 1 of 3 pigs in the Needle-IM group, indicating that PCV2 may be 
spread among animals through vaccination procedures with a shared needle.  
As all animals were housed together, it is possible that transmission within the room 
occurred once one animal became infected. Previous work has shown that the mean time for 
a newly infected animal to infect a susceptible animal is approximately 18 days when naïve 
animals are placed into the same pen as the experimentally-infected animals (Andraud et al., 
2008). Therefore, it is possible that within the Fecal-Oral, Nasal-Nasal and Nasal-IP groups, 
not all the 3 pigs within each group were infected (primary infection) by the original 
inoculation, and that other pig(s) may subsequently become infected (secondary infection) 
from contact with the initial infected animal(s). While ideally each pig would have been 
housed individually to perform replicates of the experiment, the conditions of Trial 3 closely 
mimic field situations and thus answer the question of whether or not a group of animals can 
be infected by a particular route. Trends in the data suggest that the nasal route may be more 
effective than either the fecal or oral route. Additionally, at 69 DPI Trial 2 pigs had a 
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significantly (P<0.05) higher amount of PCV2 DNA in nasal swabs in comparison to fecal 
swabs and serum, suggesting that contact with nasal secretions may be a more important 
route for transmission than fecal-oral, especially in persistently infected animals.  
 
CONCLUSION  
This study documented the longest period of PCV2 viremia under controlled 
conditions (181 day observation period). It was also demonstrated that in both experimental 
and natural PCV2 infections, PCV2 is shed in high amounts in nasal, oral and fecal 
excretions for extended periods of time. Additionally, this study confirms that naïve animals 
can be infected with PCV2 present in nasal secretions, oral secretions and fecal material via 
the intraperitoneal route, with PCV2 present in feces via the oral route, with PCV2 present in 
nasal secretions via the intranasal route and potentially through contaminated needles.  
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Table 1. Experimental design. Abbreviations used: DPF=days post-farrowing; DPI=days post-inoculation; IM=intramuscular; 
IN=intranasal; IP=intraperitoneal. 
Trial PCV2 status  Age at trial 
initiation 
No. of 
rooms 
Group 
designation 
n Inoculum Route of 
infection 
Time unit 
used 
Necropsy 
Trial 1 
Determined to be 
PCV2 PCR and 
ELISA positive at 
13 DPF 
28 days 1 
Naturally 
infected pigs 
4 None Unknown DPF 209 DPF 
Trial 2 Naïve 21 days 1 
Experimentally 
infected pigs 
5 PCV2b IM and IN DPI 69 DPI 
Trial 3 Naïve 42 days 8 
Negative 
controls 
3 None None 
DPI 42 DPI 
Oral-IP 3 
PCV2b positive 
oral fluid 
IP 
Fecal-IP 3 
PCV2b positive 
feces 
IP 
Nasal-IP 3 
PCV2b positive 
nasal secretions 
IP 
Oral-Oral 3 
PCV2b positive 
oral fluid 
Oral gavage 
Fecal-Oral 4 
PCV2b positive 
feces 
Contaminated 
feed 
Nasal-Nasal 4 
PCV2b positive 
nasal secretions 
IN 
Needle-IM 3 
Contaminated 
needle 
IM 
1
1
5
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Table 2. Detection of PCV2 DNA by PCR in oral, nasal, serum, or fecal samples (no. 
positive/ total no. tested) of Trial 1 animals from days post farrowing (DPF) 97 to 209. 
Before DPF 97, all samples from all animals were positive.  
DPF Oral swabs Nasal swabs Serum Fecal swabs 
97 3/4 4/4 4/4 4/4 
106 3/4 4/4 4/4 4/4 
114 1/4 3/4 4/4 4/4 
120 1/4 0/4 4/4 2/4 
126 2/4 3/4 3/4 0/4 
133 3/4 4/4 2/4 2/4 
141 3/4 3/4 2/4 3/4 
147 1/4 2/4 4/4 2/4 
154 1/4 3/4 1/4 0/4 
161 2/4 3/4 2/4 1/4 
168 1/4 2/4 1/4 1/4 
174 1/3 1/3 3/3 0/3 
182 1/3 2/3 1/3 1/3 
189 2/3 3/3 2/3 2/3 
196 0/3 2/3 3/3 1/3 
203 1/3 2/3 2/3 1/3 
209 0/3 1/3 3/3 2/3 
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Table 3. Detection of PCV2 DNA by PCR in oral, nasal, serum, or fecal samples (no. 
positive/total no. tested) of Trial 2 animals from days post inoculation (DPI) 0 to 7. After DPI 
7, all samples from all animals were positive until the termination of the study at DPI 69.  
DPI Oral swabs Nasal swabs Serum Fecal swabs 
0 0/5 0/5 0/5 0/5 
1 4/5 5/5 5/5 4/5 
2 5/5 5/5 5/5 4/5 
3 5/5 5/5 5/5 4/5 
4 5/5
 
 5/5
 
 5/5
 
 1/5
 
 
5 2/5 5/5
 
 5/5
 
 5/5
 
 
6 4/5 4/5 5/5 5/5 
7 3/5 5/5
 
 5/5
 
 5/5 
118 
 
 
Table 4. Serological response in Trial 3 animals: Number of anti-PCV2 IgG positive 
animals/total number of animals following intramuscular inoculation with a contaminated 
needle (Needle-IM); intraperitoneal inoculation with feces, nasal secretions or oral secretions 
(Fecal-IP, Nasal-IP, Oral-IP respectively); oral gavage with oral secretions (Oral-Oral); or 
oral inoculation with pooled fecal material (Fecal-Oral). Serum samples were considered 
positive if the sample-to-positive (S/P) ratio was greater than 0.2. 
*One animal in this group died of Mulberry Heart Disease on DPI 8. 
**Not applicable.
Group DPI Time to 
Seroconversion 
DPI 42 
Anti-PCV2-IgG 
S/P ratio 
0 7 14 21 28 35 42 Mean days ± SE Mean ± SE 
Oral-IP 0/3 0/3 0/3 0/3 1/3 2/3 3/3 35.0 ± 4.0 0.48 ± 0.07 
Fecal-IP 0/3 0/3 0/3 1/3 3/3 3/3 3/3 25.7± 2.3 0.67 ± 0.05 
Nasal-IP 0/3 0/3 0/3 1/3 1/3 3/3 3/3 30.3 ± 4.7 0.54 ± 0.15 
Oral-Oral* 0/4 0/4 0/4 0/3 0/3 0/3 0/3 NA** NA** 
Fecal-Oral 0/4 0/4 0/4 0/4 1/4 1/4 2/4 35.0 ± 7.0 0.22 ± 0.16 
Nasal-Nasal 0/4 0/4 0/4 1/4 2/4 4/4 4/4 29.8 ±3.4 0.64 ± 0.12 
Needle-IM 0/4 0/4 0/4 0/4 0/4 0/4 0/4 NA NA 
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Table 5. PCV2 viremia in Trial 3 animals: Number of of PCV2 viremic animals/total number 
of animals following intramuscular inoculation with a contaminated needle (Needle-IM); 
intraperitoneal inoculation with feces, nasal secretions or oral secretions (Fecal-IP, Nasal-IP, 
Oral-IP respectively); oral gavage with oral secretions (Oral-Oral); or oral inoculation with 
pooled fecal material (Fecal-Oral). Time to viremia (days ± std. err) and group mean log10 
genomic copies/ml ± std. err of PCV2 at days post inoculation (DPI) 42 are provided. 
*One animal in this group died of Mulberry Heart Disease at DPI 8. 
**Not applicable.
Group DPI Time to 
viremia 
DPI 42 Log10 
PCV2 
genomic 
copies/ml 
0 7 14 21 28 35 42 
Mean 
days ± SE 
Mean ± SE 
Oral-IP 0/3 0/3 0/3 3/3 2/3 3/3 3/3 21.0±0.0 4.69±0.23 
Fecal-IP 0/3 2/3 2/3 3/3 3/3 3/3 3/3 11.7±4.7 4.37±0.48 
Nasal-IP 0/3 1/3 1/3 2/3 3/3 3/3 3/3 18.7±6.2 4.58±0.48 
Oral-Oral* 0/4 0/3 0/3 0/3 0/3 0/3 0/3 NA** NA** 
Feces-Oral 0/4 0/4 0/4 1/4 1/4 2/4 4/4 35.0±4.9 4.41±0.53 
Nasal-Nasal 0/4 2/4 2/4 3/4 4/4 4/4 4/4 15.8±5.3 4.60±0.44 
Needle-IM 0/4 0/4 0/4 0/4 0/4 0/4 1/4 42.00 5.07 
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Table 6. Microscopic lesions (Group mean ± SE) and number of PCV2 antigen (as 
determined by  immunohistochemistry) positive Trial 3 pigs /total number of Trial 3 pigs per 
group following intraperitoneal inoculation with feces, nasal secretions or oral secretions 
(Fecal-IP, Nasal-IP, Oral-IP respectively); oral gavage with oral secretions (Oral-Oral); oral 
inoculation with pooled fecal material (Fecal-Oral); intramuscular inoculation with a 
contaminated needle (Needle-IM). One group (Negative) remained un-inoculated. 
 
 
 
 
 
 
* An overall microscopic lymphoid lesions score which accounts for lymphoid depletion, 
histiocytic inflammation, and PCV2-antigen present in lymphoid tissues was calculated for 
each pig and ranged from 0=normal to 9=severe.  
Group Overall lymphoid 
lesion score* 
PCV2 antigen 
Oral-IP 3.7±0.6 3/3 
Fecal-IP 0.7±0.7 1/3 
Nasal-IP 3.7±1.4 3/3 
Oral-Oral 0.0±0.0 0/3 
Fecal-Oral 1.4±0.5 3/4 
Nasal-Nasal 2.1±1.2 2/4 
Needle-IM 0.8±0.8 1/4 
Negative 0.0±0.0 0/3 
  
Figure 1. Mean group log10 genomic PCV2 copies/ml oral fluid, nasal secretions, serum and feces (lines) and mean group ELISA 
sample-to-positive (S/P) ratio (bars) in four pigs naturally infected with PCV2 (Trial 1). An S/P ratio of 0.2 or greater was 
considered to be positive.  
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Figure 2. Mean group log10 genomic PCV2 copies/ml oral fluid, nasal secretions, serum and feces (lines) and mean group 
ELISA sample-to-positive (S/P) ratio (bars) in five pigs experimentally infected with PCV2 (Trial 2). An S/P ratio of 0.2 or 
greater was considered to be positive.  
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CHAPTER 5.   Efficacy of experimentally-produced spray-dried plasma on infectivity 
of porcine circovirus type 2 (PCV2) 
 
A paper submitted to the Journal of Animal Science  
 
Abby R. Patterson, Darin M. Madson, Tanja Opriessnig
 
 
 
ABSTRACT: The value of incorporating spray-dried plasma (SDP) into the diet of weanling 
pigs to improve feed intake and growth performance has been well documented. However, 
limited work has been done to confirm that the spray-drying process eliminates all viral 
contaminates including porcine circovirus type 2 (PCV2). To determine the effect of spray-
drying on PCV2 infectivity, colostrum-fed, crossbred, specific-pathogen-free (SPF) pigs 
were inoculated with PCV2-contaminated SDP intraperitoneally (SDP-IP) or by oral gavage 
(SDP-OG), inoculated intraperitoneally with PCV2-positive plasma (POS), or left un-
inoculated (NEG). The plasma used for the experimentally produced SDP was collected from 
a SPF pig experimentally-infected with a PCV2b isolate. Pigs in the NEG group remained 
seronegative and PCV2 viremia was not detected.  All pigs in the POS group became PCV2 
viremic by 14 days post-inoculation (DPI) and seroconverted by 28 DPI. In the SDP-IP 
group, all pigs became viremic by 35 DPI and seroconverted by 49 DPI. In the SDP-OG 
group, all animals became viremic by 35 DPI and 2/3 pigs seroconverted by 35 DPI. There 
were no significant differences between anti-PCV2-IgG antibody sample-to-positive (S/P) 
ratios among pigs in the POS, SDP-OG, or SDP-IP groups. This work provides direct 
evidence that the experimental spray-drying process used in this study was not effective in 
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inactivating PCV2b in the plasma of a PCV2-infected pig based on a swine bioassay using 
PCV2 naïve pigs. This work suggests that spray dried plasma sourced from pigs could 
represent a biosecurity risk for the industry.  
 
Key words:  porcine circovirus type 2, seroconversion, spray-dried plasma, viremia 
 
INTRODUCTION 
Porcine circovirus type 2 (PCV2) is the primary component of PCV associated 
disease (PCVAD), a systemic infection that can result in mortality rates of 70-80% in 
clinically affected pigs (Opriessnig et al., 2007). While the virus was first associated with 
disease in the late 1990’s (Allan et al., 1998), between 2004 and 2005 an increase in the 
number and severity of PCVAD cases was reported in Canada (Carman et al., 2006), and in 
Kansas, Iowa and North Carolina (Cheung et al., 2007). Interestingly PCV2b, a strain of 
PCV2 not previously isolated in North America, was identified (Cheung et al., 2007). The 
source and route of transmission of PCV2b in North America is currently unknown. Potential 
routes of PCV2 transmission include direct contact with infected animals and contaminated 
fomites or vertical transmission. Horizontal transmission of PCV2 through spray-dried 
plasma (SDP) products is another hypothesis.  
The value of incorporating SDP protein into the diet of weanling pigs to improve feed 
intake and growth performance, especially following disease challenge has been well 
documented (Coffey and Cromwell, 2001; Hansen et al., 1993; Lawrence et al., 2004; 
Torrallardona, 2010; Zhao et al., 2007). PCV2 is a small circular DNA virus and has been 
shown to be extremely resistant to inactivation as evidenced by a 1-log reduction after dry-
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heat treatment of freeze-dried PCV2 at 120°C for 30 min (Welch et al., 2006) and resistance 
to a 15 min 70°C heat treatment in cell culture (O'Dea et al., 2008). 
Commercially manufactured SDP protein containing 2.47 × 10
5
 PCV2 genomic 
copies per ml fed to weaning pigs did not result in seroconversion or viremia during the 45 
day observation period (Pujols et al., 2008). However, pigs had low levels of maternally-
derived PCV2 antibodies before initiation of the trial based on an immunoperoxidase 
monolayer assay (IPMA) (Pujols et al., 2008).      
To investigate whether PCV2 remains infectious after the spray-drying process, SDP 
derived from a pig experimentally-infected with PCV2b was tested in a swine bioassay using 
PCV2 naïve animals.   
 
MATERIALS AND METHODS 
Animals and housing 
The experimental protocol in this study was approved by the Iowa State University 
Institutional Animal Care and Use Committee. Colostrum-fed, crossbred, specific-pathogen-
free (SPF) pigs were purchased from a herd that is routinely tested for major swine pathogens 
and known to be free of PCV2, porcine reproductive and respiratory syndrome virus 
(PRRSV), porcine parvovirus (PPV) and swine influenza virus (SIV). Twelve pigs obtained 
from 2 litters were weaned at 3 weeks of age and transported to the Livestock Infectious 
Disease Isolation Facility at Iowa State University, Ames, Iowa. Upon arrival, the pigs were 
ear-tagged, randomly divided into groups of three pigs using a random permutation generator 
(freeware available online at http://www.randomization.com) and housed in four separate 
rooms; there were no partitions separating the three animals within each room. Each room 
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had 18 m
2
 of solid concrete floor space, separate ventilation systems and one nipple drinker. 
All groups were fed a balanced, pelleted, complete feed ration free of animal proteins (with 
the exception of whey) and antibiotics (Nature’s Made, Heartland Coop, Alleman, Iowa, 
USA) once a day.  
Experimental design 
Pigs were left un-inoculated (NEG), inoculated with an experimentally-produced 
reconstituted PCV2-infected SDP product intraperitoneally (SDP-IP) or by oral gavage 
(SDP-OG), or inoculated intraperitoneally with plasma from a PCV2-infected pig (POS). 
Blood samples were collected weekly after inoculation for 7 weeks and tested for the 
presence of anti-PCV2-IgG antibodies and PCV2 DNA.   
PCV2-contaminated plasma source 
The source of plasma inoculum was blood from a colostrum-fed, crossbred, SPF pig 
experimentally-infected with 5 × 10
4.0
 50% tissue culture infectious dose (TCID50) of PCV2b 
(GenBank # EU340258) at 3 weeks of age as part of a separate study (A. Patterson, 
unpublished data). At 35 days post inoculation (DPI), the pig was euthanized with an 
overdose of pentobarbital (Fatal Plus®, Vortech Pharmaceutical, Dearborn, Michigan, USA) 
due to development of clinical signs consistent with PCVAD including severe dyspnea, 
diarrhea, and loss of condition. After euthanasia, 2 liters of blood were collected in jars 
containing 14,300 USP Heparin Units (Hospira, Inc., Lake Forest, Illinois, USA) per liter of 
blood. The plasma was immediately centrifuged at 2000 x g for 10 min at 4°C in 50 ml 
centrifuge tubes and stored at 4°C until use. The plasma was tested for the presence of PCV2 
DNA by quantitative PCV2 PCR; 7.75 log10 PCV2 genomic copies per ml of plasma were 
detected. The diagnosis of PCVAD in the donor pig was further confirmed by the presence of 
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intense PCV2 antigen staining by immunohistochemistry (IHC) (Sorden et al., 1999) in the 
lungs, intestine and lymphoid tissues. Transmissible gastroenteritis virus (TGEV), rotavirus, 
and Lawsonia intracellularis were not detected by IHC. PCR tests for PRRSV (Prickett et al., 
2007), SIV (Richt et al., 2004), and Mycoplasma hyopneumoniae (Calsamiglia et al., 1999) 
were negative. The IHC assays and PCR tests were performed according to the standard 
operating procedures for the Iowa State University Veterinary Diagnostic Laboratory.   
Spray-drying process 
Three-hundred ml of the collected plasma was spray-dried using a bench-top spray 
dryer (Yamato Model ADL310, Yamato Scientific Co., LTD, Tokyo, Japan). To ensure that 
the spray dryer was not contaminated with PCV2 before the initiation of the run, it was 
disinfected with an oxidizing disinfectant (Virkon® S, Dupont, Pharmacal Research 
Laboratories, Inc., Naugatuck, Connecticut, USA) according to the manufacturers’ 
recommendations. Ten swabs were then taken from various components of the apparatus, 
placed in sterile saline and were confirmed to be PCV2 negative by real-time PCR 
(Opriessnig et al., 2003).   
For drying of the plasma, the bench-top spray-drier manufacturer’s recommendations 
were followed. A 0.4 mm nozzle was used with the following parameters:  Tinlet (inlet air 
temperature) of 166°C, aspiration rate of 0.6 m
3
/min, Toutlet (outlet temperature) of 67°C, and 
an 820 ml/hr sample flow rate under 0.1 MPa of pressure. The resulting SDP product was 
stored at 4°C until use at which time it was reconstituted in sterile saline to a concentration of 
0.33 g/ml. This concentration was based on the amount of available product, the number of 
animals in the study and the amount of saline needed to reconstitute the SDP product. Some 
of the differences between the experimentally-produced SDP used in this study and 
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commercially-produced SDP include, but are not limited to, the source animal(s), disease 
status, pooling effects, processing temperatures, product retention time and post drying 
conditions (Table 1).   
Inoculation 
Pigs in the SDP-IP and SDP-OG groups were inoculated with 3 ml of the 
reconstituted SDP product as described above. Pigs in the POS group were inoculated 
intraperitoneally with 3 ml of the untreated plasma. Pigs in the NEG group were sham-
inoculated intraperitoneally with 3 ml of sterile saline.  
Anti-PCV2-IgG antibodies  
Blood samples were collected on the day of inoculation, and weekly thereafter until 
49 DPI. The blood was collected in 8.5 ml serum separator tubes (Fisher Scientific, 
Pittsburgh, Pennsylvania, USA), immediately centrifuged at 2000 x g for 10 minutes at 4°C 
and stored at      -80°C until use. Serum samples were tested by an open-reading frame (ORF) 
2-based PCV2 IgG ELISA as previously described and were considered positive if the 
calculated sample-to-positive (S/P) ratio was 0.2 or greater (Nawagitgul et al., 2002).  
PCV2 DNA quantification  
DNA-extraction on all serum samples was performed using the QIAamp® DNA Mini 
Kit (Qiagen, Valencia, California, USA). DNA-extracts were used for quantification of the 
PCV2 genomic DNA copy numbers by real-time PCR. Previously described primers for 
ORF1 of PCV2 (Opriessnig et al., 2003) were used for quantification of the PCV2 genomic 
DNA copy numbers by real-time PCR. The PCR reaction consisted of 25 µl PCR mixtures 
that
 
contained 12.5 µl of commercially available master mix
 
(TaqMan Universal PCR Master 
Mix, Applied Biosystems), 2.5
 
µl DNA extract, 1 µl forward and reverse
 
primers, and 0.5 µl 
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detection probe with concentrations of 10 µM. On each plate five progressive 1:10 dilutions 
of a known
 
copy number of PCV2 genomic DNA excised from a purified PCV2
 
DNA clone 
were included to generate a standard curve. Each plate
 
was run in the sequence detection 
system (7500 Sequence
 
Detection System, Applied Biosystems) under the following 
conditions: 2 min at 50°C, 10 min
 
at 95°C, followed by 40 cycles of 15 sec at 95°C and 1 
min
 
at 60°C.
  
Sequencing 
PCR products amplified from virus recovered from a 49 DPI serum sample from one 
animal in the SDP-IP, SDP-OG and POS groups was sequenced and compared with the 
inoculum. A nested PCR was used to amplify the entire ORF2 gene for sequencing 
(Opriessnig et al., 2006b). PCR products were purified using the QIAquick PCR purification 
kit (Qiagen, Valencia, California, USA) per the manufactures directions and sequenced at 
Iowa State University DNA facility. Sequences were analyzed with Sequence Scanner 1.0 
(Applied Biosystems) and compared with the sequence of the inoculum using the BLAST 
(basic local alignment search tool) (Zhang et al., 2000). 
Necropsy 
All pigs were necropsied at 49 DPI. Severity of macroscopic lung lesions (scored 
from 0 to 100% of the lung affected) and the size of lymph nodes (score ranged from 0 to 3; 
0 [normal], 1 [two times the normal size], 2 [three times the normal size], 3 [four times the 
normal size]) were estimated in a blinded fashion as described previously (Opriessnig et al., 
2006a). Sections of lymph nodes (superficial inguinal, mediastinal, tracheobronchial, 
mesenteric), tonsil, thymus, ileum, kidney, colon, spleen, and liver were collected at 
necropsy and fixed in 10% neutral-buffered formalin and routinely processed for histological 
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examination. 
Histopathology and immunohistochemistry (IHC) 
Microscopic lesions were evaluated by a pathologist blinded to treatment groups. 
Lung sections were scored for the presence and severity of interstitial pneumonia ranging 
from 0 (normal) to 4 (severe interstitial pneumonia) as described previously (Halbur et al., 
1995). Sections of heart, liver, kidney, ileum and colon were evaluated for the presence of 
lymphohistiocytic inflammation and scored from 0 (none) to 3 (severe). Lymphoid tissues 
including lymph nodes, tonsil, and spleen were evaluated for the presence of lymphoid 
depletion ranging from 0 (normal) to 3 (severe) and histiocytic inflammation and 
replacement of follicles ranging from 0 (normal) to 3 (severe) (Opriessnig et al., 2004).  
Detection of PCV2-specific antigen in selected formalin-fixed and paraffin-embedded 
sections of lymph nodes (superficial inguinal, mediastinal, tracheobronchial, and mesenteric), 
tonsil, spleen, Peyer’s patches, and thymus was performed by using IHC and a rabbit 
polyclonal antiserum as described previously (Sorden et al., 1999). PCV2-antigen scoring 
was done by a pathologist blinded to treatment groups. Scores ranged from 0=no signal to 
3=more than 50% of the lymphoid follicles contain cells with PCV2-antigen staining 
(Opriessnig et al., 2004). 
An overall microscopic lymphoid lesions score which accounts for lymphoid 
depletion, histiocytic inflammation, and PCV2-antigen present in lymphoid tissues was 
calculated for each pig as previously described (Opriessnig et al., 2004) and ranged from 
0=normal to 9=severe.   
Statistical analysis 
To test the null hypothesis that there was no effect of time on differences between the 
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groups, a repeated measures analysis of variance (ANOVA) was used (James and 
McCulloch, 1990). The experimental unit was the individual pig. For the model, group 
(NEG, SDP-IP, SDP-OG, and POS) was the fixed, independent variable and the continuous 
data (log transformed genomic copies/ml or anti-PCV2-IgG S/P ratios) were dependent 
variables. If a significant effect (P < 0.05) was noted in the repeated measures analysis, a 
one-way ANOVA was performed at each DPI using the previously described model to assess 
significant differences between groups. For statistical analysis of lymphoid lesions, a one-
way ANOVA was performed using the overall microscopic lymphoid lesions score as a 
dependent variable and group (NEG, SDP-IP, SDP-OG and POS) as the fixed, independent 
variable in the ANOVA. If an ANOVA was significant, pairwise comparisons using the 
Tukey-Kramer adjustment were done to determine which groups were different. Statistical 
analysis was performed using JMP® 7 (SAS Institute, Inc., Cary, North Carolina, USA). 
  
RESULTS 
Clinical presentation and macroscopic lesions 
Clinical disease was not observed in any of the pigs for the duration of the study. No 
remarkable gross lesions were observed. Individual pigs in the POS, SDP-IP and SDP-OG 
groups had slightly enlarged mediastinal lymph nodes compared to the NEG group. 
Anti-PCV2-IgG antibody levels 
Group mean and standard errors for anti-PCV2-IgG antibody S/P ratios are presented 
in Fig. 1. Pigs within the NEG group remained seronegative throughout the duration of the 
trial. By DPI 21, 2/3 pigs in the POS group seroconverted; by DPI 28 all three pigs had 
seroconverted. In the SDP-IP group, 2/3 pigs seroconverted on DPI 35; by DPI 49 all pigs 
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had seroconverted. In the SDP-OG group, 2/3 pigs seroconverted by DPI 35 and one animal 
remained negative through DPI 49. Throughout the trial, there were no significant differences 
between anti-PCV2-IgG antibody S/P ratios among pigs in the POS, SDP-OG, or SDP-IP 
groups. At 49 DPI, POS, SDP-OG and SDP-IG pigs had significantly higher group mean S/P 
ratios compared to the NEG group. 
PCV2 DNA quantification and sequencing 
Group means and standard errors for log10 transformed PCV2 genomic copies/ml are 
presented in Fig. 2. Pigs within the NEG group remained negative throughout the duration of 
the trial. In the POS group, all pigs were viremic by DPI 14. In the SDP-IP group, 1/3 pigs 
were viremic on DPI 14, 2/3 pigs were viremic on DPI 21, and by DPI 35 all three pigs were 
viremic.  In the SDP-OG groups, one pig became viremic at DPI 14, 2/3 pigs were viremic 
by DPI 28 and all three pigs were viremic at DPI 35. A difference (P < 0.05) in amount of 
PCV2 DNA was observed between the POS and the SDP-IP at DPI 14 and between the SDP-
IP and SDP-OG groups at DPI 49 (Fig. 2). No other differences were noted between the 
POS, SDP-IP and SDP-OG groups. By DPI 35, all groups had significantly higher amounts 
of PCV2 DNA compared to the NEG group. Sequence analysis of the PCV2 recovered from 
one pig from each group which became viremic had 100% similarity with the inoculum.  
Histopathology and immunohistochemistry 
Pigs within the NEG control group had no microscopic lesions associated with 
PCVAD (overall microscopic lymphoid lesions score of 0) and no lung lesions. Pigs within 
the POS control group had a mean overall microscopic lymphoid lesions score (± standard 
error) of 3.3 ± 0.2. Specifically, there was mild-to-moderate lymphoid depletion and 
histiocytic replacement of lymphoid follicles in 3 of 3 pigs which was associated with low 
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levels of PCV2 antigen in 2 of 3 pigs in the POS control group. Pigs within the SDP-IP and 
SDP-OG groups had a mean overall microscopic lymphoid lesions score of 3.7±2.8 and 
2.7±1.2, respectively. Specifically, there was moderate lymphoid depletion and histiocytic 
replacement of follicles in lymphoid tissues in 1 of 3 animals and low-to-moderate amounts 
of PCV2 antigen were demonstrated in 3 of 3 animals in the SDP-IP group. In the SDP-OG 
group, there was mild lymphoid depletion in lymphoid tissues in 3 of 3 animals and low-to-
moderate amounts of PCV2 antigen were present 2 of 3 animals. There was no significant 
difference in overall microscopic lymphoid lesions scores among the POS, SDP-IP and SDP-
OG groups. Lesion scores in all groups were numerically higher in comparison to NEG pigs; 
however, the difference was significant only for the SDP-IP group. Significant differences in 
lung lesions were not observed among treatment groups.   
 
DISCUSSION 
The source of the apparent introduction of PCV2b into multiple locations in North 
America during a short period of time in 2004 is currently unknown. Before 2004, only the 
PCV2a genotype had been isolated (Larochelle et al., 2002). Between 2004 and 2005 a 
marked increase in the numbers of severe PCVAD cases were noted in Canada (Carman et 
al., 2006) and in the United States (Cheung et al., 2007). Sequence analysis of these cases 
confirmed the first occurrence of PCV2b in North America.  
PCV2 is known to be shed in feces, urine, nasal and oral secretions (Segalés et al., 
2005) and remain in tissues for extended periods of time (Bolin et al., 2001). Vertical 
transmission of the virus has also been documented (Madson et al., 2009). The combination 
of multiple shedding routes with the viruses’ ability to withstand environmental stress, leads 
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to the possibility of horizontal transmission. Potential routes for horizontal transmission 
include direct contact with infected animals or indirect contact with contaminated fomites, 
aerosols, or mechanical vectors. Based on previous work, direct contact with infected 
animals is likely more efficient than other sources of transmission (Andraud et al., 2008).  
One potential mechanism for the spread of PCV2b that has not been thoroughly 
investigated is transmission through SDP products. However, several studies have reported 
lack of viability of viruses in SDP. Pseudorabies virus (PRV) and PRRSV were not detected 
in a study where bovine plasma was spiked with the aforementioned viruses, spray-dried and 
tested in cell culture for presence of infectious virus (Polo et al., 2005). In addition, 
commercially produced SDP product incorporated into the diet of weanling pigs did not 
result in seroconversion to any of the tested viruses (Polo et al., 2005). Similarly, when 
porcine plasma was spiked with 10
6
 TCID50 swine vesicular disease virus (SVDV) per ml, 
virus was not detected in spray-dried samples by virus isolation (Pujols et al., 2007). In 
contrast to PRRSV, PRV and even other stable, non-enveloped viruses such as SVDV 
(Turner and Williams, 1999), PCV2 has been shown to be extremely resistant and to 
maintain viability at temperatures of 60°C for 24 hrs and 75°C for 15 min (O'Dea et al., 
2008; Welch et al., 2006).   
The bench-top model of a spray-dryer used in this experiment uses a co-current flow 
of heated air and atomized spray in an open-cycle system to evaporate moisture from an 
aqueous or organic solution (Buchi training papers - spray drying; Buchi Labortechnik AG, 
1997-2002). Although inlet temperatures of 240°C can be achieved during this process, the 
time in which the product is exposed to this temperature is short. This design enables drying 
of plasma products without the destruction of various proteins including antibodies to PCV2, 
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Mycoplasma sp., PRRSV, TGEV and SIV (Borg et al., 2002). There are differences between 
a bench-top model and commercial units, the main one being size which affects the retention 
time of the product within the chamber. The retention time is balanced through control of 
various parameters (inlet temperature, liquid feed rate, etc.) to minimize damage to the 
proteins and maximize the efficiency of the drying process (Maa et al., 1998). 
It has been demonstrated that when SDP products are incorporated into the diets of 
weanling pigs, dietary plasma proteins promote immune modulation of pro- and anti-
inflammatory cytokines resulting in improvements in growth parameters (Moreto and Perez-
Bosque, 2009). This same process which allows proteins to remain stable, may allow 
extremely resistant viruses such as PCV2 to retain infectivity. For example, the outlet 
temperature can be generalized as the maximum product temperature (Buchi training papers - 
spray drying; Buchi Labortechnik AG, 1997-2002). Using this generalization, the 
temperature of the experimentally-produced SDP in this experiment was between 67 to 71°C; 
similar to previously reported temperatures where PCV2 remained viable for 15 min (75˚C) 
or 24 hrs (60°C) (O'Dea et al., 2008; Welch et al., 2006). Therefore, the ability of PCV2 to 
cause seroconversion and viremia in naïve animals in this study was not unexpected. The 
parameters used in this study were based on recommendations of the manufacturer of the 
bench-top spray-dry unit used. Further determination of the necessary inactivation 
temperature for PCV2 by this method is warranted. 
Based on the development of viremia and time of seroconversion, it is highly 
probable that within the SDP-IP and SDP-OG group intra-pen transmission occurred. 
Previous work has shown that the mean time for a newly infected animal to infect a 
susceptible animal is approximately 18 days when naïve animals are placed into the same pen 
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as experimentally infected animals (Andraud et al., 2008). While ideally each pig would have 
been housed individually to perform replicates of the experiment, the conditions of the trial 
answer the question of whether a group of animals can be infected with PCV2 through 
exposure to an experimentally generated SDP product containing PCV2. However, this study 
does not indicate the relative magnitude and importance of this source of infection under 
field conditions. 
Transmission of PCV2 from external sources into the experimental rooms was 
controlled in this study by utilizing multiple sampling teams whenever possible. If entering 
multiple rooms on the same day was absolutely necessary, a shower was taken between 
rooms and different face masks, gloves and coveralls were worn in each room. Throughout 
the study, negative control animals housed under the same conditions as experimental groups 
failed to seroconvert or become viremic. Additionally, sequence analysis of the PCV2 
recovered from one viremic pig from each group confirmed 100% similarity with the 
inoculum.  
In contrast to the results of this experiment, in a study in which SDP was incorporated 
into the diet of three-to-four week old SPF pigs, neither seroconversion nor viremia was 
detected (Pujols et al., 2008). In contrast to the present study, in which PCV2-naïve pigs 
were utilized, pigs with low levels of passively-derived anti-PCV2-IgG as determined by 
IPMA (all pigs were negative based on a capture ELISA) were used by Pujols et al. (2008) 
which is more representative of commercial pigs. The increased sensitivity of the IPMA in 
comparison to the capture ELISA, likely indicates that the levels of passively-acquired 
antibody were low (Pujols et al., 2008). Possible passively-acquired antibodies that may have 
remained undetected by the ORF-2 ELISA in the animals used in the current study can be 
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ruled out as the PCV2-naïve status of the source herd was monitored over time and also 
confirmed by additional serological assays on the entire sow population (data not shown). 
Previously, in animals with high levels of passively-acquired antibodies decreased viremia 
and seroconversion following experimental challenge with PCV2 was observed; however, 
low levels of passively acquired antibody titers were not found to be generally protective 
(McKeown et al., 2005). As anti-PCV2 antibodies can mask or delay infection we decided to 
use a bioassay model based on naïve pigs.  
Additional differences to the study by Pujols et al. (2008) include the use of different 
sources of SDP and a different route of inoculation. In the current study, plasma containing 
5.63 × 10
7
 PCV2 genomic copies per ml from an experimentally inoculated pig with clinical 
and histological evidence of PCVAD was used to directly inoculate the animals in the POS 
control group and to generate the SDP product used to inoculate the animals in the SDP-IP 
and SDP-OG groups. In the study by Pujols et al. (2008), commercially-processed SDP 
containing 2.47 × 10
5
 PCV2 DNA copies/ml was used. While information is not available on 
the minimum infectious dose for PCV2, in previous work by the authors, oral administration 
of meat containing 10
4
 PCV2 DNA copies per ml of homogenized tissue resulted in 
seroconversion and viremia in naïve animals (Opriessnig et al., 2009). In published 
experimental studies, the most common route of infection is the intra- or oronasal route using 
doses ranging from 10
2
 TCID50 per ml to 10
6
 TCID50 per ml (Tomás et al., 2008). In the 
current study, the main objective was to determine if SDP was infectious. Therefore, pigs 
were inoculated via intraperitoneal injection and by oral gavage in a tightly controlled 
bioassay model. In contrast, Pujols et al. (2008) incorporated the SDP in the diet of pigs for 
45 days which more closely simulates field conditions.  
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This work provides direct evidence that experimentally-produced spray-dried porcine 
plasma collected from a PCV2b-experimentally infected pig is infectious to naïve animals 
through the intraperitoneal and oral gavage routes. However, commercially produced 
products utilize pooled plasma from clinically healthy pigs and it is not appropriate to fully 
extrapolate results from this experimentally-produced SDP process to the commercially-
produced spray dried porcine plasma process and product used in the swine industry today. 
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Table 1. Summary of important differences in the production of the experimentally produced spray-dried plasma used in this study 
and typical products produced for commercial use.  
 Experimental plasma used Typical commercial plasma  
Overall health status 
Clinical signs of PCVAD (severe 
dyspnea, diarrhea, and loss of 
condition) requiring euthanasia 
Ambulatory and free of clinical signs of disease; inspected by 
federal authorities and passed as fit for slaughter for human 
consumption 
Age at plasma collection 8 weeks 25 weeks (mature; market weight) 
PCV2 status 
High PCV2 viremia and no anti-PCV2 
IgG antibodies 
Unknown 
Pooling Not pooled (1 pig) Pooled (8,000 to 20,000 pigs) 
Inlet temperature 166°C 200°C to 240°C 
Outlet temperature 67°C to 71°C 80°C to 90°C 
Dwell/Retention time 
(drying chamber) 
Less than 1 sec 20 sec to 1 min 
Post drying 
configuration (cyclone, 
bag house) 
Immediate cooling to ambient 
temperature 
Extended time for dissipation of heat due to packaging  
(25 kg bags or 1 ton totes) 
1
4
5
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Figure Legends 
 
Fig. 1. Group mean anti-PCV2-IgG sample-to-positive (S/P) ratios and standard error results 
for pigs intraperitoneally inoculated with spray-dried plasma (SDP-IP), pigs orally gavaged 
with PCV2-infected spray-dried plasma (SDP-OG), pigs intraperitoneally inoculated with 
PCV2-positive plasma (POS) or pigs which were non-inoculated (NEG). Group means and 
standard errors were calculated using all three animals in each group at each time point. S/P 
ratios equal or greater than 0.2 are considered positive. Significant different group means at a 
given time point are indicated by different superscripts (A, B). 
 
  
0
0.1
0.2
0.3
0.4
0.5
7 14 21 28 35 42 49
A
n
ti
-P
C
V
2
-I
g
G
 s
am
p
le
:p
o
st
iv
e 
ra
ti
o
Days post inoculation
SDP-IP SDP-OG POS NEG
A
A,B
A,B
A,B
A,B
A,B
A,B
A,B
B B B B B
A
A
A
A
A
147 
 
 
Fig. 2. Group mean log10 PCV2 genomic copies per ml serum and standard errors for pigs 
intraperitoneally inoculated with PCV2- infected spray-dried plasma (SDP-IP), pigs orally 
gavaged with PCV2- infected spray-dried plasma (SDP-OG), pigs intraperitoneally 
inoculated with PCV2-positive plasma (POS) or pigs which were non-inoculated (NEG). 
Group means and standard errors were calculated using all three animals in each group at 
each time point. Significant different group means at a given time point are indicated by 
different superscripts (A, B). 
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CHAPTER 6.   Disinfection protocols reduce the amount of porcine circovirus type 2 
(PCV2) in contaminated livestock transport vehicles 
 
 
A paper submitted to the Journal of Swine Health and Production  
 
Abby R. Patterson, Rodney B. Baker, Darin M. Madson, Adam L. Pintar, Tanja Opriessnig 
 
 
ABSTRACT 
Objective: To evaluate the ability of four disinfection methods to reduce porcine circovirus 
type 2 (PCV2) in livestock trailers. Materials and Methods: Trailer models were 
contaminated with intestinal content collected from a pig experimentally infected with PCV2, 
washed, and then disinfected with one of four disinfection protocols. Between each step, six 
swabs of each trailer were taken and tested by PCV2 PCR. The disinfection protocols were: 
DISF1 (quaternary ammonium compound), DISF2 (oxidizing agent containing potassium 
peroxomonosulfate), DISF3 (combined glutaraldehyde and quaternary ammonium product) 
and DISF4 (DISF2 followed by a sodium hypochlorite compound). Also included were 
PCV2 contaminated, non-washed, non-disinfected trailers (POS control treatment) and an 
uncontaminated trailer (NEG control treatment). Two PCV2-naïve pigs were placed in each 
trailer for two hours. Blood samples were collected weekly for seven weeks and tested for the 
presence of anti-PCV2-IgG antibodies and PCV2 DNA. Results: In all four disinfection 
protocols the initial wash step significantly (P<0.05) reduced the mean amount of PCV2 
DNA present compared to the POS control treatment; however, only DISF4 (P<0.0001) 
reduced the mean amount of PCV2 DNA compared to the amount present after the wash 
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step. After disinfection, between 1.5 and 5.2 log10 PCV2 genomic copies/ml were identified 
in the trailers. While animals exposed to POS control trailers became viremic and 
seroconverted, no seroconversion or viremia was detected in animals exposed to disinfected 
trailers. Implications: Although PCV2 DNA was detected in all trailers after disinfection, 
PCV2 was not transmitted to naïve animals exposed to the trailers under the study conditions. 
 
Keywords: Porcine circovirus type 2, transmission, transportation, swine 
 
Porcine circovirus type 2 (PCV2) is a small, non-enveloped, circular, single stranded DNA 
virus that was first isolated from pigs exhibiting multisystemic wasting disease in the late 
1990’s.1 Since the initial description, PCV2-associated disease (PCVAD) has been reported 
in most pig producing countries worldwide and the virus is now considered ubiquitous.
18
 
PCVAD is now manifested in a variety of ways including multisystemic disease with 
wasting, reproductive failure, enteritis, respiratory disease, porcine dermatitis and 
nephropathy syndrome or a combination of these.
15
 In cases of PCVAD, a morbidity rate of 
4-30% with a mortality rate of 70-80% in affected animals has been reported.
20 
Commercial 
PCV2 vaccines are now available and have generally been very effective in reducing 
morbidity and mortality in the field
5
 and under experimental conditions.
6
 
 
PCV2 has been shown to be shed in respiratory secretions, oral secretions, urine and feces.
20
 
It is a hardy virus that is quite stable in the environment. In an in vitro study
12
, PCV2 virus 
stock was subjected to various heat treatments ranging from 56°C to 85°C for 15 min. 
Following incubation, the virus stock was added to PK-15 cells and evidence of PCV2 
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infection was documented. Under these conditions, PCV2 antigen staining was not detected 
at treatment temperatures between 75°C to 85°C although PCV2-PCR products were 
identified in samples treated at 75°C. In other studies, dry-heat treatment of freeze-dried 
PCV2 at 120°C for 30 min resulted in only a 1 log reduction of the virus
23
 and PCV2 
retained an infectivity titer of 1 × 10
2.7 
following exposure to a pH of 2 for 30 min and a titer 
of 1 × 10
2.5 
following incubation at 70°C for one hour.
9
  
 
Previous work also suggests that under in vitro conditions, mean PCV2 titers were reduced 
but not completely eliminated following exposure to various disinfectants with oxidizing 
products and aldehyde/quaternary ammonium combination products showing the highest 
efficacy.
10,19,24
 In a separate study, exposure of PCV2 cell suspensions to an oxidizing 
product or to a sodium hydroxide compound led to a complete reduction in PCV2 infectivity 
following a 10 min incubation period.
8
 However, neither a cytotoxicity control nor a virus 
control (virus plus media alone) were used in this study. While the above information exists 
on the effectiveness of disinfectants under in vitro conditions, to the authors’ knowledge no 
information exists on the effectiveness of disinfectants under field conditions. 
 
Knowledge of the modes of transmission of PCV2 is vital in understanding the ecology, 
epidemiology and control of PCVAD.
3
 Specific information on the horizontal transmission of 
PCV2 via fomites such as commercial livestock transport trailers is lacking. The increased 
use of multi-site production facilities has led to an increased frequency of animal movement 
and with this there is an increased risk of pig exposure to pathogens while in transport. To the 
authors’ knowledge, no information exists to date on the ability of commercial transport 
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trailers to aid in transmission of PCV2 or on the ability of various disinfectant protocols to 
decrease or eliminate the risk of transmission of PCV2 via this route. The objective of this 
study was to evaluate the ability of four disinfection protocols with known in vitro 
effectiveness against PCV2 to prevent transmission of PCV2 under simulated field 
conditions. To accomplish this, the amount of PCV2 DNA present in PCV2 contaminated, 
washed, disinfected trailers (DISF1-4 treatments) was compared to the amount of PCV2 
DNA present in a PCV2 contaminated, non-washed, non-disinfected trailer (POS control 
treatment). In order to determine the infectivity of the PCV2 DNA detected by PCR, naïve 
pigs were exposed to trailers with either DISF1-4 treatments, POS control treatments, or an 
uncontaminated trailer (NEG control treatment). 
 
MATERIALS AND METHODS 
Experimental design 
The experimental protocol in this study was approved by the Iowa State University 
Institutional Animal Care and Use Committee. The first objective of the study was to 
determine if the disinfection step reduced the amount of PCV2 present on the trailer surface. 
To accomplish this, trailer models (experimental unit) were contaminated with fecal material 
collected from a pig experimentally infected with PCV2 and showing clinical signs 
consistent with PCVAD (n=11) or remained uncontaminated (n=1). Six swabs (subsamples 
taken from six different trailer surface locations, Figure 1 B-G) were taken of each trailer 
following contamination, designated as “Post-contamination” samples and tested for the 
presence of PCV2 DNA by real-time PCR.
17
 Following PCV2 contamination, positive 
control trailers (n=4) were not washed. All other trailers (n=7) were washed. Six swabs of 
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each of the washed trailers were taken, designated as “Post-wash” and tested by real-time 
PCV2 PCR.
17
 Following the wash step, the trailers were disinfected with one of four 
disinfection protocols (DISF1-4). Six swabs of each of the disinfected trailers were taken, 
designated as “Post-disinfection” and tested by PCV2 real-time PCR.17 A summary of the 
number of replicates and swabs taken at each sampling point is outlined in Table 1. High 
numbers of replicates of the POS control treatment were done to gain a statistically more 
precise estimate of a subset of the collected data (post-contamination vs. post-wash, and post-
contamination vs. post-disinfection).   
 
The second objective of the study was to determine whether the PCV2 DNA present in 
disinfected trailers (DISF1-4) was infectious to naïve animals. To answer this question, a 
total of 24 PCV2 naïve pigs were used by placing pigs in groups of two into trailers which 
were randomly assigned to a treatment (POS control, n=8 pigs; NEG control, n=2 pigs; or 
DISF1-4, n=14 pigs). The pigs were exposed to the trailers for a total of two hours. After 
this, the pigs were moved to the research facility and were kept by group in rooms for 49 
days following trailer exposure. The pigs were monitored on a weekly basis for development 
of anti-PCV2-antibodies by ELISA
11
 and PCV2 viremia by real-time PCR.
17
 
 
For this portion of the study, an incomplete block design with three experimental units 
(trailers containing two pigs) per block, four blocks, and six treatments was used (Table 2.). 
Within each block, the trailer was considered the independent experimental unit and 
treatments were randomly assigned to trailers. Each block included a POS control treatment 
and two of the remaining five possible treatments (DISF1-4 or NEG control). There were two 
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replicates each for the DISF1, DISF2, and DISF3 treatments. There was one replicate each of 
the NEG control and DISF4 treatments because those treatments were expected to be the 
most different from the POS control based on previous in vitro work.
10,19
 Blocks were 
included in the study to account for variation in environmental conditions. 
 
PCV2 contaminated fecal material 
A colostrum-fed, crossbred, specific-pathogen-free, PCV2-naïve pig was inoculated with 5 
ml (3 ml intranasally and 2 ml intramuscularly) of 10
4.0
 50% tissue culture infectious dose 
(TCID50) per ml of PCV2b isolate NC-16845 (accession no. EU340258) at 3 weeks of age. 
At 35 days post inoculation, the pig was euthanized with an overdose of pentobarbital (Fatal 
Plus®, Vortech Pharmaceutical, Dearborn, Michigan, USA) due to the development of 
clinical signs consistent with PCVAD including severe dyspnea, diarrhea, and loss of 
condition. After euthanasia, the complete contents of the small intestine, cecum and colon 
were collected. Twenty ml aliquots of intestinal contents were transferred into 50 ml 
centrifuge tubes and stored at -20°C until use. A portion of the fecal material was tested for 
the presence of PCV2 DNA by real-time PCR
17
; 10.8 log10 genomic copies/ml of PCV2 
DNA were recovered. PCV2 systemic infection of the animal was further confirmed by the 
presence of intense PCV2 antigen staining by immunohistochemistry (IHC)
21
 in the lungs, 
intestine and lymphoid tissues. Transmissible gastroenteritis virus antigen, rotavirus type 2 
antigen, and Lawsonia intracellularis antigen were not detected by IHC. Porcine 
reproductive and respiratory syndrome virus (PRRSV) RNA, swine influenza virus (SIV) 
RNA, and Mycoplasma hyopneumoniae DNA were not detected by PCR. All of the tests were 
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performed following the standard operating procedures for the specific tests at the Iowa State 
University Veterinary Diagnostic Laboratory.  
 
Trailers 
For each block, three model trailers were used to evaluate three of the six treatments. Trailers 
were designed and constructed by a company specializing in standard and custom aluminum 
livestock transportation equipment (EBY Inc., Story City, Iowa, USA). The trailer models 
were specifically designed to accurately portray a standard semi-livestock trailer used in the 
transportation of commercial swine. The models were composed of 29 mm thick 6061 T-6 
aluminum alloy diamond plate flooring welded and riveted to tubular extruded aluminum 
cross-members, 19 mm thick aluminum smooth sheet side walls with both large (25.4 cm × 
14.9 cm) and small (8.9 cm × 7.0 cm) ventilation holes with an overlapped seam at the side 
post, extruded aluminum side posts with integral closure track, a hinged aluminum rear door, 
a center divide gate and a simulated roll-up door (Figure 1). Final dimensions were 0.62 m 
(width) × 0.82 m (height) × 1.11 m (length). The trailer models were 1:61 scale models of a 
full sized trailer and had a floor space of 0.69 m
2
 which corresponded to 41.85 m
2
 (2.59 m 
wide and 16.16 m long) for the full-sized trailer, and a constant animal density of 0.34 m
2
 
(trailer floor space in m
2
 divided by number of animals per trailer).  
 
Trailer sampling protocol 
At each of the four sampling points (pre-contamination, post-contamination, post-wash, post-
disinfection) six swabs (polyester-tipped swab, Fisher Scientific Inc., Pittsburgh, 
Pennsylvania, USA) were taken of each trailer (Figure 1, B-G). Each swab was placed into 1 
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ml of sterile saline (0.9% sodium chloride solution, Fisher Scientific Inc.), used to swab a 5.5 
cm diameter area (using a template) and then returned for storage at -80°C in a 5 ml plastic 
tube (BD falcon tube, Fisher Scientific Inc.) prior to testing by PCR. To prevent carryover 
contamination between trailers during a certain sampling step, a new template was used for 
each trailer, and new gloves were used by the investigator. To prevent carryover between 
sampling steps, templates were submerged in an oxidizing disinfectant (Virkon®S, DuPont 
Chemical Solutions Enterprise, Wilmington, Delaware, USA) for 10 min between sampling 
points.  
 
Trailer contamination protocol 
To contaminate each of the trailers (except the trailer used for the NEG control treatment), a 
20 ml aliquot of the PCV2 contaminated fecal material was thawed at 4°C overnight and 
spread on the walls and floor of the trailer by the same investigator for each trailer within a 
block. Following contamination, 200 g of bedding (woodchips; Theisen’s, Ames, Iowa, 
USA) were placed on the floor of the trailer. In order to maintain similar experimental 
conditions between groups bedding was also placed in the trailer assigned to the NEG control 
treatment. 
 
Trailer washing protocol 
To prevent cross-over contamination from the previous step, investigators changed gloves 
prior to the wash step. The trailers were washed using the following protocol: The trailer was 
first rinsed using a low pressure (50 psi) nozzle to flush out the majority of woodchips and 
gross debris, then washed with 48.9°C water using a high-pressure (2400 psi) nozzle for 
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approximately 30 sec and last rinsed using a low pressure nozzle to remove any remaining 
gross debris.  
 
Trailer disinfection protocol 
To prevent cross-over contamination from the previous step, a new investigator or an 
investigator who had showered and changed clothes and gloves applied disinfectant to the 
trailer. Gloves were changed between trailers and ample room was available to prevent cross-
over of disinfectants between trailers within a block. Disinfectants were applied using a 
liquid concentrate sprayer (H.D. Hudson Manufacturing Company, Chicago, Illinois, USA) 
attached to a garden hose. The following disinfectants which correspond to the experimental 
design in Table 1 were used: DISF1, a quaternary ammonium compound (PI Quat 20®, 
Preserve International, Reno, Nevada, USA); DISF2, an oxidizing agent containing a 
potassium peroxomonosulfate (Virkon®S); DISF3, a combined glutaraldehyde and 
quaternary ammonium product (Synergize®, Preserve International, Reno, Nevada, USA); 
and DISF4, an application of two disinfectants in tandem, the first being the previously 
described oxidizing agent (Virkon®S,) followed by a chloride compound (Clorox® Bleach, 
The Clorox Company, Oakland, California, USA). Disinfectants were applied at the 
following rates based on the respective manufacturers’ recommendations: DISF1 was applied 
at a rate of 59 ml/18.9 liter (2 oz/5 gal) of water, DISF2 was reconstituted to a concentration 
of 100 g/liter and applied at a rate of 30 ml/3.8 liter (1 oz/gal) water, and DISF3 was applied 
at a rate of 15 ml/3.8 l (0.5 oz/gal) water. For DISF4, the oxidizing agent was applied at the 
previously described rate and the chloride compound was applied at a rate of 177.4 ml/3.8 
liter (6 oz/gal) of water. Disinfectants were applied and after 10 min of contact time the 
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trailers were rinsed with water. The temperature through the disinfectant process was similar 
(20˚C) for all blocks. 
 
Decontamination protocol between blocks 
To ensure that residual contamination of the trailer between the four blocks did not occur, 
trailers were washed with 48.9°C water using a high-pressure (2400 psi) nozzle, scrubbed 
with a detergent product (Ultra Palmolive® OXY® plus with Bleach Alternative, Colgate-
Palmolive Company, New York, New York, USA), thoroughly rinsed, disinfected with an 
oxidizing agent (Virkon®S) and allowed to dry completely. This process was repeated until 
PCV2 DNA was not detected by real-time PCR from six different trailer surface locations 
(Figure 1, B-G) by using swabs. 
 
Animals 
Blocks no. 1 and no. 2 were performed with animals from source A in September 2008 and 
blocks no. 3 and no. 4 were performed using pigs from source B in February 2009. Obtaining 
pigs from two sources was not part of the study design, but it was necessary due to the 
inability to obtain PCV2 naïve animals from source A in February of 2009. The use of blocks 
accounted for the variability introduced from using two pig sources. In both sources, pigs 
were colostrum-fed, crossbred, specific-pathogen-free conventional pigs purchased from 
herds that were routinely tested for major swine pathogens and known to be free of PCV2, 
PRRSV, porcine parvovirus and SIV. Source A pigs were weaned at three weeks of age and 
raised to approximately 18-27 kg at which time they were transported to the Livestock 
Infectious Disease Isolation Facility (LIDIF) at Iowa State University, Ames, Iowa. Source B 
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pigs weaned at two weeks of age and raised to approximately 10-22 kg at which time they 
were transported to the LIDIF. Pigs were housed in groups of two in separate rooms. Each 
room had 18 m
2
 of solid concrete floor space, separate ventilation systems and one nipple 
drinker. All groups were fed a balanced, pelleted, complete feed ration free of animal 
proteins (excluding whey) and antibiotics (Nature’s Made, Heartland Coop, Iowa, USA) once 
a day. Pigs were tested upon arrival at the facility by real-time PCV2 PCR
17
and PCV2 
ELISA
11
 on serum to confirm that they were PCV2 free prior to initiation of the trial.  
 
Exposure of the pigs to the trailer models 
Following disinfection, the three model trailers were placed into a clean equine trailer (no 
prior exposure to swine) and separated by clear polyethylene sheeting. Two pigs were placed 
in each trailer for a total exposure time of two hours. During this time, the trailers were 
driven on a specific route which included approximately 32.2 km of interstate, 56.3 km of 
state highway, and 32.2 km unpaved (gravel) road through Hardin, Story and Hamilton 
counties in the state of Iowa. Following the two hour exposure period, pigs were placed in 
isolation rooms by treatment group. At the time of block no. 1, the temperature was 22.8°C 
and it rained throughout the time of transport. At the time of block no. 2, the temperature was 
29.4°C with no precipitation. At the time of block no. 3, the temperature was 1.1°C with no 
precipitation. At the time of block no. 4, the temperature was -12.2°C with no precipitation.  
 
Anti-PCV2-IgG antibodies and PCV2 DNA quantification and sequencing 
Blood samples were collected on the day of exposure, and weekly thereafter until 49 days 
post trailer exposure. The blood was collected in 8.5 ml serum separator tubes (Fisher 
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Scientific Inc., Fair Lawn, New Jersey, USA), immediately centrifuged at 2000 x g for 10 
min at 4°C and stored at -80°C until use. Serum samples were tested by an ORF2-based 
PCV2 IgG ELISA and were considered positive if the calculated sample-to-positive (S/P) 
ratio was 0.2 or greater as previously described.
11
 DNA-extraction on serum samples was 
performed using the QIAamp® DNA Mini Kit (Qiagen Inc., Valencia, California, USA). 
Previously described primers for ORF 1 of PCV2
17
 were used for quantification of the PCV2 
genomic DNA by real-time PCR. The PCR reaction consisted of 25 µl PCR mixtures that
 
contained 12.5 µl of commercially available master mix
 
(TaqMan Universal PCR Master 
Mix, Applied Biosystems Inc., Foster City, California, USA), 2.5
 
µl DNA extract, 1 µl 
forward and reverse
 
primers, and 0.5 µl detection probe with concentrations of 10 µM. On 
each plate five progressive 1:10 dilutions of a known
 
copy number of PCV2 genomic DNA 
excised from a purified PCV2
 
DNA clone was included to generate a standard curve. Each 
plate
 
was run in the sequence detection system (7500 Sequence
 
Detection System; Applied 
Biosystems Inc.) under the following conditions: 2 min at 50°C, 10 min
 
at 95°C, followed by 
40 cycles of 15 sec at 95°C and 1 min
 
at 60°C.
 
Samples which did not generate a signal 
following 40 cycles were considered negative. PCR products amplified from virus recovered 
from a serum sample from one animal in each of the positive control groups, was sequenced 
and compared with the PCV2 in the fecal material used to contaminate the trailers. A nested 
PCR was used to amplify the entire ORF2 gene for sequencing as previously described.
14
 
PCR products were purified using the QIAquick PCR purification kit (Qiagen Inc.) per the 
manufactures directions and sequenced at Iowa State University DNA facility. Sequences 
were analyzed with Sequence Scanner 1.0 (Applied Biosystems Inc.) and compared with the 
sequence of the PCV2 present in the fecal material using the basic local alignment search 
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(BLAST) tool.
25
 
 
Necropsy 
All pigs were necropsied at 49 days post trailer exposure. Severity of macroscopic lung 
lesions ranging from 0 to 100% of the lung affected were estimated and the size of lymph 
nodes was scored from 0 (normal) to 3 (four times the normal size) in a blinded fashion as 
described previously.
13
 Sections of lymph nodes (superficial inguinal, mediastinal, 
tracheobronchial, mesenteric), tonsil, thymus, ileum, kidney, colon, spleen, and liver were 
collected at necropsy and fixed in 10% neutral-buffered formalin and routinely processed for 
histological examination. 
 
Histopathology 
Microscopic lesions were evaluated by a pathologist blinded to treatment groups. Lung 
sections were scored for the presence and severity of interstitial pneumonia ranging from 0 
(normal) to 4 (severe interstitial pneumonia) as described previously.
7
 Sections of heart, 
liver, kidney, ileum and colon were evaluated for the presence of lymphohistiocytic 
inflammation and scored from 0 (none) to 3 (severe). Lymphoid tissues including lymph 
nodes, tonsil, and spleen were evaluated for the presence of lymphoid depletion ranging from 
0 (normal) to 3 (severe) and histiocytic inflammation and replacement of follicles ranging 
from 0 (normal) to 3 (severe).
16
  
 
Immunohistochemistry (IHC) 
IHC for detection of PCV2-specific antigen was performed on selected formalin-fixed and 
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paraffin-embedded sections of lymph nodes (superficial inguinal, mediastinal, 
tracheobronchial, and mesenteric), tonsil, spleen, Peyer’s patches, and thymus using a rabbit 
polyclonal antiserum as described previously.
21
  PCV2-antigen scoring was done by a 
pathologist blinded to treatment groups. Scores ranged from 0 (no signal) to 3 (more than 
50% of the lymphoid follicles contain cells with PCV2-antigen staining).
16
 
 
Statistical analysis 
The statistical analysis for objective 1, to determine if disinfection reduced the amount of 
PCV2 present on the trailer surface, focused on the differences in log genomic copies of 
PCV2 between three steps of each treatment protocol (post-contamination, post-washing, and 
post-disinfection) and between four disinfectants. The experimental unit was the trailer 
within a block. The assumption of independence of experimental units was reasonable 
because each trailer was carefully cleaned to eliminate carryover between blocks. The 
amount of PCV2 DNA was measured on six swabs (subsamples) at each step within an 
experimental unit; these were averaged before statistical analysis.   
 
Trailers assigned to DISF1-4 treatments were sampled at four steps of the decontamination 
process (pre-contamination, post-contamination, post-washing, and post-disinfection). 
Trailers assigned to the POS control treatment were sampled only twice (pre-contamination 
and post-contamination). Trailers assigned to the NEG control treatment were sampled only 
once. Data from the pre-contamination step and the NEG control treatment were excluded 
from the analysis because no PCV2 DNA copies were detected. The POS control and DISF1-
4 treatments were used to define three unique sampling steps: post-contamination (POS 
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control treatment; DISF1-4), post-washing (DISF1-4 combined), and individual post-
disinfection treatments (DISF1, DISF2, DISF3, or DISF4). This is appropriate because after 
contamination (prior to washing) all trailers were treated alike and after washing (prior 
disinfection) all washed trailers were treated alike.  
 
The statistical analysis accounted for correlation between the three repeated measurements 
on the disinfected trailers (post-contamination, post-washing, and post-disinfection) by 
including a random effect for the experimental unit. Data was analyzed using PROC MIXED 
in SAS version 9.2 (SAS Institute, Inc., Cary, North Carolina, USA). The variation in 
environmental temperatures was accounted for by including block as a fixed effect in the 
model.  Variance components were estimated using REML and the Satterthwaite 
approximation was used to compute degrees of freedom. The type 3 F test of treatments was 
considered significant if the p-value was < 0.05. Differences of least squares means using the 
Tukey-Kramer adjustment were evaluated if the F test was significant.  
 
There was no statistical evaluation for objective 2 of the experiment as neither 
seroconversion nor viremia was detected in any of the animals exposed to disinfected 
(DISF1-4) trailers. 
 
RESULTS 
Amount of PCV2 DNA was reduced on the trailer surfaces following the wash step 
The mean amounts of PCV2 DNA (log10 genomic copies/ml) obtained for each of three 
sampling points (post-contamination, post-wash, and four levels of post-disinfection) are 
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presented in Table 1. The F-test of equal treatment means was highly significant (P<0.0001). 
Differences of least squares means using the Tukey-Kramer adjustment indicated a 
significant reduction in mean log10 genomic copies/ml of PCV2 DNA between the post-
contamination step and the post-wash step. Only the DISF4 protocol significantly (P<0.0001) 
reduced the mean amount of PCV2 DNA present compared to that present after the post-
wash step.  
Evidence of PCV2 infection was not present in naïve animals exposed to contaminated, 
disinfected trailers 
Clinical disease was not observed in any of the pigs for the duration of the study. 
Seroconversion to PCV2 was not detected in the any of the animals exposed to the NEG 
control, DISF1, DISF2, DISF3, or DISF4 treatments during any of the replicates. Both 
positive control pigs seroconverted by 28 days post trailer exposure in blocks no. 1, 2 and 4. 
In block no. 3, one positive control pig seroconverted by 14 days post trailer exposure and 
the other by 42 days post exposure. Viremia was not detected in any of the animals exposed 
to trailers treated with DISF1, DISF2, DISF3, or DISF4 protocols or the NEG control 
treatment during any of the replicates. Both pigs in the POS control group became PCV2 
viremic by 21 days post exposure in blocks 1, 3, and 4. Both POS control pigs in block no. 2 
became PCV2 viremic by 14 days post exposure. Characteristic microscopic lesions of PCV2 
infection or PCV2 antigen staining were not noted in any of the animals from the NEG 
control, DISF1, DISF2, DISF3, or DISF4 groups. In POS control pigs (n=8), there was mild 
to moderate depletion of follicles in the tonsil (1/8) and in lymph nodes (5/8). Histiocytic 
replacement of lymphoid germinal centers was observed in 2/8 animals. Low to moderate 
amounts of PCV2 antigen were detected in the tonsil of 4 of the 8 pigs and in lymph nodes of 
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6 of the 8 pigs. Mild lymphoplasmacytic myocarditis, hepatitis and interstitial nephritis were 
noted in 3/8, 2/8 and 3/8 animals, respectively.  
 
DISCUSSION 
The overall objective of this study was to evaluate the ability of four disinfection protocols 
with known in vitro effectiveness against PCV2 to prevent transmission of PCV2 under 
simulated field conditions. Previous work has shown oxidizing agents, aldehyde compounds 
and quaternary ammonium compounds have efficacy against PCV2 under in vitro 
conditions.
9,10,19
 While in vitro efficacy data is useful, field efficacy of a disinfectant depends 
on the type of surface and the presence of organic material and other variables.
1
 To evaluate 
the effectiveness of the disinfection protocols under simulated field conditions, PCR analysis 
of trailers following the contamination, wash and disinfection steps was preformed to assess 
whether virus was present following each of the steps in the protocols. Second, the infectivity 
of the PCV2 DNA detected on the trailer surface was evaluated by exposing naïve animals to 
the trailers for two hours.   
 
The results of the study indicated that the wash step significantly reduced the amount of 
PCV2 DNA present in the trailers in comparison to the POS control treatment. However, 
following the disinfection step, between 1.5 and 5.2 log10 PCV2 genomic copies/ml were 
identified in the DISF1-4 trailers. This is in agreement with previous in vitro work which 
found that mean PCV2 titers were reduced but not completely eliminated following exposure 
to various disinfectants.
10,19
 Interestingly, washing the trailer alone significantly reduced the 
amount of PCV2 DNA present in the trailers and there was not a significant difference 
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between the washing and disinfection steps when only one disinfectant was applied (i.e. 
excluding DISF4 protocol where two disinfectants were applied). This supports the principle 
that thorough removal of organic material prior to application of a disinfectant is essential to 
the cleaning process. While it is possible that the small number of replicates performed for 
each of the disinfectants hindered the ability to detect a difference between the washing and 
disinfectant steps, a significant difference was detected in the disinfectant protocol with the 
least number of replicates (DISF4). In regards to the significant reduction of PCV2 DNA 
noted in the DISF4 protocol, it is unknown whether the combination of the two disinfectants 
or just the additional rinsing associated with the application of two disinfectants was 
responsible for the outcome and additional studies in this area are warranted. 
 
The detection of PCV2 in trailers following disinfection does not necessarily correlate with 
transmission as detection of virus by PCR does not confirm that the virus is infectious. While 
virus isolation could have been performed to determine the infectivity of the detected PCV2, 
it is documented that PCV2 grows slowly, requires optimized culture conditions and that 
virus isolation is not always successful.
22
 Additionally, viral isolation of PCV2 from rectal 
swabs in experimentally infected cesarean-derived, colostrum-deprived pigs showing clinical 
signs of PCVAD was infrequent even though virus isolation from serum was successful up to 
five weeks post-infection.
2
 Therefore, we elected to do a bioassay where naïve animals were 
exposed to the trailers.  
 
To accurately simulate field conditions, 1:61 scale model trailers were designed and 
manufactured by a company specializing in standard and custom aluminum livestock 
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transportation equipment with the exact materials used during commercial production. 
Trailers were manufactured purposely to contain areas where fecal material would likely 
accumulate and sampling of the trailers was concentrated on these areas to accurately 
determine viral concentration within the trailer following each step in the protocol. 
Interestingly, the thorough disinfection protocol used on trailers between blocks to prevent 
carryover contamination needed to be performed multiple times, especially in block no. 3 and 
no. 4 where environmental temperatures prevented exposure of the trailers to natural 
ultraviolet light. This confirmed that the sampling areas were able to harbor PVC2 DNA. By 
design, the model trailers used in the study provided adequate space to allow animals to turn 
completely around. This allowed for increased exposure to areas where contaminated feces 
may have accumulated. Although effort was made to ensure similarity with field conditions, 
changes associated with normal wear of a trailer were not replicated as trailers were 
manufactured from new materials and used for the first time during this trial. 
 
Fecal material from one experimentally infected animal at the peak of infection was used in 
this study to provide a consistent, high amount of virus in each trailer (10.8 log10 PCV2 
genomic copies/ml). All pigs in the POS control trailers seroconverted and became viremic 
indicating that in each of the blocks the virus was infectious to naïve animals. Previously 
published information suggests the presence of approximately 2 to 6 log PCV2 genomic 
copies/ml in fecal samples from clinically healthy animals, animals with mild PCV2 
associated lesions and animals with moderate to severe microscopic lesions associated with 
PCVAD.
20
 Based on the above data, the concentration of virus used in this study was above 
what would be expected under field conditions.  
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During the study, naïve animals were exposed to the trailer models for two hours and 
transported over paved and unpaved roads in counties in Iowa with high densities of swine 
operations. This contact time is similar to trials done with PRRSV
4
 and is representative of 
transport of pigs between local geographic areas. However, the study is not representative of 
transport between distant geographic areas in which animals may be transported for 12 to 20 
hours. Examples of this would include transport of weaned piglets from farrowing facilities 
in Canada or North Carolina to finisher facilities in the Midwest. As 1.45 ± 0.6 log10 genomic 
copies of PCV2 remained in the trailer following the most efficacious disinfectant protocol, it 
is possible that longer exposure periods could have resulted in transmission of PCV2 to naïve 
animals. 
 
Great effort was made to ensure washing and disinfectant application was similar to field 
conditions. Specifically, a protocol (D. Miller, personal communication) similar to one used 
in a commercial truck wash facility including a low pressure rinse, a high pressure wash and 
a final low pressure rinse to remove gross debris was followed. However, in commercial 
truck wash facilities worker speed to ensure a certain number of trailers per hour are cleaned 
may lead to less diligence toward the cleaning and disinfection process in comparison to the 
experimental conditions of this study.  
 
In this study, PCV2 was not transmitted to naïve animals after application of any of the four 
disinfection methods even though the following conditions were true: (1) naïve animals were 
exposed to a concentration of infectious virus above that which has been reported from fecal 
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samples of naturally infected animals, (2) naïve animals had more than the typical amount of 
floor space in the trailer allowing increased movement and exposure to fecal material 
containing virus, and (3) model trailers were designed to include places in which feces are 
typically difficult to thoroughly remove. However, the number of animals used was low. The 
upper 95th percentile for the probability of infection [Pinfect=exp(ln(1-Pdetect)=N) where N= 
the number of animals in each replicate and Pdetect = 0.95] was 0.53 and 0.78 for DISF1-3 and 
DISF4, respectively.  
 
Implications 
 Washing the trailer with water alone significantly reduced the amount of PCV2 DNA 
present in the trailers. 
 There was no significant difference between the washing and disinfection steps when 
only one disinfectant was applied.  
 DISF4 (DISF2 oxidizing agent followed by a sodium hypochlorite compound) 
treatment significantly (P<0.0001) reduced the mean amount of PCV2 DNA 
compared to the amount present after the wash step. 
 Although between 1.5 and 5.2 log10 PCV2 genomic copies/ml remained in the trailer 
models after disinfection, under the conditions of this study PCV2 was not 
transmitted to naïve animals.   
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Table 1: Mean log10 genomic copies/ml of PCV2 DNA from each of the three sampling 
points (post-contamination, post-wash, post-disinfection). Data from swabs taken from the 
post-contamination step were considered in the same group regardless of which disinfection 
step it was followed by. A similar approach was used for data from the post-wash step. Post-
disinfection samples were considered independently for each disinfection protocol (DISF1-
4). The number of replicates and swab samples used in the statistical analysis are provided in 
the table. 
Step Replicate # Swab # Log10 genomic PCV2 
copies/ml
* 
SE 
1 Post-contamination 11 66 7.0
a 
0.2 
2 Post-wash 7 42 5.7
b 
0.2 
3 
Post-disinfection (DISF1)
 †
 2 12 5.3
b 
0.5 
Post-disinfection (DISF2)
 ‡
 2 12 4.8
b 
0.5 
Post-disinfection (DISF3)
 ∫
 2 12 5.2
b 
0.5 
Post-disinfection (DISF4)
 δ
 1 6 1.5
c 
0.6 
*
Different superscripts (a,b,c) within a column indicate significant (P<0.05, Tukey-Kramer 
adjusted t-value for differences of least squares means) differences among steps. 
†
DISF1, a quaternary ammonium compound (PI Quat 20®, Preserve International, Reno, 
Nevada, USA) 
‡
DISF2, an oxidizing agent containing a combination of potassium peroxymonosulfate and 
sodium chloride (Virkon®S, DuPont Chemical Solutions Enterprise, Wilmington, Delaware, 
USA)
 
∫
DISF3, a combined glutaraldehyde and quaternary ammonium product (Synergize®, 
Preserve International, Reno, Nevada, USA)
 
δ 
DISF4, an application of two disinfectants in tandem, the first being an oxidizing agent 
(Virkon®S, DuPont Chemical Solutions Enterprise, Wilmington, Delaware, USA) followed 
by a chloride compound (Clorox® Bleach, The Clorox Company, Oakland, California, USA)  
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TABLE 2:  Incomplete block design using three trailers and four replicates to determine 
whether PCV2-naïve animals would become PCV2 seropositive or viremic following a 2 hr. 
exposure period to PCV2 contaminated, non-washed, non-disinfected trailers (POS control 
treatment); PCV2 contaminated, washed, disinfected trailers (DISF1-4 treatment) or 
uncontaminated trailers (NEG control treatment). 
Replicate Trailer 1 Trailer 2 Trailer 3 
1 DISF1
*
 NEG POS 
2 POS DISF2
†
 DISF1 
3 DISF2 POS DISF3
‡
 
4 POS DISF3 DISF4
 δ
 
*
DISF1, a quaternary ammonium compound (PI Quat 20®, Preserve International, Reno, 
Nevada, USA) 
†
DISF2, an oxidizing agent containing a combination of potassium peroxymonosulfate and 
sodium chloride (Virkon®S, DuPont Chemical Solutions Enterprise, Wilmington, Delaware, 
USA) 
‡
DISF3, a combined glutaraldehyde and quaternary ammonium product (Synergize®, 
Preserve International, Reno, Nevada, USA) 
δ
 DISF4, an application of two disinfectants in tandem, the first being an oxidizing agent 
(Virkon®S, DuPont Chemical Solutions Enterprise, Wilmington, Delaware, USA) followed 
by a chloride compound (Clorox® Bleach, The Clorox Company, Oakland, California, USA)  
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Figure 1: Trailer models designed as 1:61 scale models of a full sized standard semi-
livestock trailer used in the transportation of commercial swine (A). The models were 
composed of aluminum smooth sheet side walls welded and riveted to tubular extruded 
aluminum cross-members (B), a hinged aluminum simulated roll-up rear door (C), aluminum 
alloy diamond plate flooring (D), a latch (E), an overlapped seam at the side post (F) and 
center divide gate (G). Final dimensions were 0.62 m width × 0.82 m height × 1.11 m length.  
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CHAPTER 7.   Establishment and maintenance of a porcine circovirus type 2 (PCV2)-
free research breeding herd on a site that experienced a natural outbreak of PCV2-
associated reproductive disease  
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ABSTRACT 
The objectives were to document a porcine circovirus type 2 (PCV2)-associated reproductive 
failure outbreak in a closed, PCV2-naïve specific pathogen free herd in Iowa in 2009, to 
describe the elimination of infectious PCV2 from the breeding herd site, to report the 
outcome after repopulation, and to attempt to derive PCV2 negative animals by offsite 
segregation. Clinical signs were limited to an increased incidence of mummified fetuses. 
After confirmation of PCV2-associated lesions in the fetuses and PCV2 viremia in dams, the 
herd was depopulated. Cleaning and disinfection of the premise prior to repopulation 
included removal of gross organic material, exposure of equipment to natural UV light, 
multiple applications of disinfectant, and application of paint or sealer to porous surfaces. 
During the 63 day clean-up period, no pigs were on the site. An improved biosecurity plan 
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was also implemented. The herd was repopulated and a PCV2-naïve population has since 
been maintained at the facility to date (>300 days). Attempts to derive PCV2 negative pigs 
from the positive herd following offsite segregation were unsuccessful. The combination of a 
multistep cleaning and disinfection protocol with a strict biosecurity plan can result in the 
maintenance of PCV2 naïve animals on a previously contaminated site.     
 
Key words: Porcine circovirus type 2, swine, disinfection, biosecurity 
 
Porcine circovirus type 2 (PCV2) is a small, non-enveloped, single-stranded DNA virus
 
which emerged in the 1990’s as an economically important swine pathogen.6 The first report 
of PCV2 reproductive disease occurred in a commercial 450-head herd composed entirely of 
first parity dams.
38
 The timing of infection was not determined in that case and clinical signs 
on the farm included late-term abortions (losses after 13 weeks of gestation), decreased 
farrowing rates and increased stillborns and mummified fetuses; no clinical signs were 
reported in the gilts. In one of nine examined fetuses, myocarditis and abundant PCV2 
antigen was identified in fetal myocardium. Other common pathogens associated with 
reproductive disease were not detected.
38
 Multiple case reports on PCV2-associated 
reproductive failure have subsequently been described in seropositive herds
8,22
 or in start-up 
herds or gilt populations which may have been serologically naïve to PCV2.
2,19,20,29
 Common 
clinical features included increased numbers of mummified fetuses and stillborns at 
parturition, none or low numbers of dams exhibiting clinical signs, and resolution of clinical 
signs between two to five months following initial detection.  
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PCV2 is quite stable in vitro
24,37
 and many disinfectants do not completely eliminate the virus 
under in vitro conditions.
11,17,31
 To our knowledge, no documented information exists on 
facility disinfection procedures for establishment and maintenance of a PCV2 negative herd. 
However, a procedure for room decontamination used successfully by researchers at Iowa 
State University to disinfect rooms between PCV2-animal inoculation studies was recently 
described.
5
 
 
The objectives of the current study were to document a natural outbreak of PCV2 in a high 
health population previously known to be free of PCV2, to describe the procedure used to 
disinfect the premise, report the outcome after repopulation, and document an attempt to 
derive PCV2 negative animals by offsite segregation. 
 
GENERAL INFORMATION 
Building descriptions 
The source herd was housed in a facility located in Iowa originally built in the 1970’s. The 
facility is composed of five 22.8 m × 15.2 m buildings in close proximity (15-30 m) to each 
other with an associated waste lagoon (Figure 1). An uncovered concrete walkway (Figure 1) 
connects the individual buildings and was installed after herd depopulation following the 
2009 outbreak. 
 
General building: Building 1 is used as the general services building which is divided into 
two sides by a concrete wall. Side one is used as the entrance to the facility with office space, 
shower, laundry and locker room. Side two is used as storage for feed and equipment and 
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tools for building maintenance. Building 1 has one door for entry into the sign-in area, a door 
that leads out from the office area and a garage door for entry into a feed and equipment 
storage area.  
 
Animal buildings: Buildings designated 2 through 5 are used for animal housing. The animal 
buildings are completely enclosed, power ventilated, and partially slated with pull-plug 
drains. Animal buildings 2, 3, and 5 have a center concrete wall which divides the building 
into two halves; each half has a separate access point. Building 2, 3, and 5 have each two 
manure pits which are 1.2 m wide, 3.4 m long and 0.9 m deep. Building 4 has one manure pit 
which is 1.2 m wide, 22.8 m long and 0.9 m deep.  
 
Herd description and housing prior to complete depopulation in May 2009 
Naïve sows and gilts were placed on site approximately two years prior to the described 
outbreak; no new animals were brought to the facility from the time of initial population in 
December 2007 until depopulation in May of 2009. Sows were cross-bred, specific-
pathogen-free (SPF) animals [PCV2, porcine reproductive and respiratory syndrome virus 
(PRRSV), swine influenza virus (SIV), and porcine parvovirus (PPV) naïve] of mixed 
parities. Sows and gilts were housed in buildings 2 and 3 during gestation and moved into 
building 5 prior to farrowing. Building 3 also contained mature boars in addition to gestating 
sows. Building 4 was primarily used as a nursery unit. During the observation period, there 
were a total of 38 breeding animals onsite (n=12 in building 2; n=13 in building 3; n=2 in 
building 4, n=11 in building 5).  
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PCV2-ASSOCIATED REPRODUCTIVE DISEASE OUTBREAK  
Outbreak detection and confirmation 
The details on the timeline of the PCV2 outbreak are summarized in Figure 2. The PCV2 
outbreak was first noted on January 29, 2009 when a portion of weaned two week old pigs 
from building 4 were routinely screened and found to be positive for the presence of anti-
PCV2 antibodies based on a previously described ELISA.
21
 Subsequently, the presence of 
anti-PCV2 antibodies in the samples was confirmed by an in-house IFA assay
30
 and PCV2 
DNA was detected by using a quantitative real-time PCR.
27
 Serum samples were collected 
from all sows and a mixture of seropositive non-viremic animals, seropositive viremic 
animals and seronegative viremic animals were detected in buildings 2, 3 and 5. Neither anti-
PCV2 antibodies nor PCV2 DNA were detected in the serum of the two gilts housed by 
themselves in one half of building 4. The exact timing of infection was not deduced from this 
data. However, based on a high proportion of sows in which PCV2 DNA was detected 
without detectable anti-PCV2 antibody in building 2 (66.7% seropositive sows) and 3 (45.2% 
seropositive sows), infection was apparently most recent in these building and of longer 
duration in building 5 (90.9% seropositive sows).  
To further characterize the PCV2 strain that infected the herd, PCV2 open reading frame 2 
(ORF2) sequencing was performed on extracted DNA from two sow serum samples and one 
piglet serum sample using a nested PCR as previously described.
25
 The PCR products were 
purified using the QIAquick PCR purification kit (Qiagen, Valencia, California, USA) per 
manufacturers’ instructions and sequenced at the Iowa State University DNA facility. 
Sequences were analyzed with Sequence Scanner software v1.0 (Applied Biosystems) and 
compared with four common PCV2a and PCV2b strains using the basic local alignment 
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search tool (BLAST)
39
and the isolate was identified as PCV2b (100% homology with 
GenBank Accession No. EU340258).  
 
Reproductive parameters and clinical observations in breeding animals from May 2008 to 
April 2009  
Farrowing data from the 38 sows between May 2008 and April 2009 was recorded by 
Laboratory Animal Resources (LAR) personnel. Reproductive failure was evident in one sow 
that farrowed a term litter composed of 13 mummies in February 2009. Microscopic 
evaluation of the mummified fetal tissues revealed multifocal, severe, myocardial necrosis 
with mineralization. Abundant PCV2 antigen was detected by immunohistochemistry (IHC) 
in the fetal myocardium.
35
 One sow was euthanized in May 2008 due to hind limb paresis 
associated with a vertebral abscess. No other clinical signs were reported in the breeding herd 
during this time period. The approximate time of PCV2 infection of the breeding herd was 
between December 2008 and January 2009. The PCV2 status of 10 sows at mid-gestation 
(approximately 57 days; February 3, 2009) and their litter characteristics (number of 
mummified fetuses, stillborns, and born-alive piglets) at farrowing are summarized in Table 
1.  
 
REMOVAL OF PCV2 FROM THE FARM ENVIRONMENT  
Facility biosecurity protocols 
Access to the facility is through a gated entrance that is locked when employees are not 
present. An additional perimeter fence encloses the swine facility, where a biosecurity sign is 
posted. To further limit the number of personal that have access, all animal buildings are 
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locked at all times. At entry to the facility, a change of clothes is required. The only vehicles 
granted access to the swine facility include a non-swine-facility-specific snow blower and a 
lawn mower which are used for property maintenance. All equipment that is needed in the 
facility is disinfected with Virkon® S (Dupont, Pharmacal Research Laboratories, Inc., 
Naugatuck, Connecticut, USA) prior to entrance through the biosecurity gate. Upon access to 
the facility the use of foot baths are required between all animal buildings. A custom-fitted 
system for air filtration was installed on the outside of air inlets in each building using air 
filters (3M Filtrete™ Micro Particle Reduction Filter 700, 3M Co., Ames, Iowa, USA) and 
custom frames. Pits are emptied once a week into a nearby lagoon. The lagoon is emptied 
once per year in the fall by facility employees and spread onto an adjacent field. Rodent 
control is done by using four bait boxes per building which are filled with a brodifacoum product 
(Havoc® Rodenticide Bait Pack, Hacco, Inc., Randolph, Wisconsin, USA). For bird control, foam 
insulation (Great Stuff™ insulating foam, Dow Chemical Company, Midland, Michigan, USA) was 
placed into openings between the roof and walls. Specific differences in the biosecurity protocol 
on animal movements between buildings, personal movements between buildings, semen 
usage, feed delivery, equipment disinfection, visitor entry procedures, air management, 
manure pit management and daily chores prior to the PCV2 outbreak and following 
repopulation of the herd are summarized in Table 2.   
 
Disinfection of the premise 
General building. All disposable supplies were discarded including shelving units, cleaning 
supplies, clothing and boots and all movable equipment (i.e. facility washer and dryer) was 
moved outside the building. This was followed by thorough cleaning and disinfection of the 
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building and equipment. Specifically, floors were scrubbed with a degreaser (PRL-Grease 
Free
®
, Pharmacal Research Laboratory Inc., Naugatuck, Connecticut, USA) followed by 
rinsing and disinfection with a chloride compound (Clorox® Bleach, The Clorox Company, 
Oakland, California, USA). The surface of the washer and dryer were cleaned with general 
household cleaning products and exposed to natural UV sunlight. In addition, a cycle of hot 
water with bleach was run through the washing machine prior to replacement into the cleaned 
facility. New shelving units for clothing, cleaning supplies, and other supplies were placed 
into the office. All tools were cleaned with water and sprayed with disinfectant (Virkon® S, 
Dupont, Pharmacal Research Laboratories, Inc., Naugatuck, Connecticut, USA).   
 
Buildings 2-5: Animals were removed from the buildings 2-5 starting on May 14, 2009. 
Complete depopulation of the site was achieved on May 29, 2009. Steps used in the cleaning 
and disinfection of the animal facilities are outlined in Table 3.  
 
Monitoring of the disinfection success of the premise 
Following application of disinfection in step 4 (Table 2), 10 swabs of each building were 
taken in areas which would likely contain virus (pit, floor, louvers, etc.). The surface swabs 
(polyester-tipped swab, Fisher Scientific Inc., Pittsburgh, Pennsylvania, USA) were 
collected, placed into 1 ml of sterile saline (0.9% sodium chloride solution, Fisher Scientific 
Inc.) and stored at -80°C until tested by quantitative PCR for presence and amount of PCV2 
DNA. PCV2 DNA was found on a plastic sort panel, in 2 of 10 samples taken from the office 
(a shelf and under a computer cabinet), the door and floor of building 5, the drain and floor of 
building 4, the floor and drain in building 2, and in several swabs from the pit grate and pit 
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floor in all buildings (2, 3, 4 and 5). The mean log10 genomic PCV2 DNA/ml ± std err for 
these positive samples was 4.48±0.14. Other locations sampled where PCV2 DNA was not 
detected included gating, light switches, foot baths, water nipples, pig transport carriers, the 
desk in the office area, the storage room floor, louvers, electrical boxes, and fan inlets.   
 
Repopulation of the site 
A single building (building 5) was initially repopulated with PCV2 naïve animals (negative 
for anti-PCV2-IgG antibodies and PCV2 DNA in serum) at the end of August 2009 (63 days 
following depopulation) (Figure 1). Blood was drawn monthly and tested for evidence of 
seroconversion to PCV2 by ELISA. Due to an increase in size of the animals and 
subsequently a need for more space, a portion of the animals were placed in buildings 3 and 4 
in November of 2009. Animals were placed into building 2 on March 12, 2010. Neither 
viremia nor seroconversion to PCV2 has been detected in any of the animals during the 
approximately 10 months (>300 days) of operation. The first PCV2 naïve litters were born in 
May 2010 (Figure 1). 
 
ATTEMPT TO DERIVE NEGATIVE ANIMALS FROM PCV2-INFECTED SOWS 
DURING THE OUTBREAK 
Piglets from sows which farrowed at the beginning of April 2009 were bled at 13 days post 
farrow (DPF). Of these, 15 female piglets from four litters which were not PCV2 viremic at 
the time of sampling were weaned at 22-27 days of age and placed into a BSL-2 facility at a 
different site. The pigs were housed in four separate rooms by litter. All rooms had a solid 
concrete floor, a separate ventilation system and one nipple drinker. The pigs were fed a 
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balanced, pelleted, complete feed ration free of antibiotics and animal proteins other than 
whey (Nature’s Made, Heartland Coop) once a day. Piglets were bled monthly; serum was 
used to determine levels of anti-PCV2 IgG and the PCV2 viremia status of the animals by 
ELISA
21
 and PCR
27
, respectively. The experimental protocol was approved by the Iowa State 
University Institutional Animal Care and Use Committee. Anti-PCV2 antibodies were 
detectable in all piglets from all litters at DPF 13. As a numeric trend toward decline of 
antibodies was noted between DPF 13 and DPF 204, these antibodies were assumed to be of 
maternal origin (Figure 3). At DPF 145, eight pigs were serologically negative; and anti-
PCV2 antibodies declined to a S:P ratio below 0.2 in the remaining two animals by DPF 176 
(Figure 3). PCV2 DNA was not detected in the piglets at 13 DPF; however, by 21 DPF one 
pig in each of three rooms had detectable amounts of PCV2 DNA and were removed from 
the study. By DPF 204 100% of the remaining piglets had detectable amounts of PCV2 DNA 
(Figure 3). Therefore, the study was terminated and pigs were euthanized. 
 
DISCUSSION 
The objectives of this study were to document a natural outbreak of PCV2-associated 
reproductive disease in a closed, high health population, to describe the procedure used to 
disinfect the premise before repopulation with PCV2-naïve animals, to report the outcome 
after repopulation, and to attempt to derive PCV2 negative animals by offsite segregation. 
The PCV2 outbreak in the research breeding herd was originally detected based on 
serological evaluation of recently weaned piglets and later confirmed by PCV2 IHC staining 
on mummified fetuses, detection of anti-PCV2 antibodies by IFA and ELISA and detection 
of PCV2 DNA by PCR on serum samples from sows. Viremia was detected in eight mid-
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gestation sows (approximately 57 days) and PCV2 antigen was demonstrated by IHC on 
mummies from one sow. This is consistent with previous studies involving experimental-
PCV2 infection of sows indicating that early infection (1-35 days of gestation) resulted in 
embryonic death
12
, irregular returns to estrus
18
, pseudopregnancy
10
 or small litter sizes;
38
 
infection at mid gestation (35-70 days) resulted in mummified fetuses and abortion;
12
 and 
infection during late gestation (70-115 days) resulted in mummified fetuses
9
, stillborns
23
, 
weak-born piglets
22
, delayed farrowing
13
, normal litters
15
, or abortion.
3
    
 
The exact timing of PCV2 infection in the research breeding herd remains undetermined. It 
can be assumed that initial infection occurred sometime after December 11, 2008 (last batch 
of naïve animals taken from the herd) and before January 27, 2009 (first detection of PCV2 
in weaned pigs). Similarly, it is difficult to retrospectively determine the building into which 
PCV2 was first introduced. However, based on a higher proportion of sows with anti-PCV2 
antibodies the introduction of PCV2 to the site is assumed to have occurred in building 5. 
The source strain of infection was determined to be a PCV2b isolate. Similar isolates were 
used commonly in a research laboratory 8 km to the North. Horizontal transmission likely 
occurred from either contaminated equipment or people. However, there are a large number 
of possible routes by which horizontal transmission may have occurred due to the design of 
the facility and concurrent responsibilities of personnel who visited the research herd.   
 
Attempts to derive PCV2 negative animals from the herd following the outbreak by offsite 
segregation by litter were unsuccessful. In the current investigation, pigs which were non-
viremic at 13 DPF were separated by litter and placed in groups of three to four animals in an 
187 
 
 
off-site BSL-2 facility. As soon as animals became PCV2 viremic, they were removed from 
the study. By 204 DPF all the remaining animals were viremic. The inability to derive 
negative pigs was likely due to the presence of an active PCV2 outbreak and localized 
persistent PCV2 infection of the piglets with viral replication following the decline of 
maternal antibodies. 
 
Major risk factors which were identified following the outbreak included frequent movement 
of animals and people between buildings with minimal biosecurity, lack of maintaining a 
shower-in-shower-out facility, preparation of semen extender at an off-site facility, use of a 
common tractor between the swine facility and other areas of the farm, lack of concrete paths 
between buildings, and transport of feed directly into the facility. To address these issues, 
specific changes were made to the facility itself and to the way in which the facility was 
operated. The major changes included the enforcement of strict biosecurity protocols for 
movement of people and equipment into and on the facility, the addition of concrete paths 
between buildings which were put in place to reduce organic contamination of boot baths, 
installation of a building for feed fumigation, and the purchase of PCV2 negative semen 
(based on PCV2 PCR testing of each semen batch). Another minor change included the 
addition of air filters over inlets and outlets. This change was considered minor as only one 
site containing pigs (housed approximately 100 sows) is within a five mile radius of this site. 
In addition, while little information exists on aerosol transmission of PCV2, in the single 
study which evaluated the presence of PCV2 DNA in aerosol samples, PCV2 DNA was not 
detected.
7
 The risk of PCV2 transmission from rodents or birds was also considered low and 
modifications to the current rodent control protocol were not made. Previous studies have 
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demonstrated PCV2 replication in mice
4
 and a 2010 study reported that 65% and 23.8% of 
the mice and rodents from PCV2 infected swine premises were PCV2 positive, 
respectively.
14
 However, PCV2 was not detected in rodents outside of the premises.
14
 This 
information combined with the distance to the nearest swine farm makes transmission from 
rodents unlikely. To date no information exists to the author’s knowledge on whether indirect 
transmission of PCV2 can occur between avian and porcine species. However, due to lack of 
detection of PCV2 in species other than swine
33
 and the host specificity of circoviruses 
within avian species
36
, transmission by this route seems unlikely.   
 
Disinfection of a facility contaminated with PCV2 is an arduous task. PCV2 is known to be 
shed by numerous routes including nasal and oral secretions, urine and feces.
34
 In addition, 
viremia can persist in animals for extended periods. PCV2 viremia was previously reported 
in pigs for 140 days post infection.
26
 PCV2 has been shown to be transmitted both by 
horizontal
1
 and vertical routes
16
.
 
The virus is also extremely stable 
24,37
and many disinfectants 
do not completely eliminate the virus under in vitro conditions.
11,17,31
 Clinical disease 
associated with PCV2 in breeding herds is rarely observed and typically resolves following 
exposure of a potentially naïve population to PCV2 between 8 and 20 weeks following the 
initial detection.
23,32,38
Vaccination programs have been shown to be highly effective in 
reducing mortality associated with PCV2 infection
28
; however, they do not eliminate 
shedding of PCV2. Based on the combination of the above factors, PCV2 naïve breeding 
herds are extremely rare. However, high health animals free of common viruses and bacteria 
are required for researchers to further advance understanding of the pathology and 
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epidemiology of swine pathogens. Therefore, documentation of the ability to successfully 
eliminate PCV2 from a farm is important.   
 
In this study, the combination of thorough removal of organic material using a detergent, 
followed by exposure of equipment to natural UV light and multiple applications of a 
disinfectant were used. In addition, all disposable equipment was discarded and surfaces 
which would likely retain virus (pit covers, gating, cement, etc.) were either painted or 
sealed. Finally, the facility remained without animals for 63 days. As downtime was 
combined with thorough cleaning and disinfection, it is unknown whether downtime alone 
would have led to a similar elimination of PCV2 from the premise. However, the detection of 
PCV2 DNA within the pits following thorough cleaning and disinfection suggests that 
downtime alone would not be enough to prevent transmission from a contaminated building 
to naïve animals. After using the described decontamination protocol and enforcing a strict 
biosecurity protocol, the repopulated herd has remained PCV2 naïve (based on routine PCR 
and ELISA screening) for at least 300 days.   
 
IMPLICATIONS 
 The current study documented a natural outbreak of PCV2 in a high health research 
breeding herd, and similar to previous work, increased numbers of mummies were the 
major clinical sign.  
 Several procedures used on the farm were identified as potential risk factors for 
transmission of PCV2 and were modified following the outbreak. The factors 
included frequent movement of animals and people between buildings with minimal 
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biosecurity, lack of maintaining a shower-in-shower-out facility, preparation of 
semen extension at an off-site facility, use of a common tractor between the swine 
facility and other areas of the site, and the lack of concrete paths between barns. 
 The described procedure used for disinfection of the premise and enhanced 
biosecurity protocols have resulted in the maintenance of PCV2-free animals for 
approximately 10 months (300 days) to date.  
 Attempts to derive PCV2 negative replacement animals from the herd during the 
outbreak by offsite segregation by litter were unsuccessful. 
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Table 1: Dam PCV2 antibody and viremia status at approximately 57 days of gestation (3-
Feb-09) and characteristics of their litters at the time of farrowing where M = mummies, S = 
stillborns and BA = Born Alive 
Sow 
ID 
Building Anti-PCV2 
antibodies 
Viremia Litter characteristics 
ELISA* IFA 
Log10 PCV2 
DNA/ml 
M S BA 
93 2 0.149 Negative 4.08 0 3 15 
48 2 0.078 Negative 3.49 0 0 14 
5 3 1.154 Positive 5.39 0 1 11 
96 3 0.484 Positive 0.00 4 5 4 
97 3 0.088 Negative 4.65 0 2 13 
186 3 0.044 Negative 0.00 0 4 7 
237 3 0.912 Positive 5.45 3 0 0 
307 3 0.722 Positive 3.88 1 3 11 
397 3 0.498 Positive 4.14 0 2 14 
836 3 0.044 Negative 3.97 0 2 1 
* Sample to positive ratio (S:P ratio) 
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Table 2: Outline of specific biosecurity protocols used at the site prior to the PCV2 outbreak 
and following repopulation of the herd. 
Task Protocol prior to outbreak Protocol following repopulation 
Animal 
movement 
between 
buildings 
No PCV2 testing prior to movement 
of animals between buildings 
PCV2 testing (PCR and serology) of 
animals prior to movement between 
buildings. Animals must be PCV2 negative 
Pig transport carrier not specific to 
the swine facility 
Semi-enclosed, custom built cart for pig 
transport used only in the swine facility 
Non-swine-facility-specific tractor* 
used to transport crate  
Non-swine-facility-specific tractor* is no 
longer used 
Routine washing and disinfection of 
transport crate after usage 
Routine washing and disinfection of 
transport crate prior to and after usage 
Personnel 
movement 
between 
buildings 
Street shoes were changed in the 
locker room in the general building 
Street shoes are changed in the laundry 
room; separate general building designated 
boots are used in each room of the general 
building 
 Shower is required at entry to the facility  
Between animal buildings, clothes 
change or showering is not required  
Between animal buildings, clothes change 
and showering are required 
No gloves were worn between office 
and animal buildings 
Separate latex examination gloves worn 
between office and animal buildings. 
Gloves are disposed of prior to entry into 
animal building. 
One set of boots worn between office 
and animal buildings and also inside 
animal buildings  
Specific boots worn between office and 
animal buildings which are removed prior 
to entry 
No designated path and no sidewalk 
between buildings 
Concrete paths from building to building 
were installed to minimize debris entering 
the building 
 Specific boots and separate latex 
examination gloves are worn in each 
building 
Semen On farm source Commercial source 
Semen was diluted on-site using 
extender re-constituted in an off-site 
laboratory 
Diluted semen is purchased 
Semen not tested for PCV2 prior to 
use 
Semen tested by PCV2 PCR prior to entry 
into the facility 
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Table 2:  (Continued) 
Task Protocol prior to outbreak Protocol following repopulation 
Feed 
delivery 
Feed unloaded from feed delivery 
truck at the general building 
Feed truck unloaded from feed delivery 
truck at a gate near the main road (800 m 
from the general building) 
Transported to the general building 
with a non-swine-facility-specific 
tractor* 
Transported to the general building by 
facility personnel by hand following 
fumigation with (Virkon® S, Dupont, 
Pharmacal Research Laboratories, Inc., 
Naugatuck, Connecticut, USA) 
Equipment  Non-swine-facility-specific tractor* 
allowed in areas between buildings 
The non-swine-facility-specific tractor* 
has no access to the swine facility 
 All equipment is re-disinfected within the 
general building prior to movement into 
the animal buildings 
Entry 
procedure 
 
 
Visitor sign-in book was located in 
room 2 of the general building 
Visitors sign-in book directly upon entry 
into room 1 of the general building 
No strict policy was in place for 
downtime 
All visitors must have a minimum 72 hrs 
down-time 
 Biosecurity protocol is posted on entry 
door into the facility 
Air Air filter present over air inlets Air filters are present over air inlets and 
outlets 
*Tractor is also used in cattle, horse and small ruminant facilities in close proximity to the 
swine facility.
  
Table 3: Stepwise cleaning and disinfection protocol used following the PCV2 outbreak. 
Step Procedure 
1 All equipment in all buildings including gating, crates, and pit cover plates were washed with 71.1°C water using a high-pressure 
(1000 psi) nozzle. Once cleaned, the equipment was removed from the building and stored outside on flatbed wagons, scaffolding, 
and hand carts that had constant, natural UV exposure. All water lines, gas lines, and heaters inside the buildings were removed 
and discarded. All fluorescent bulbs were discarded and exposed electrical parts of light fixtures were covered with tape.   
2 Using portable lighting, the buildings, including the ceiling, light fixtures and outlets, controls, fan blades, louvers, and pits, were 
scrubbed by hand with brushes using a detergent (PRL-Grease Free
®
). Following scrubbing, the detergent was allowed 10-15 min 
of contact time prior to washing with a high-pressure washer as described in Step 1.   
3 Following the initial cleaning phase, the buildings stood empty for several weeks while general repairs were made (holes in the 
walls were repaired, the brick was replaced where necessary). All metal pit covers were painted on both sides with a primer (DTM 
Bonding Primer, Sherwin Williams, Cleveland, Ohio, USA) and paint (PRO INDUSTRIAL™ Pre-catalyzed waterbased semi-
gloss epoxy, Sherwin Williams, Cleveland, Ohio, USA). Approximately 216 g of an oxidizing agent (Virkon® S) was placed into 
the pits which were filled two thirds of the way full with water for 3 days. Following removal of the disinfectant, the concrete in 
the buildings was sealed (Concrete seal, product #2977, Spartan Chemical Company, Inc., Maumee, Ohio, USA). During this 
general repair phase, the building was disinfected three times with a chloride compound (Clorox® Bleach, The Clorox Company, 
Oakland, California, USA). 
4 Disinfection of the buildings was done by applying a primary disinfectant at the manufacturer’s recommended concentration 
(Synergize®, Preserve International, Memphis, Tennessee, USA) using a 56.8 liter sprayer (Fimco Industries, Dakota Dunes, 
South Dakota, USA). The disinfectant was allowed to completely dry (2-3 days). The building was then fumigated with a second 
disinfectant (Virkon® S) at the manufacturers’ recommended concentration. Again, the buildings were allowed to completely dry 
(2-3 days). 
5 The entire interior of the buildings including ceiling, walls, light fixtures, gating and doors was spray painted (PRO 
INDUSTRIAL™ Pre-catalyzed waterbased semi-gloss epoxy, Sherwin Williams, Cleveland, Ohio, USA). After the paint dried, 
new light bulbs, heaters, gas lines, PVC water lines, cabinets, water line hook-ups, feed barrels, garbage cans, gating and garden 
hoses with associated hangers were installed into the buildings. In addition, PVC boot racks were installed on the outside and 
inside of entrances to buildings.  
6 The buildings were re-disinfected as described in Step 4. 
1
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Figure 1: Diagram of the swine researc breeding facility. 
 
 
201 
 
 
Figure 2: Time-line of the PCV2 outbreak detection and repopulation of a naïve research 
breeding herd. 
 
 
 
 
 
 
 
 
 
 
 
  
Repopulation of half of 
building 3 and building 
4 
17-Nov-09 
07-May-10 
15-Dec-09 
Repopulation of the other half of 
building 3 
All animals in all 
buildings were 
seronegative for PCV2 
Last batch of PCV2-naïve 
piglets was farrowed at the 
breeding herd facility 
11-Dec-08 
Complete depopulation of the 
breeding herd 29-May-09 
All sows were bled at the 
breeding facility. A mixture of 
PCV2 seropositive and viremic 
animals were detected in 
buildings 2, 3, and 5 
3-Feb-09 
Weaned pigs were moved from 
breeding herd facility (building 
4) to a BSL-2 facility at a distant 
location  
27-Jan-09 
Weaned pigs in BSL-2 
facility were bled and 
found to be 
seropositive for PCV2 
and PCV2 viremic. 
Sequencing confirmed 
the presence of PCV2b 
 
29-Jan-09 
One of 10 sows did not 
farrow on the expected 
date; 13 mummies 
were expelled 
11-Feb-09 
Repopulation of building 5 is 
repopulated 
31-Jul-09 
12-Mar-10 Repopulation of building 2 
First PCV2 negative litters  19-May-10 
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Figure 3. Mean pig anti-PCV2 sample-to-positive (S:P) ratio (line) and percentage of PCV2-
PCR positive piglets (bar) at different days post farrowing. 
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CHAPTER 8.  General Conclusions 
 
At the time of this dissertation, little published information exists on the diagnostic 
agreement between serological assays used to determine the timing of PCV2 infection.  In 
addition, it is known that horizontal transmission of PCV2 occurs by direct contact with 
infected animals or their secretions; however, limited information is available on indirect 
horizontal transmission of PCV2.  
The first objective of this dissertation was to address the question of whether 
commercial and in-house serological assays for PCV2 are in agreement. Because receiver 
operating characteristic analysis has become an increasingly valuable tool for comparison of 
diagnostic tests (Gardner and Greiner, 2006; Zweig and Campbell, 1993) this method was 
used instead of the kappa statistic which has limitations in agreement analysis (Sim and 
Wright, 2005). Interestingly, all four assays evaluated had high area under the curve (AUC) 
values indicating good discrimination between known positive and negative samples. This 
information alone would suggest that practitioners could choose either an in-house or 
commercial assay and receive similar results. However, assays which had similar, high AUC 
values had differences in sensitivity and specificity using laboratory specific cut-offs. This 
implies that for accurate depiction of trends in the sero-prevalence of PCV2 in herds, samples 
should be consistently run on the same serological assay. This is due to the variation noted in 
the sensitivity of the assays when laboratory specific cut-offs were applied to the data set. 
The analysis using laboratory specific cut-offs also indicated that (1) the usefulness of both 
the commercial and the in-house assay is limited early in the infectious process due to lower 
sensitivity; (2) later in the infectious process, the in-house assay had a higher sensitivity and 
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specificity in comparison to commercial assays; (3) early in the infectious process, IFA 
assays may provide greater utility in comparison to ELISAs; and (4) the limited number of 
samples tested in this trial may have been an important factor for the differences in optimized 
and established cut-offs; therefore, further studies with larger sample sizes are necessary to 
determine an appropriate cut-off for these assays. A secondary finding was that currently 
offered assays are detecting both anti-PCV2a and anti-PCV2b antibodies following both 
natural infection and vaccination. As there has been a global shift of PCV2 genotypes from 
PCV2a to PCV2b (Dupont et al., 2008), it is important for veterinary diagnosticians and 
practitioners to be confident current assays are detecting both genotypes.    
The second objective of this dissertation was to gain insight into several aspects of 
horizontal transmission. Vital to this objective is knowledge of characteristics of the virus, 
including but not limited to routes of shedding, amount of virus present in various secretions 
and excretions, stability, and efficacy of disinfection protocols. Previous information has 
documented that PCV2 is shed by numerous routes including nasal and oral secretions, urine 
and feces (Segalés et al., 2005b); however, limited or no information is available on the 
quantity and infectious nature of the detected PCV2 in these samples. In addition, it is known 
that viremia can persist in animals for extended periods; PCV2 viremia was detected in 
animals at 140 days post inoculation (DPI) (Opriessnig et al., 2010). PCV2 is also extremely 
stable (O'Dea et al., 2008; Welch et al., 2006) and many disinfectants do not completely 
eliminate the virus under in vitro conditions (Kim et al., 2009; Royer et al., 2001). The 
combination of these viral characteristics and the high worldwide seroprevalence 
(Ramamoorthy and Meng, 2009) provide evidence that horizontal transmission is likely an 
important factor in maintenance of the virus in swine populations. To date, the majority of 
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published literature addresses vertical transmission or horizontal transmission through direct 
contact. Little information is available on the role of indirect contact in the transmission of 
PCV2. Specific questions that have not been previously addressed which were evaluated in 
this work included the following: (1) how long is PCV2 DNA present in various secretions 
and excretions, (2) is the PCV2 DNA detected in secretions and excretions infectious to 
naïve animals, (3) does routine disinfection of commercial transport trailers prevent 
transmission of PCV2 to naïve animals, and (4) can PCV2 remain infectious during the spray 
drying process and be spread to naïve animals via spray-dried plasma.  
To answer the question of how long PCV2 DNA can be detected in various secretions 
from PCV2-infected animals and whether the detected PCV2 DNA was infectious, a cohort 
and bioassay study were designed. Specifically, naturally PCV2-infected pigs and PCV2-
naïve pigs experimentally inoculated with PCV2 at 21 days of age were routinely sampled 
(fecal, oral and nasal swabs and serum samples) until 209 days post-farrowing (DPF; natural 
infection) or until 69 days post-inoculation (DPI; experimental infection). The results of this 
study documented the longest period of PCV2 viremia under controlled conditions (181 day 
observation period). It was also demonstrated that in both experimental and natural PCV2 
infections, PCV2 is shed in high amounts in nasal, oral and fecal excretions for extended 
periods of time. In addition, naïve animals were inoculated by various methods with different 
samples (oral fluid, nasal secretions, feces or a contaminated needle) taken from the 
experimentally infected animals at the time of expected peak shedding.  This study confirms 
that naïve animals can be infected with PCV2 present in nasal secretions, oral secretions and 
fecal material via the intraperitoneal route, with PCV2 present in feces via the oral route, 
with PCV2 present in nasal secretions via the intranasal route and potentially through 
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contaminated needles.  However, future studies in which replicates of naïve animals are 
inoculated with serially diluted concentrations of PCV2 DNA are needed to identify the 
infectious dose for each route of exposure. 
The question of whether routine disinfection of commercial transport trailers prevents 
transmission of PCV2 to naïve animals is of concern to practitioners and producers as large 
numbers of animals are transported between facilities on a daily basis.  Previous work has 
shown oxidizing agents, aldehyde compounds and quaternary ammonium compounds have 
efficacy against PCV2 under in vitro conditions (Kim et al., 2009; Royer et al., 2001) (11, 
20). While in vitro efficacy data is useful, field efficacy of a disinfectant depends on the type 
of surface and the presence of organic material among other variables (Amass, 2004). To 
accurately simulate field conditions, 1:61 scale model trailers were designed and 
manufactured by a company specializing in standard and custom aluminum livestock 
transportation equipment with the exact materials used during commercial production. 
Trailers were manufactured purposely to contain areas where fecal material would likely 
accumulate and sampling of the trailers was concentrated on these areas to accurately 
determine viral concentration within the trailer following each step in the protocol. The 
results of this study indicate that following the disinfection step, between 1.5 and 5.2 log10 
PCV2 genomic copies/ml were identified in the trailers and only one disinfection protocol 
(DISF 4; an application of two disinfectants in tandem, the first being an oxidizing agent 
(Virkon®S, Pharmacal Research Laboratories Inc., Naugatuck, CT) followed by a chloride 
compound (Clorox® Bleach, The Clorox Company, Oakland, California, USA) significantly 
reduced the log10 PCV2 genomic copies/ml compared to the log10 PCV2 genomic copies/ml 
present in the post-wash step. Interestingly, although the trailers were contaminated with a 
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consistent, high amount of virus (10.8 log10 PCV2 genomic copies/ml) and PCV2 DNA was 
detected in trailers following disinfection, transmission to naïve animals within a two hour 
period did not occur. As 1.45 ± 0.6 log10 PCV2 genomic copies remained in the trailer 
following the most efficacious disinfectant protocol, it is possible that longer exposure 
periods could have resulted in transmission of PCV2 to naïve animals. In addition, it would 
be of benefit to repeat the study to increase the probability of detecting infection. Also of 
interest would be a comparison between the infectious dose of PCV2 needed to initiate 
infection using this model in comparison to other routes including intraperitoneal, oral, etc. 
The last potential mechanism for horizontal transmission of PCV2 evaluated in this 
dissertation is horizontal spread through spray-dried plasma (SDP) products. Several 
previous studies have reported the lack of viable pseudorabies virus (Polo et al., 2005), 
porcine reproductive and respiratory syndrome virus (Polo et al., 2005), and swine vesicular 
disease virus (SVDV) (Pujols et al., 2007) within SDP. In contrast to PRRSV, PRV and even 
other stable, non-enveloped viruses such as SVDV (Turner and Williams, 1999), PCV2 has 
been shown to be extremely resistant maintaining viability at temperatures of 60°C for 24 hrs 
and 75°C for 15 min(O'Dea et al., 2008; Welch et al., 2006). In addition, although inlet 
temperatures of 240°C can be achieved during this process, the time in which the product is 
exposed to this temperature is short. This design was made to enable efficient drying of 
plasma products without the destruction of various proteins including antibodies to PCV2, 
Mycoplasma sp., PRRSV, TGE and SIV (Borg et al., 2002). Last, a previous study detected 
PCV2 DNA in commercially SDP but failed to determine whether it was infectious or not in 
PCV2 naïve animals (Pujols et al., 2008). 
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 It was therefore, the objective of this portion of the dissertation to use a bench-top 
commercial spray-dryer according to the manufacturer’s recommendations to spray-dry 
experimentally infected plasma. Following generation of the SDP, it was intraperitoneally 
inoculated into PCV2-naïve animals to determine the ability of PCV2 to withstand the 
process. Reasons for using this method in contrast to the previous study by Pujols et al., 
included: (1) elimination of the question of whether maternal antibodies affect infection 
following consumption of SDP containing PCV2 DNA and (2) use of the most sensitive 
method available (swine bioassay) to detect the presence of PCV2. The results of this study 
provided direct evidence that porcine SDP collected from a PCV2b-experimentally infected 
pig is infectious to naïve animals through the intraperitoneal and oral gavage route. This 
combined with the knowledge that PCV2 DNA is present in commercially produced SDP 
(Pujols et al., 2008) indicates that SDP sourced from pigs could represent a biosecurity risk 
for the swine industry. However, due to the large number of studies which have cited 
favorable production parameters following the incorporation of SDP into nursery diets, 
further studies are necessary to validate the infectivity of PCV2 DNA in PCV2-naïve pigs 
through incorporation into the diet (i.e. a realistic exposure model) and to determine the 
infectious dose of PCV2 via this route of exposure.   
While animal work was ongoing for the data discussed above, a unique opportunity 
arose to implement the knowledge gained from the previous work in the field. Specifically, 
the swine herd supplying PCV2 naive animals for these studies underwent a natural PCV2 
outbreak and the decision was made to roll the herd over in order to allow future research to 
continue.  Therefore, it was the final objective of this dissertation to document a natural 
outbreak of PCV2 in a specific disease free population, to describe the procedure used to 
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disinfect the premise, and to document the attempt to derive PCV2 negative animals for use 
as replacement stock in the facility.  The PCV2 outbreak was originally detected based on 
serological evaluation of recently weaned piglets and later confirmed by 
immunohistochemistry staining on mummified fetuses, IFA, PCR and sequencing of samples 
from sows and a piglet.  Clinical signs were absent in sows, with increased numbers of 
mummified fetuses being the primary clinical sign. This is similar to previous case reports in 
which outbreaks were characterized by an increased percentage of mummies and stillborns 
within the population with minimal clinical signs noted in the dams (O'Connor et al., 2001; 
West et al., 1999). The exact timing of infection was not determined due to the variation in 
serological and viremia response in the sows.  However, sequencing of the ORF2 region of 
the PCV2 recovered from both a sow and piglet during the outbreak had 100% nucleotide 
homology with NC-16845 isolate (GenBank#EU340258) which was used commonly in a 
nearby (8km) research laboratory for experimental infection of naïve animals. The premise 
was depopulated and cleaned by thorough removal of organic material using a detergent, 
exposure of equipment to natural UV light followed by multiple applications of a 
disinfectant.  All disposable equipment was discarded and surfaces which would likely retain 
virus (pit covers, gating, cement, etc.) were either painted or sealed.  In addition, a strict 
biosecurity protocol was put into place to minimize the risk of horizontal transmission.  
Using the described decontamination protocol and enforcing a strict biosecurity protocol, the 
site was re-stocked with PCV2-naïve pigs 63 days later and the population has remained 
PCV2 naive (based on PCR and ELISA screening) to date (>300 days).  However, an attempt 
to derive PCV2 negative replacement animals from non-viremic piglets weaned during the 
outbreak was not successful.  While, the majority of herds worldwide are seropositive for 
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PCV2, documentation of the disinfection process used in this study is important to producers 
and researchers and likely can be extrapolated to herd roll-overs following contamination 
with other viral pathogens.   
In summary, the research described in this dissertation provides significant 
contributions to the knowledge of horizontal transmission of PCV2 specifically relating to 
the role of transmission of PCV2 through contact with contaminated secretions, transport 
trailers, and spray-dried plasma.  In addition, this work provides information on the 
diagnostic agreement among serological assays and documents the roll-over of a specific 
pathogen free herd following a natural PCV2 infection. 
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